Submitted in partial fulfilment of the Lancaster University Doctorate in Clinical
Psychology, May 2016.
Doctoral Thesis:
Psychological characteristics related to epileptic and non-epileptic seizures

Liz Tallentire

Doctorate in Clinical Psychology

Division of Health Research, Lancaster University

# **Statement of word count for thesis sections**

	Text	References, Tables, & Appendices	Total
Thesis Abstract	282	0	282
Literature Review	7,893	7,331	15,224
Empirical Paper	7,979	7,294	15,273
Critical Review	3,993	981	4,974
<b>Ethics Section</b>	2,353	5,891	8,244
Totals	22,500	21,497	43,997

#### **Abstract**

This thesis consists of a quantitative systematic review, a quantitative empirical research paper, and a reflective critical appraisal. The review included 16 published empirical research papers. It examined how psychological characteristics have been used to differentiate subgroups of people who experience non-epileptic seizures (NES) and contextualised subgroup differences in theories of NES aetiology. Results indicated that trauma experiences, alexithymia, and presence of intellectual disability were characteristics that were important in differentiating subgroups.

The aims of the empirical paper were to check data against hypotheses based on previous research, before comparing the psychological characteristics of people who reported experiencing NES and epileptic seizures (ESs). Data were collected via online surveys. NES subgroups were formed using cluster analysis of alexithymia and childhood trauma data. Subgroups were found to differ on childhood trauma, alexithymia, and adult attachment style.

There were parallels between the subgroups indicated in the review and empirical paper, which are explored further in the empirical paper discussion and critical appraisal. The empirical paper and systematic review emphasised the complexity of NESs and the importance of assessing and understanding individual differences in research and clinical settings. The alexithymia and adult attachment measures used in the empirical project may be useful as part of an assessment of individual differences. These measures could form a basis for psychological assessment and formulation for NES patients, and may help identify ES patients with attachment and/or alexithymia difficulties who may benefit from psychological assessment and therapy. The two research papers also make recommendations for research relating to treatments appropriate to the identified subgroup characteristics. The critical appraisal reflects on

the impact of mind-body dualism in the other two papers and discusses how such considerations may influence clinical practice.

## **Declaration**

This thesis represents work undertaken for the Doctorate in Clinical Psychology at Lancaster University, Division of Health Research, from March 2014 to April 2016.

The work presented is the author's own, except where due reference is made. The work has not been submitted for the award of a higher degree elsewhere.

Name: Liz Tallentire

Signature:

Date:

#### Acknowledgements

Firstly, I would like to thank the participants who completed the online survey and members of forums who supported the research. I would also like to recognise the support of the NHS organisations, charities, and support groups who assisted with recruitment.

I would like to express my gratitude to Dr Ian Fletcher (senior lecturer in research methods, Lancaster University) for his input and support throughout the process and Dr Jayne Martlew (Clinical Lead for the Neuropsychology Service, The Walton Centre) for her valuable contributions from a clinical perspective. I would like to recognise the contributions made by Dr Emma Eastoe (lecturer in statistics, Lancaster University) in her role as statistical consultant.

I would like to thank my friends and family for their support and belief in me, and especially my Dad for his help with proof reading.

# **Contents**

# **Section One: Literature Review**

Title Page	1-1
Abstract	1-3
Introduction	1-5
Method	1-10
Results	1-16
Discussion	1-30
Conclusion	1-40
References	1-42
Figures	1-51
Tables	1-53
Appendices	1-62
Section Two: Empirical Paper	
Title Page	2-1
Abstract	2-3
Introduction	2-5
Method	2-10
Results	2-18
Discussion	2-33
Conclusion	2-43
References	2-45
Figures	2-55
Tables	2-58
Appendices	2-64

# **Section Three: Critical Appraisal**

Title Page	3-1
Introduction	3-3
Design	3-9
Implementation	3-12
Analysis and interpretation	3-13
Dissemination	3-14
Future research`	3-14
Clinical implications	3-15
Conclusion	3-16
References	3-17
Appendix	3-21
Section Four: Ethics	
Title Page	4-1
National Research Ethics Service Approval Letter	4-2
NHS REC Application Form	4-7
Research Protocol	4-33
Results, forwarding, and support information sheet	4-47
Study Poster	4-48
Study Cards	4-49
Online Forum Advert	4-51
Online Survey Sample	4-52
Gant Chart Submitted with Ethics Application	4-53
Chief Investigator Curriculum Vitae	4-54

Academic Supervisor Curriculum Vitae	4-55
Thesis Review Process Evidence	4-57
Insurance Documentation	4-59
Sponsorship Letter	4-62

Section One: Lite	erature Review
	al characteristics of subgroups of adults who epileptic seizures: A systematic review.
Liz Tallentire	
Doctorate in Clinical	Psychology
Division of Health Re	esearch, Lancaster University
Word Count:	7,893 excluding tables, figures, references, & appendices
	15,224 in total excluding author guidance of 7,135 words
	pared in accordance with the guidelines of the target journal Seizure. e is included in Appendix A.

#### **ABSTRACT**

*Purpose:* To identify how people who have experienced non-epileptic seizures (NESs) have been split into subgroups, based on psychological characteristics, and to explore what these subgroups' reveal about the aetiology of NESs.

Methods: Systematic review of peer reviewed published literature. Empirical articles (n=16) were identified via a systematic search, using Academic Search Complete, AMED, CINAHL, MEDLINE, and PsycINFO databases and manual searching. Reported methods of differentiating subgroups and psychological characteristics that significantly differentiated these subgroups were reviewed.

Results: Investigators' methods of splitting their NES samples into subgroups fell into nine different categories. They examined a broad range of psychological characteristics and there was little consensus on subgroup attributes. However, there was evidence from four studies to support the existence of NES subgroups who have experienced more trauma, and more mental health difficulties than average for the overall NES groups. There were some indications of subgroups with intellectual disabilities, which were more likely to have environmental triggers for NESs, and subgroups who were described as 'over-controlled' in their emotion regulation.

Conclusion: The different subgroups outlined above may be consistent with integrated, behavioural, and psychodynamic theoretical models respectively. This research further establishes the complexity of NESs aetiology and emphasises the need for comprehensive psychological assessment and formulation of people experiencing NESs, in order to identify which theoretical model(s) are most useful in their therapy. Trauma, and alexithymia measures, and presence of intellectual disability and mental health problems may be useful to inform these formulations and could be used to identify subgroups in future research.

#### Key words:

Non-epileptic, subgroups, psychological characteristics, aetiology, systematic review.

Highlights for the journal are provided in Appendix B.

#### Introduction

Non-epileptic seizures (NESs) have been defined as episodes during which a person's behaviour and sensations resemble those during epileptic seizures (ESs) but without any abnormal electrical discharge in the brain <sup>1</sup>. The prevalence of people experiencing NESs in the general population is estimated to be between 1.5 and 4.9 per 100,000 <sup>2</sup>. Research has indicated that around 1 in 5 patients attending hospital due to a seizure, and 1 in 7 of those attending a 'first fit' clinic, experience NESs 3. NESs is not a diagnosis in itself, and their complexity is reflected in the number of diagnostic labels with which they are associated. In the diagnostic and statistical manual of mental disorders, 5th edition (DSM-5) 4 they are considered a possible symptom of conversion disorder (functional neurological symptom disorder). They may also be part of a wider range of medically unexplained symptoms and labelled as somatic symptom disorder, or be part of a dissociative disorder and receive a label, such as depersonalization disorder. NESs have been referred to with many different names including, nonepileptic attack disorder (NEAD), pseudo seizures, and psychogenic non-epileptic seizures (PNESs). In this research the term 'non-epileptic seizures' is used, consistent with the International League Against Epilepsy (ILAE, 2015)<sup>5</sup> report.

Due to the similarity in appearance of ESs and NESs, concern about the accuracy of diagnosis has raised issues in relation to the risks posed to patients who are inappropriately prescribed medication with potentially severe side effects, demands on health services, and neglect of unrecognised psychological distress <sup>6</sup>. Differentiating between ESs and NESs can be difficult and costly for health services <sup>7</sup>. Research has indicated that the most reliable way to differentiate between ESs and NESs is video-electroencephalography <sup>8</sup>. However, even this is not entirely accurate <sup>9</sup>, partly due to high levels of comorbidity of ESs and NESs, which Hoepner et al. <sup>10</sup> reported as 36% in a

sample of 114 people who experienced NESs. Therefore, it is important that clinicians understand the aetiology of NESs so that they are better equipped to recognise this difficulty and support patients.

# Aetiology of NESs

At present, there is no consensus in the theoretical or empirical literature about the aetiology of NESs. They have been described as caused by psychological processes and contrasted with epileptic seizures (ESs) which are described as caused by physical processes <sup>11</sup>. However, this distinction is probably too simplistic as physiological differences, for example interictal abnormalities, have been noted in both ES and NES patients <sup>12</sup>. Research has suggested that patients see ESs and NESs as both psychological and physical conditions <sup>13</sup>.

Some psychological models of functional symptoms, such as NESs, conceptualise symptoms as the result of emotions that are too difficult to process. According to a psychoanalytic perspective first proposed by Freud the underlying cause of the difficulty with processing emotions is trauma, often of a sexual nature <sup>6</sup>. A related theory was that NESs may be a dissociative response that provides relief from intolerable feelings, including the unpleasant anticipation of the seizure itself <sup>14</sup>. These models appear to be consistent with a neurological model of NESs in conversion disorder, which has suggested that emotion systems (the limbic system and densely connected areas) override the sensory and motor cortex to produce neurological symptoms <sup>15</sup>. This model has received support from functional magnetic resonance imaging (fMRI) studies, which have shown differences in the patterns of neurological activity between NES patients and controls <sup>16, 17</sup>. The psychological and neurological

models above appear to be describing a similar process at a different level of explanation.

An alternative model is provided by behavioural theory, which proposed that NESs are learned patterns of behaviours that enable a person to avoid responsibility and escape from stressful situations. The person may or may not be conscious of the reasons for their behaviour, and the pattern is proposed to be reinforced by the way others respond to them when they exhibit seizures <sup>6</sup>. In some ways, this behavioural model could be similar to the models linked to emotion processing above, as both avoid something difficult. However, it is different in terms of the process it is proposing. The emotion processing models seem to be describing a system that becomes emotionally overloaded producing seizures as a direct result, whereas the behavioural model is describing a system that is learning to use the seizures as a protective strategy. These two processes could happen within the same person in parallel; the seizures could initially be due to emotional overloading but then become a learnt behaviour due to their consequences having some benefit.

Bodde et al. <sup>18</sup> proposed a model of NES aetiology illustrating the interaction of risk factors on several levels. This model appears to incorporate the aforementioned psychoanalytic, neurological, and behavioural theoretical models into an integrative model, with similar features to a generic psychological formulation. Bodde et al.'s <sup>18</sup> model is reproduced in Figure 1. The model starts at level 1, with a cause, such as traumatic experiences. These causes interact with level 2, the person's emotional and neurological characteristics, and are shaped by factors at level 3 into seizures rather than other functional symptoms. Level 4 represents triggers of NESs and level 5 are factors, including coping strategies, which lead to maintenance of NESs.

<<INSERT FIGURE 1>>

To date, research studies do not support any one of the above aetiological theories exclusively. Previous reviews have found that empirical research has identified differences in a variety of psychological factors, when they compared people who experience NESs with those who have ESs or with control groups. These factors included experiences of abuse or trauma, difficulties with emotion regulation, primary or secondary gain (where the patient benefits in some way either consciously or unconsciously from the seizures), and experience of epilepsy (self or others) <sup>18</sup>. However, a lack of consistency in the findings has suggested, more recently, that people who experience NESs are not a homogenous group, but fall into subgroups with differing aetiologies <sup>14, 18-20</sup>. This may help explain the difficulties in research relating to appropriate treatments; a Cochrane review examined the evidence for treatment of NESs and found there was very little reliable evidence that could inform the choice of treatment <sup>2</sup>.

Consequently, this review focussed specifically on NES subgroups, in contrast to previous reviews that considered people who experienced NESs as one group <sup>6, 14, 18-23</sup>. It used a systematic search strategy and quality appraisal, in order to reduce the risk of bias. Quantitative empirical research was reviewed in order to examine reported methods of subgroup differentiation and differences between subgroups on measures of psychological characteristics. This information about psychological characteristics was then related to NES theoretical models to explore what it revealed about NES aetiology.

#### Methods

The research question and search criteria for this systematic review were developed in a conjunction with a PICO analysis (Appendix C) in accordance with methods described by Cherry and Dickson <sup>24</sup>. Based upon the PICO analysis, it was

decided that the target population of studies for review related to adults who experienced NESs, and used quantitative measurement of psychological characteristics. The setting the research took place in was not restricted.

# *Identifying search terms*

Two sets of search terms were identified by using thesauruses, searches on electronic database search engines, consulting key words in relevant articles, reading articles, and consulting a clinician who works with people who experience seizures. The PsycINFO thesaurus<sup>25</sup> and American Psychological Association (APA) glossary of psychological terms<sup>26</sup> were also consulted. However, they did not include entries for non-epileptic seizures. The terms related to a) subgroups and b) NESs. The main terms are given in Table 1. In the final search, the NES terms (except PNES and conversion disorder) were combined in turn with the words seizures, attacks, and convulsions; alternative spellings and spacing of words were included. See Appendix D for a full list of the search terms.

<<INSERT TABLE 1>>

The sets of search terms relating to NESs and subgroups were joined with 'AND'.

As the number of search terms in the NES set exceeded the field length on the search engine, three separate searches were completed and the results were combined.

The Academic Search Complete, AMED, CINAHL, MEDLINE, and PsycINFO databases were searched between 01/08/2014 and 05/02/2016, using the EBSCO host, which automatically removes duplicates. In addition, relevant references from review articles and the studies included in the full text read were included for abstract reading. The process is summarised in Figure 2.

<<INSERT FIGURE 2>>

#### Inclusion and exclusion criteria

The results were not restricted by publication date because no previous reviews have specifically considered subgroups within the population of people who experience NESs. Peer reviewed published literature only was searched, in order to control for quality of research and adhere to review time constraints. The inclusion and exclusion criteria are shown in Appendix E. In addition to the details in Appendix E, a further table was developed to clarify what were included and not included as psychological characteristics. This list is included to enable replication because what constitutes a psychological characteristic is debatable. Examples of included psychological characteristics were personality measures, emotion processing characteristics, adult attachment style, mental health, and intelligence. Examples of excluded characteristics were gender, features of the seizures, and medication use; the full list is presented in Appendix F. Childhood attachment style was excluded as the review focussed on adults and adult characteristics. One study used 'active high speed referral' as the criteria for defining subgroups, this article was included, as the authors stated that they assumed referral speed was related to patient characteristics, as there had been no changes to referral criteria <sup>27</sup>.

## Quality of the reviewed literature

All except one of the articles identified for inclusion in this review used a cross-sectional design. Searches of published literature and key websites did not reveal any validated quality assessment tools specific to cross-sectional design, except one which was only available in Spanish <sup>28</sup>, and the strengthening of the reporting of observational studies in epidemiology (STROBE) guidance and checklist <sup>29, 30</sup>. The STROBE checklist evaluates the quality of reporting in studies, not the methodological quality. Following a

trial quality analysis using STROBE it was decided to pursue a more comprehensive quality analysis tool that included consideration of possible sources of bias in the results. Therefore, the Downs and Black <sup>31</sup> checklist (Appendix G) was used to assess quality of the articles included in this review. This checklist includes sections on reporting and quality, and has been tested on cross-sectional studies and found to have good inter-rater agreement for total scores and specific domains <sup>32</sup>.

Due to the studies mostly using cross sectional designs, not all the Downs and Black checklist items could be applied. For example, question 19, 'was compliance with the intervention/s reliable?' could not be applied, as there were no interventions in the cross sectional studies. However, the same set of 20 items was applied to each article. For the reporting section 9 out of 10 items were applied, for external validity 3 out of 3, for internal validity risk of bias 3 out of 7, for internal validity confounding 4 out of 6 and for power 1 out of 1 items were applied. All items had possible scores of 0 or 1 except for power, which had 0, 1, 2 or 3. The scores were calculated for each section of the Downs and Black checklist as well as an overall score (Appendix H). They were converted to percentages, by dividing the score by the total possible score for each section.

Scoring was completed following Downs and Black's recommendations with the exception of question 27 (Power). In order to assess the adequacy of study sample sizes and allocate a power score (0-3), minimum sample sizes were calculated using G\*Power  $^{33}$ , that would enable reliable detection of small, medium, and large effect sizes. These were calculated for the tests relevant to this review i.e. those at a subgroup level. The calculations were based on Cohen's rules of thumb  $^{34}$   $^{35}$  with a power of 0.8 and the  $\alpha$  error probability of 0.05. Power scores were allocated as detailed in Appendix I. For example, a study using a T-test to compare two NES subgroups, with a sample of 130

would score two, because its sample size is above the minimum (n=128) required to reliably detect a medium effect size using a T-test (table N.1).

The GRADE approach was then used to assess the quality of evidence across the studies <sup>36</sup>.

#### **Procedures**

Titles and abstracts were read for the articles identified from searches and references in other literature. Where there was any uncertainly about inclusion of an article, the full text of it was examined. Reasons for exclusion were recorded throughout, and a summary of the reasons for not including articles at each stage is provided in Figure 2 and Appendix J. The most common reasons for exclusion at the abstract reading stage were that the articles related to secondary data only (n=20), that they did not include subgroups (n=17) and that the subgroups were not formed based on psychological characteristics (n=16). Appendix K lists articles that were included in the full-text reading but not included in the final review, and the reasons for their exclusion.

Following the initial full text read, included articles were re-read in order to extract data and complete the quality analysis. The quality analysis is provided in Appendix H, and a sample of the summary data extraction table in Appendix L. Data were extracted from each article relating to the: country in which the research took place, type of setting, methodology, sample type, sample number, key exclusion criteria, measures used, number of subgroups identified, and author's subgroup labels. In addition, a short summary, and notes on strengths and weaknesses of the study were made.

Studies that used factor or cluster analysis were then grouped together and their results compared, by extracting data on psychological factors that differentiated the subgroups. This included Cohen's d effect sizes (d), and odds ratios (OR). Studies that split their sample of people with NESs based on predetermined categories were grouped according to the type of category they used. For example, all studies using presence or absence of trauma to split their sample into subgroups were analysed together. Where studies used categories common to two or more studies, the results of psychological characteristics showing a significant difference between the subgroups were extracted and compared. Where a study used more than one method or category to differentiate subgroups, it was included in the analysis for each. Where effect sizes were not reported, they were calculated if sufficient data were provided to do so. Calculation used equations provided by Field<sup>37</sup>. Attempts were made to contact authors who did not provide sufficient information to calculate effect sizes. In order to compare effect sizes across studies, Cohen's rules of thumb were used to identify small, medium, and large effect sizes for each statistic as detailed in appendix H. Odds ratios (OR) less than one were converted using 1/OR for ease of comparison. In factor analysis factor loadings greater than 0.4 (explaining more than 16% of the variance) were considered important<sup>37</sup>.

PRISMA reporting guidelines have been followed for this systematic review, and a PRISMA checklist<sup>38</sup> was completed (Appendix M).

## Results

All the studies except one used a cross sectional design. This one exception used an experimental design <sup>39</sup>. Eight (50%) of the studies investigated differences between means of psychological characteristics for the study subgroups <sup>27, 39-45</sup> and one used

logistic regression <sup>46</sup> to compare subgroup characteristics. Two studies noted they used correlational approaches <sup>27</sup> or regression analyses <sup>47</sup> subsequent to tests comparing means of subgroups. Five studies used cluster or factor analysis with other tests <sup>45, 48-51</sup> and two studies did not use any statistical tests <sup>52</sup> at the subgroup level. Table 2 summarises the studies included in this systematic review. It is notable that the studies were all located in Europe or the USA. Sample sizes ranged from 20<sup>52</sup> to 288<sup>46</sup> with a mean of 110 and a median of 65.5. A large number of measures related to psychological characteristics were used, with one article reported using 11 in the same study<sup>45</sup>.

#### Study Quality Analysis

Table 2 includes the total quality score as a percentage and summarises effect sizes for each article, for detailed scoring see appendix H. The quality of studies varied; out of a possible score of 22 on each paper, the median was 14 (64%), with a range from 8 (36%) to 18 (82%). The majority of studies (81%) scored 67% or more (6 out of a possible 9 points) on the reporting section. Internal validity, risk of bias, was a strength overall, with all except one study scoring 2 or 3 out of a possible 3 points, indicating that the studies clearly described their measures and used appropriate statistical tests. Eight of the 16 studies (50%) scored zero for external validity <sup>27, 40-42, 44, 45, 47, 52</sup>, largely due to samples taken from one specific specialist clinic and there being no information to help judge if the sample was representative of the entire population. None of the studies reported power calculations. Quality analysis of power indicated that none of the sample sizes were large enough to detect small effect sizes at the subgroup level. Four out of sixteen (25%) of the studies were able to detect a medium effect size or larger, four out of 16 (25%) were able to detect a large effect size or greater. Eight out of sixteen (50%) had insufficient power to detect a large effect size; two of these studies did not carry out any statistical tests at the subgroup level.

#### Effect sizes

Eight (50%) of the studies reported medium or large significant effect sizes for differences between subgroups on psychological characteristics (table 2). Three (19%) reported small to large effect sizes. These studies had comparatively large sample sizes (n=288<sup>46</sup>, 288<sup>41</sup>, 176<sup>43</sup>) and two of them appeared to use the same sample. It was not possible to calculate effect sizes for five (31%) studies because they did not do statistical tests at subgroup level or it was not possible to obtain sufficient data to

calculate effect sizes (table 2). Large effect sizes were reported for differences between subgroups in personality, mental health, learning disability, health related trauma experiences, cognitive functioning, and presence of environmental triggers. Medium effect sizes were reported for differences relating to personality measures, engagement in therapy, comorbid PTSD, comorbid epilepsy, trauma symptoms, somatization, and life complaints.

# Subgroups

The studies used methods that fell into nine different categories to identify subgroups in their samples of people who experienced NESs. These methods and the subgroups are summarised in table 3. In ten studies<sup>27, 39, 41-47, 53</sup> (63%) the subgroups were decided in advance based on characteristics or experiences known to be associated with NESs, for example, comparing people who have reported experiencing sexual abuse with those who have not <sup>43</sup>. These predetermined characteristics fell into seven categories, trauma, personality disorders, dissociation, mental health, cognitive functioning, daily hassles, and referral speed. The first five were used by more than one study and are explored in subsequent sections.

In five studies (31%), subgroups were identified through cluster or factor analysis <sup>45, 48-51</sup> (one of these also used predefined groups<sup>45</sup>). One study used a points scoring system linked to mental health to allocate people to subgroups<sup>40</sup> and in another article it was unclear how subgroup membership was decided<sup>52</sup>.

# <<INSERT TABLE 3>>

Trauma

Seven (47%) of the studies split their sample of people who experienced NESs into subgroups based on whether or not they had experienced trauma. Table 4 summarises psychological characteristics which showed significant differences (p<0.05) between these subgroups, full details are located in Appendix N. Most significant differences were reported in only one study each, but avoidant behaviour<sup>45</sup>, <sup>47</sup>, self-harm<sup>43, 46</sup>, and history of engaging with mental health support<sup>43, 47</sup> have each been reported in two studies, all of which were higher in subgroups who had reported experiencing trauma. Comorbid mood disorders or symptoms of mood difficulties associated with trauma experience have been reported in three studies<sup>43, 44, 47</sup>. The results indicated that those people with NESs who have experienced trauma, when compared to people with NESs who have not experienced trauma, had greater levels of personality difficulties (e.g. interpersonal difficulties  $d\approx 1.5^{45}$ ; tendency to blame  $d\approx 0.8$ <sup>45</sup>; demoralisation, sense of guilt, being a failure and helplessness d=0.80 <sup>47</sup>; and personality disorder diagnoses OR 7.9 43) and more mental health problems (e.g. selfharm OR 4.3 43, OR 3.3 46 and incidence of mood disorders 47, d=0.86, 44 OR 1.8 43). There were some indications that specific areas of cognitive functioning (processing speed d≈2 <sup>45</sup> and delayed verbal semantic memory d=1.1 <sup>42</sup>) were worse for those who had experienced trauma. It appeared that those people with NESs who had reported experiencing sexual abuse were less likely to have a learning disability OR 0.15  $(1/OR=6.67)^{46}$  or to have experienced health related trauma OR 0.09  $(1/OR=11.11)^{46}$ .

Bakvis at al.  $^{39}$  did not find any significant differences between patients, with (n=7) and without (n=11) a sexual trauma history. They did report results approaching significance (p=0.067), for differences in basal diurnal cortisol rates, which indicated

that for those who had experienced trauma, the body's stress system may have been more activated at baseline, suggesting they were hyper vigilant for dangers.

Overall power in this group was mixed. Two studies had sufficient power (0.8) to reliably detect medium or greater effect sizes, two large or greater, and three insufficient to reliably detect a large effect size (Appendix H).

<<INSERT TABLE 4>>

# Personality Disorders

Three of the studies split their sample of people who experienced NESs into subgroups based upon presence or absence of personality disorder <sup>44</sup>, or type of personality disorder <sup>52, 53</sup>. Magaudda et al. <sup>52</sup> and Harden et al. <sup>53</sup> did not report any statistical tests comparing the psychological characteristics of the subgroups. Baillés et al. <sup>44</sup> reported that scores on the Paranoia (d=1.4) and Mania (d=0.66) subscales of the MMPI were significantly higher (p<0.05) for those with personality disorders (effect size calculated, using the stated standard deviation for those who did not have a personality disorder diagnosis). All three of these studies scored zero in the power section of quality analysis indicating that the likelihood of them missing a large effect size or smaller (type two errors) was outside of accepted limits (0.2 or 20%).

## Dissociation

Two studies considered differences between subgroups based upon experiences of dissociation  $^{44,45}$ . Baillés et al.  $^{44}$  did not find any significant differences when comparing presence and absence of dissociative experiences. Bodde et al. (2013)  $^{45}$  reported significant differences, with medium effect size, between people having higher and lower dissociation tendency on measures of somatization (r=0.35, p=.027), life complaints (r=0.41, p=0.012) and tendency to blame others (r=0.33, p=0.042). Both these studies were underpowered as indicated by scoring zero in the power quality analysis.

## Mental Health

Two studies split their NES groups according to measures related to mental health. Bodde et al. (2013) 45 used scores above and below zero on the psychopathology

scale of the short MMPI, and found no significant differences between these two groups. Baslet, Roiko and Prensky  $^{40}$  reported that their subgroup labelled 'psychiatric burden' was significantly more likely to have experienced trauma than the 'neurological burden' (p=0.013, OR  $\infty$ ) or 'no burden' (p<0.001, OR  $\infty$ ) subgroups. The psychiatric burden group were also more likely to have a diagnosis of type B personality disorder than the neurological burden group (p=0.018, OR  $\infty$ ) or the no burden group (p=0.037, OR 10). The psychiatric burden group were significantly more likely to have 'cognitive complaints' than the no burden group (p=0.032, OR 6). These two studies had sufficient power to be likely to detect large and above effect sizes. Baslet et al.'s  $^{40}$  method for distinguishing subgroups was different to that used in other articles in that it involved a points system based on various symptoms or diagnoses agreed by the researcher clinicians.

## Cognitive functioning

Four studies split their sample of people with NESs into subgroups based on their level of cognitive function <sup>41, 45, 46, 52</sup>. The studies considered different factors and the only common single factor was the increased likelihood of seizures having an environmental trigger in people who have a learning disability (OR 20.83 <sup>46</sup>, OR 14.74 <sup>41</sup>). Details of differences found between subgroups in each study based on cognitive functioning are presented in Appendix O. Two of these studies had sufficient power to be likely to detect medium effect sizes <sup>41, 46</sup>, the other two insufficient to detect large sizes.

# Factor and cluster analysis

Table 5 provides a summary of the psychological factors that were reported to differ between subgroups identified through factor or cluster analysis; further details

are provided in Appendix P, Tables P.1 and P.2. The most common measures assessed either mental health  $^{48-50}$  or alexithymia  $^{48,\,49,\,51}$ . Analysis of power, in relation to ability to differentiate between subgroups, indicated that two of these studies had insufficient power to be likely to detect large effect sizes  $^{50,\,51}$ , one would be likely to detect large effect sizes and above $^{48}$  and the other medium effect sizes and above $^{49}$ .

<<INSERT TABLE 5>>

## **Discussion**

The purpose of this review was to establish how people who experience NESs have been split into subgroups, and what these subgroups' psychological characteristics indicate about NES aetiologies. The 16 reviewed studies have used methods falling into nine different categories to split their samples into subgroups. These methods included cluster analysis and predetermined characteristics, such as trauma experience. The studies compared their subgroups on a diverse range of psychological characteristics including cognitive abilities, mental health, coping strategies, and personality.

There were few significant findings for some methods of splitting the samples, such as those based on dissociation or personality disorder. However, the studies in these areas were all underpowered. Therefore, it is possible there were differences between subgroups that were not detected (type II errors).

There was congruence for some psychological characteristics between subgroups formed in more than one way. For example, when subgroups were formed based on presence or absence of trauma, three studies indicated that those who had experienced trauma had significantly more mental health problems (table 4), and when subgroups were formed based on presence or absence of mental health problems, Baslet et al. <sup>40</sup> reported that those with more mental health difficulties were more likely to have experienced trauma. Mental health and trauma experience were also differentiating factors in the studies that used factor or cluster analysis, although they were not considered together in any of the studies. These results were consistent with each other, and indicated that those people with NESs who report trauma experiences are likely to have worse mental health than those who do not. Two studies also indicated that experiences of trauma were associated with problematic coping strategies such as avoidant behaviour and blaming (table 4).

There is a degree of concordance between Bodde et al.'s<sup>18</sup> model (figure 1) and these subgroups with trauma experiences, increased mental health problems, and problematic coping strategies. Experiences of trauma (level 1 – psychogenic causation), are associated with increased mental health problems (level 2 – emotional 'make-up') and coping strategies that may maintain the NESs (level 5 – 'prolongation').

Contrarily, there were subgroups of people in the studies that assessed trauma, who were not reporting a history of trauma, appeared to have fewer mental health problems, fewer detrimental coping strategies and experience NESs. These subgroups would appear inconsistent with the psychodynamic theory of NES aetiology, which has proposed trauma as a causal factor. Possible reasons include: (1) Many of these people may have experienced some type of trauma but under reported it, or it may have been of a type not assessed by the measures used in the research. For example, the TEC used by Bakvis at al. <sup>39</sup>, and Bodde et al. (2013) <sup>45</sup> assessed sexual, physical and emotional trauma, but not health related trauma. (2) The aetiology of the subgroup(s) that did not report trauma could be different.

Duncan and Oto (2008a) <sup>46</sup> (n=288) identified that people who experienced NESs and reported having experienced sexual abuse (n=94) were less likely to have reported health related trauma. They also noted that health related trauma was not related to self-harm or other medically unexplained symptoms whereas sexual abuse was related to these factors. None of the other studies assessed medical trauma specifically except for Myers et al. (2014) <sup>42</sup> who reported that nine of their sample of people with NESs (n=66) had experienced medical trauma. Baillés et al. <sup>44</sup> may have included medical trauma as they included car accidents (n=3) and other traumas (n=4), in their sample (n=30). Myers et al. (2014) <sup>42</sup> and Baillés et al. <sup>44</sup> did not analyse differences between groups of people who had experienced different types of trauma. While we need to be

cautious drawing conclusions from a single study, Duncan and Oto's (2008a) <sup>46</sup> data may indicate that people who have developed NESs after experiencing health related trauma may have different psychological characteristics to those who have developed seizures following other types of trauma.

Many of the studies found significant differences on personality measures, such as alexithymia, shyness, and avoidant behaviour. It is difficult to compare the findings relating to personality across the different studies in the review due to the studies having used different measures, and different methods for identifying subgroups <sup>44, 45, 47, 49, 50</sup>. However, alexithymia and emotion regulation are closely related concepts<sup>54</sup>. Considering, emotion regulation and alexithymia together they are reported to show a significant difference between subgroups in three studies that used factor or cluster analysis (table 5). These findings indicate that alexithymia is an important area of difference between NES subgroups.

When Reuber, Pukrop, Bauer, Derfuss and Elger <sup>49</sup> made a comparison between their subgroups of patients with NESs and healthy controls, one subgroup, whom they described as similar to borderline personality disorder (n=43, 51% of sample), scored significantly higher on most measures of personality pathology. However, a second group (n=37, 44% of sample), whom they described as over-controlled, scored significantly lower or had no significant differences from healthy controls (n=100) on most measures (e.g. anxiousness, self-harm and suspiciousness), except for compulsivity, on which they scored significantly higher. Reuber et al. <sup>49</sup> suggested that this indicates a group that are over-controlled in their emotion regulation, perhaps separating themselves from their own feelings to an extent that they are unaware of them. Uliaszek, Prensky and Baslet <sup>48</sup> reported that one of their subgroups scored significantly lower than controls on some aspects of emotion regulation, which could be

consistent with Reuber et al.'s <sup>49</sup> suggestion of an over-controlled group. However, Brown et al. <sup>51</sup> reported slightly higher scores compared to epilepsy controls for their cluster with lower emotional dysregulation scores, although there was no significant difference. While we need to be cautious about these findings, future research should consider the possibility of a subgroup of people who are over-controlled or similar to normal in their emotion regulation, as part of NES aetiology. The aetiology of this group could be consistent with a psychodynamic perspective on NESs, that they are linked to repression of emotions. Whether or not some members of this subgroup have experienced trauma, which is also being repressed, and hence not reported, could be an avenue for future research.

Theoretically, alexithymia is related to disruption in childhood attachment relationships<sup>55</sup>. Cassidy suggested that emotion regulation style is an adaptive response that the child develops in relation to their caregiver's style of interaction<sup>55</sup>. For example, if the child is repeatedly rejected they minimise their emotions to avoid further rejection and decrease their need for emotional closeness. Childhood attachment may be disrupted by trauma or abuse, which prevents the child's emotions being contained and mirrored, a process proposedly essential to development of emotion regulation skills<sup>56</sup>. Therefore, it would be expected that there would be a relationship between trauma, attachment, and alexithymia for NES patients. This is not evident in this review. However, on further examination, none of the studies that measured trauma included specific alexithymia or emotion regulation measures. A related finding was that Uliaszek<sup>48</sup> reported scores on the CERQ blaming others scale were significantly higher (d=0.8) for those NES patients who had experienced trauma. This scale was described as representing an emotion regulation strategy. This indicates that relationships between trauma, attachment, and alexithymia warrants further study.

Studies that have used cognitive function to differentiate subgroups have shown little consensus, despite reports of many significant findings, and several having sufficient power to reliably detect medium effect sizes. This appears to be due to the studies examining a diverse range of psychological characteristics with few common to more than one study. In addition, people with intellectual disabilities account for a relatively small proportion of the overall NES sample (9% in Duncan and Oto's study<sup>41</sup>) and they were excluded from several studies (table 2); therefore, the available evidence is reduced.

Differences in cognitive abilities were reported in relation to subgroups formed by splitting based on trauma experience and factor or cluster analysis. Duncan and Oto (2008a) <sup>46</sup> indicated that reporting trauma was less likely for people who had a learning disability. This may be due to under reporting of traumas in people with learning disabilities, perhaps due to cognitive impairments and communication difficulties that make it difficult for them to do so, or it could mean that the aetiology is different for this group. Their aetiology may fit better with the behavioural model described in the introduction, aetiology section, which proposes that rather than having a psychogenic causation associated with trauma, NESs are a behaviour that is reinforced by the environment, including the responses of others. This would be consistent with the two studies that suggested seizures were more likely to have an environmental trigger in people who have a learning disability <sup>41,46</sup>.

Analysis of the reviewed articles suggests there is evidence for three subgroups of adults who experience NES: [1] A subgroup who have experienced trauma, elevated mental health difficulties, and more problematic coping strategies. This subgroup appears consistent with Bodde et al.'s <sup>18</sup> integrated model. [2] A subgroup with 'overcontrolled' emotion regulation, which may be consistent with a psychoanalytic model of

repression of emotion. [3] A subgroup who have intellectual disabilities and are more likely to have environmental triggers for NESs, consistent with a behavioural model.

## **Clinical Implications**

The above subgroups and associated models may be useful to help understand individual presentations. It is clear that the aetiology of NESs is complex. It is likely that more than one of these aetiologies could apply to any one individual, and that different treatments will be effective for different individuals. Therefore, comprehensive psychological assessment and formulation of each individual's circumstances will be vital to identifying appropriate treatment strategies. Recommendations for psychometrics to include in assessment are a trauma measure that includes health and other types of trauma as well as, sexual, physical, and emotional abuse; an alexithymia or emotion dysregulation measure; and possibly personality and adult attachment measures. Many of the measures used in the studies were very long and probably impractical to have as part of a battery for clinical use. For example, the MMPI-2 has 567 items. However, others such as the TAS-20 (20 items) and the DERS (36 items) may be more feasible. It is also suggested to include assessment of intellectual ability; mental health; coping strategies; and potential benefits that could maintain seizures.

Another important point in clinical practice is that the absence of trauma reporting does not exclude NESs. For some people the aetiology may not be related to trauma or it may be a type of trauma not targeted by most measures used clinically. For example, health related trauma is often not targeted by measures, as the questions usually focus on childhood trauma and sexual events, due to their hypothesised role in NES aetiology. It is therefore important that clinicians assess for a broad range of

traumas and recognise that presentations related to different types of trauma may be varied.

The aetiology of NESs may be consistent with a behavioural model for some people, and indicators for this may be presence of a learning disability, seizures linked to environmental triggers, and responses of others that reinforce the behaviour (probably inadvertently). Aetiology associated with over-controlling of behaviour and emotion, consistent with psychodynamic theory, may be indicated by near normal or lower than normal scores on emotional dysregulation or alexithymia measures, and fewer indicators of mental health distress.

Based on individual formulations, the suggestions for appropriate treatments outlined in the further research section below may be appropriate for research in a clinical setting.

## Strengths and Limitations of the reviewed literature

The variety of methods reviewed studies have used to form subgroups and the diverse range of psychological characteristics they have considered, made comparing psychological factors across the studies difficult and while there were many reported significant differences between subgroups, there appears to be little consensus. Part of the reason for this may be that some studies were measuring related factors but with different names. For example, the DERS, used to measure emotional dysregulation, contains a subscale about difficulties engaging in goal directed behaviours <sup>48</sup>, which may be similar to self-directedness in the TCI<sup>45</sup>.

Using the GRADE approach <sup>36</sup> the body of evidence reviewed was given a quality rating of low, indicating that there is risk of bias across the studies. Some studies found large effect sizes, which could have upgraded the quality rating, as they were strengths.

However, the inconsistency of results was a downgrading point; therefore, the standard rating of low quality for observational studies was allocated. One reason for inconsistency may be the differing inclusion criteria for the studies. For example, many of the studies excluded people who have learning disabilities and those who have comorbid ESs and NESs. Very few studies reported what proportions of people were excluded, which is a further limitation.

While many studies achieved high scores in their reporting and internal validity, power was a limitation as 50% of the studies scored zero in the power quality analysis. This means many differences between clusters may not have been detected. Most of the studies used small sample sizes, and tests of differences between means, which may make it difficult to represent the complexity of NES aetiology. This could be due to recruitment being a challenge, given that incidence is relatively low in the population, and treatment is via specialist clinics. Few of the studies examined the relationship between variables within clusters. External validity of the studies was a limitation, which has implications for the generalisability of findings from the review. This was often due to studies selecting a sample from one specific specialist clinic. This could be resolved in future research by recruiting across more than one clinic or research site.

## Strengths and limitations of this review

As Schwan, Hingray, Laprevote, Vignal, & Maillard <sup>57</sup> identified, NESs are important in both neurology and psychology. They suggested that research should be undertaken collaboratively across the two disciplines. The searches used in this review identified a range of articles that were aimed at neurologists, psychologists, psychologists, psychiatrists or any epilepsy practitioners. Therefore, it would have been preferable if

this literature review had been undertaken with the support of a neurologist. However, this was not possible within the study constraints.

A strength of this review was the systematic approach to reviewing the literature. A limitation is that it included only published literature, which is well known to be biased towards significant findings<sup>58,59</sup>. In addition, the review considered only the significant findings from the studies. This excluded results that may have contradicted significant findings or added to understanding by suggesting variables that are not related to each other. Given that, many of the studies were underpowered, there is a high likelihood of type two errors across this review. Therefore, a lack of significant findings in a particular area should not be interpreted as indicating that differences are not present. This recommendation is particularly relevant to the personality disorder and dissociation sections, due to all the studies in these sections being underpowered.

In future, it would be useful to consider qualitative findings to gain a greater depth of understanding about the aetiologies suggested by the quantitative research. For example, by exploring patient and/or clinician perspectives on how NESs have developed for individuals and relating this to NES theoretical models. However, before this could take place there would need to be more qualitative research in the area, as very few studies (n=5) were excluded from this review due to not being quantitative.

The quality analysis in this review lacked confirmation by a second rater; therefore, there is increased risk of bias in the results. A second reviewer will repeat a sample of the ratings and compare results prior to submitting the paper for publication.

In terms of the generalisability of the findings from this review, the studies include a range of samples from the USA and Europe, findings that were common to more than one study may be cautiously generalised in the USA and Europe. Further research would be necessary to establish generalisability outside this region. Many

studies excluded people with a dual diagnosis of epilepsy and NESs. Therefore, it would not be appropriate to generalise to this population.

## Further research

It would be useful for attempts to be made to develop consistency in research methods and measures for this area of research, so that results from different studies can be compared and contrasted more easily. As NES presentation is complex, it would be helpful if studies used larger sample sizes and sophisticated statistical techniques. This would enable the examination of the relationships between variables, within clusters, for example, using correlation or regression analyses.

Alexithymia and trauma experience were frequently indicated to differentiate subgroups and due to their theoretical link, it would make sense to consider both these factors in future research. These factors could be used to differentiate subgroups, perhaps using cluster analysis as this enables subgroups to be formed using more than one variable. Given the theoretical relationship between trauma, alexithymia, and attachment, it is suggested that an attachment measure should also be included in future research.

In order to identify appropriate treatments for NESs, as identified by Martlew et al. <sup>2</sup>, further research is needed. Given the possibility identified in this review that the aetiologies of NES subgroups may be consistent with different theoretical models, it is likely that research into treatments will need to consider subgroups that need different treatment approaches. Trans-diagnostic research regarding difficulties with alexithymia has found treatments, such as Dialectical Behavioural Therapy (DBT), improved emotion regulation and were successful <sup>60</sup>. This could be considered for people with NESs who report difficulties with emotion regulation.

Those people with who have trauma as a key part of their formulation may benefit from therapy such as CBT for trauma or EMDR. Baslet, Dworetzky, Perez, Dworetzky, and Oser <sup>61</sup> suggested that mindfulness-based therapy may be appropriate for people who experience NESs as it targets recognition and acceptance of emotional states. They completed a small (n=6) pilot with promising results in the reduction of seizure frequency. Further research could investigate the use of this therapy (which is also part of DBT) for those people whose aetiology includes overregulation of emotion. For people for whom a behaviour model of aetiology seems most appropriate, research may wish to focus on behaviourally based interventions, such as changing the environment, altering demands put on the person and positive reinforcement of behaviours other than the seizures.

## Conclusion

The literature covered a broad range of psychological characteristics associated with the aetiology of NESs. Many significant differences between subgroups of people who experienced NESs were reported, but there was a lack of consistency, which made it difficult to identify psychological characteristics of subgroups. However, there was evidence of a subgroup of people, who reported experiencing trauma, having more mental health problems, and problematic coping strategies, consistent with Bodde et al.'s <sup>18</sup> integrated model. Evidence for the characteristics of other subgroups is less clear. There is some indication of a group who have intellectual disabilities and are more likely to have environmental triggers for seizures, whose aetiology is more consistent with a behavioural model. There is also the possibility of a group that are over-controlled in their emotion regulation and behaviour, which may be linked to psychodynamic theories of NESs being linked to repression of emotion. Subgroups can

be formed using a variety of characteristics; trauma experience, alexithymia, and intellectual ability seem most likely to be effective and relevant to treatment. It is suggested that cluster or factor analysis of these measures is used to identify subgroups. The inconsistency and complexity of the reviewed empirical research indicates a complicated picture and the aetiologies discussed are unlikely to be mutually exclusive. This emphasises the importance of comprehensive assessment and formulation of people with NESs, in order to understand their individual aetiology, and treatment that is likely to be helpful. Alexithymia and trauma measures are likely to be informative in the formulation process.

Research involving larger samples, using consistent methods and measures capable of exploring relationships between variables, and qualitative research would be beneficial. It is suggested that research needs to consider how subgroups can be managed within the study design, prior to further investigation of their aetiology and efficacy of treatment strategies.

## References

- 1. Verrotti A, Pavone P, Agostinelli S, et al. Psychogenic non-epileptic seizures: A diagnostic problem difficult to solve in clinical practice. *Nöropsikiyatri Arşivi / Archives of Neuropsychiatry* 2012;49:243-247.
- 2. Martlew J, Baker GA, Goodfellow L, et al. Psychological and behavioural treatments for adults with non-epileptic attack disorder. *Cochrane Database of Systematic Reviews* 2014.
- 3. Stone J. Functional neurological symptoms. *J R Coll Physicians Edinb* 2011;41:38-41.
- 4. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 5th ed. ed: Washington, D.C.; London: American Psychiatric Association; 2013.
- 5. Jette N, Beghi E, Hesdorffer D, et al. Icd coding for epilepsy: Past, present, and future—a report by the international league against epilepsy task force on ICD codes in epilepsy. *Epilepsia* 2015;56:348-355.
- 6. Francis P, Baker GA. Non-epileptic attack disorder (NEAD): A comprehensive review. *Seizure* 1999;8:53-61.
- 7. Ahmedani BK, Osborne J, Nerenz DR, et al. Diagnosis, costs, and utilization for psychogenic non-epileptic seizures in a US health care setting. *Psychosomatics* 2013;54:28-34.
- 8. Cragar D, Berry D, Fakhoury T, et al. A review of diagnostic techniques in the differential diagnosis of epileptic and nonepileptic seizures. *Neuropsychol Rev* 2002;12:31-64.
- 9. Harden CL, Burgut FT, Kanner AM. The diagnostic significance of video-EEG monitoring findings on pseudoseizure patients differs between neurologists and psychiatrists. *Epilepsia* 2003;44:453-456.

- 10. Hoepner R, Labudda K, May TW, et al. Distinguishing between patients with pure psychogenic nonepileptic seizures and those with comorbid epilepsy by means of clinical data. *Epilepsy Behav* 2014;35:54-58.
- 11. Hubsch C, Baumann C, Hingray C, et al. Clinical classification of psychogenic nonepileptic seizures based on video-EEG
- analysis and automatic clustering. J Neurol Neurosurg Psychiatry 2011;82:955-960.
- 12. Ramchandani D, Schindler B. Evaluation of pseudoseizures: A psychiatric perspective. *Psychosomatics: J Consultation and Liaison Psychiatry* 1993;34:70-79.
- 13. Whitehead K, Kandler R, Reuber M. Patients' and neurologists' perception of epilepsy and psychogenic nonepileptic seizures. *Epilepsia* 2013;54:708-717.
- 14. Roberts NA, Reuber M. Alterations of consciousness in psychogenic nonepileptic seizures: Emotion, emotion regulation and dissociation. *Epilepsy Behav* 2014;30:43-49.
- 15. Feinstein A. Conversion disorder: Advances in our understanding. *Can Med Assoc J* 2011;183:915-919.
- 16. Li R, Li Y, An D, et al. Altered regional activity and inter-regional functional connectivity in psychogenic non- epileptic seizures. *Sci Rep* 2015;5:11635.
- 17. van der Kruijs SJ, Bodde NM, Vaessen MJ, et al. Functional connectivity of dissociation in patients with psychogenic non-epileptic seizures. *J Neurol Neurosurg Psychiatry* 2012;83:239-247.
- 18. Bodde NMG, Brooks JL, Baker GA, et al. Psychogenic non-epileptic seizures—definition, etiology, treatment and prognostic issues: A critical review. *Seizure* 2009;18:543-553.
- 19. Bodde NMG, Brooks JL, Baker GA, et al. Psychogenic non-epileptic seizures—diagnostic issues: A critical review. *Clin Neurol Neurosurg* 2009;111:1-9.

- 20. Fritzsche K, Baumann K, Götz-Trabert K, et al. Dissociative seizures: A challenge for neurologists and psychotherapists. *Deutsches Ärzteblatt International* 2013;110:263-268.
- 21. Dickinson P, Looper KJ. Psychogenic nonepileptic seizures: A current overview. *Epilepsia (Series 4)* 2012;53:1679-1689.
- 22. Reuber M, Mayor R. Recent progress in the understanding and treatment of nonepileptic seizures. *Curr Opin Psychiatry* 2012;25:244-250.
- 23. Cuthill FM, Espie CA. Sensitivity and specificity of procedures for the differential diagnosis of epileptic and non-epileptic seizures: A systematic review. *Seizure-Eur J Epilep* 2005;14:293-303.
- 24. Cherry GM, Dickson R. Defining my review question and identifying inclusion criteria. In: Boland A, Cherry GM, Dickson R, editors. *Doing a systematic review a student's guide*. Los Angeles, London, New Delhi, Singapore, Washington DC: SAGE; 2014. p. 17-34.
- 25. EBSCO. Psycinfo -- thesaurus EBSCO industries Inc.; 2016. Available at http://web.b.ebscohost.com.ezproxy.lancs.ac.uk/ehost/thesaurus?sid=8c93349d-1ddf-485b-9927-7e8bb95331cb%40sessionmgr114&vid=7&hid=116. Accessed March 22, 2016
- 26. Gerrig RJ, Zimbardo PG. Glossary of psychological terms: American Psychological Association; 2002. Available at https://www.apa.org/research/action/glossary.aspx. Accessed March 22, 2016
- 27. Bodde NMG, Lazeron RHC, Wirken JMA, et al. Patients with psychogenic non-epileptic seizures referred to a tertiary epilepsy centre: Patient characteristics in relation to diagnostic delay. *Clin Neurol Neurosurg* 2012;114:217-222.

- 28. Berra S, Elorza-Ricart JM, Estrada M-D, et al. A tool (corrected) for the critical appraisal of epidemiological cross-sectional studies. *Gaceta sanitaria / SESPAS* 2008;22:492.
- 29. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. *Lancet* 2007;370:1453.
- 30. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. *Ann Intern Med* 2007;147:W163.
- 31. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non- randomised studies of health care interventions. *J Epidemiol Community Health* 1998;52:377.
- 32. Alexander J, Josep ML, Jaume V. Suitability of three different tools for the assessment of methodological quality in ex post facto studies. *Int J Clin Health Psychol* 2012;12:97.
- 33. Faul F, Erdfelder E, Lang A-G, et al. G\* power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods* 2007;39:175-191.
- 34. Cohen J. Statistical power analysis. *Curr Dir Psychol Sci* 1992;1:98-101.
- 35. Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. *Communications in Statistics Simul Computation* 2010;39:860-864.
- 36. The Cochrane Collaboration. Cochrane handbook for systematic review of interventions, the GRADE approach 2011. Available at

- http://handbook.cochrane.org/chapter\_12/12\_2\_1\_the\_grade\_approach.htm.

  Accessed February 9, 2015
- 37. Field AP. *Discovering statistics using ibm spss statistics : And sex and drugs and rock* 'n' roll. 4th ed. ed: London : SAGE; 2013.
- 38. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta- analyses: The PRISMA statement. *Ann Intern Med* 2009;151:264.
- 39. Bakvis P, Spinhoven P, Giltay EJ, et al. Basal hypercortisolism and trauma in patients with psychogenic nonepileptic seizures. *Epilepsia* 2010;51:752-759.
- 40. Baslet G, Roiko A, Prensky E. Heterogeneity in psychogenic nonepileptic seizures: Understanding the role of psychiatric and neurological factors. *Epilepsy Behav* 2010;17:236-241.
- 41. Duncan R, Oto M. Psychogenic nonepileptic seizures in patients with learning disability: Comparison with patients with no learning disability. *Epilepsy Behav* 2008;12:183-186.
- 42. Myers L, Zeng R, Perrine K, et al. Cognitive differences between patients who have psychogenic nonepileptic seizures (PNESs) and posttraumatic stress disorder (PTSD) and patients who have PNESs without PTSD. *Epilepsy Behav* 2014;37:82-86.
- 43. Selkirk M, Duncan R, Oto M, et al. Clinical differences between patients with nonepileptic seizures who report antecedent sexual abuse and those who do not. *Epilepsia* 2008;49:1446-1450.
- 44. Baillés E, Pintor L, Fernandez-Egea E, et al. Psychiatric disorders, trauma, and MMPI profile in a spanish sample of nonepileptic seizure patients. *Gen Hosp Psychiatry* 2004;26:310-315.
- 45. Bodde NMG, van der Kruijs SJM, Ijff DM, et al. Subgroup classification in patients with psychogenic non-epileptic seizures. *Epilepsy Behav* 2013;26:279-289.

- 46. Duncan R, Oto M. Predictors of antecedent factors in psychogenic nonepileptic attacks: Multivariate analysis. *Neurology* 2008;71:1000-1005.
- 47. Myers L, Perrine K, Lancman M, et al. Psychological trauma in patients with psychogenic nonepileptic seizures: Trauma characteristics and those who develop PTSD. *Epilepsy Behav* 2013;28:121-126.
- 48. Uliaszek AA, Prensky E, Baslet G. Emotion regulation profiles in psychogenic nonepileptic seizures. *Epilepsy Behav* 2012;23:364-369.
- 49. Reuber M, Pukrop R, Bauer J, et al. Multidimensional assessment of personality in patients with psychogenic non-epileptic seizures. *J Neurol Neurosurg Psychiatry* 2004;75:743-748.
- 50. Cragar DE, Berry DTR, Schmitt FA, et al. Cluster analysis of normal personality traits in patients with psychogenic nonepileptic seizures. *Epilepsy Behav* 2005;6:593-600.
- 51. Brown RJ, Bouska JF, Frow A, et al. Emotional dysregulation, alexithymia, and attachment in psychogenic nonepileptic seizures. *Epilepsy Behav* 2013;29:178-183.
- 52. Magaudda A, Gugliotta SC, Tallarico R, et al. Identification of three distinct groups of patients with both epilepsy and psychogenic nonepileptic seizures. *Epilepsy Behav* 2011;22:318-323.
- 53. Harden CL, Jovine L, Burgut FT, et al. A comparison of personality disorder characteristics of patients with nonepileptic psychogenic pseudoseizures with those of patients with epilepsy. *Epilepsy Behav* 2009;14:481-483.
- 54. Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. *J Psychopathol Behav Assess* 2004;26:41-54.
- 55. Cassidy J. Emotion regulation: Influences of attachment relationships. *Monogr Soc Res Child Dev* 1994;59:228-249.

- 56. Bateman A, Fonagy P. *Mentalization-based treatment for borderline personality disorder*. Oxford: Oxford University Press; 2006.
- 57. Schwan R, Hingray C, Laprevote V, et al. How can we identify psychiatric morbidity in patients with psychogenic nonepileptic seizures? *Epilepsy Behav* 2012;23:507-507.
- 58. Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. *BMJ* 2000;320:1574.
- 59. Easterbrook PJ, Gopalan R, Berlin JA, et al. Publication bias in clinical research. *Lancet* 1991;337:867-872.
- 60. Neacsiu AD, Eberle JW, Kramer R, et al. Dialectical behavior therapy skills for transdiagnostic emotion dysregulation: A pilot randomized controlled trial. *Behav Res Ther* 2014;59:40-51.
- 61. Baslet G, Dworetzky BA, Perez DL, et al. Treatment of psychogenic nonepileptic seizures. *Clin EEG Neurosci* 2015;46:54-64.
- 62. Cohen J. A power primer. *Psychol Bull* 1992;112:155-159.
- 63. Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G\* power 3.1:

  Tests for correlation and regression analyses. *Behav Res Methods* 2009;41:11491160.
- 64. UCLA: Statistical Consulting Group. G\*power data analysis examples power analysis for two-group independent sample t-test 2015. Available at http://www.ats.ucla.edu/stat/gpower/indepsamps.htm Accessed October 2, 2015.
- 65. Asadi-Pooya AA, Emami M. Demographic and clinical manifestations of psychogenic non-epileptic seizures: The impact of co-existing epilepsy in patients or their family members. *Epilepsy Behav* 2013;27:1-3.

- 66. Asmussen SB, Kirlin KA, Gale SD, et al. Differences in self-reported depressive symptoms between patients with epileptic and psychogenic nonepileptic seizures. *Seizure* 2009;18:564-566.
- 67. Beghi M, Negrini P, Perin C, et al. Psychogenic non- epileptic seizures: So- called psychiatric comorbidity and underlying defense mechanisms. Neuropsychiatr Dis Treat2015. p. 2519-2527.
- 68. Brown MC, Levin BE, Ramsay RE, et al. Characteristics of patients with nonepileptic seizures. *J Epilepsy* 1991;4:225-229.
- 69. Duncan R, Oto M, Martin E, et al. Late onset psychogenic nonepileptic attacks.

  Neurology 2006;66:1644-1647.
- 70. Grimaldi I, Dubuc M, Kahane P, et al. Anxiety and depression in psychogenic movement disorder and non-epileptic seizures: A prospective comparative study. *Rev Neurol (Paris)* 2010;166:515-522.
- 71. Drake ME, Pakalnis A, Phillips BB. Neuropsychological and psychiatric correlates of intractable pseudoseizures. *Seizure-Eur J Epilep* 1992;1:11-13.
- 72. Hill SW, Gale SD. Neuropsychological characteristics of nonepileptic seizure semiological subgroups. *Epilepsy Behav* 2011;22:255-260.
- 73. Hubsch C, Baumann C, Maillard L. Psychogenic non- epileptic seizures: Clinical classification based on the video- EEG analysis of 145 seizures. *J Neurol* 2010;257:S176-S176.
- 74. Locke DC, Berry DR, Fakhoury T, et al. Relationship of indicators of neuropathology, psychopathology, and effort to neuropsychological results in patients with epilepsy or psychogenic non-epileptic seizures. *J Clin Exp Neuropsychol* 2006;28:325-340.

- 75. Martinović Ž. Dijagnostika i klasifikacija psihijatrijskih poremećaja u bolesnika s epilepsijom. = diagnosis and classification of psychiatric disorders in patients with pharmacoresistant epilepsy. *Psihijatrija Danas* 2000;32:115-128.
- 76. Pintor Pérez L, Pérez Domínguez G, Torres Mata X, et al. Psychiatric disorders, personality and traumatic experiences in conversive non- epileptic seizures patients. Actas españolas de psiquiatría 2002;30:233.
- 77. Reuber M, Jamnadas-khoda J, Broadhurst M, et al. Psychogenic nonepileptic seizure manifestations reported by patients and witnesses. *Epilepsia* 2011;52:2028-2035.
- 78. Rosenberg HJ, Rosenberg SD, Williamson PD, et al. A comparative study of trauma and posttraumatic stress disorder prevalence in epilepsy patients and psychogenic nonepileptic seizure patients. *Epilepsia* 2000;41:447-452.
- 79. Scévola L, Teitelbaum J, Oddo S, et al. Psychiatric disorders in patients with psychogenic nonepileptic seizures and drug-resistant epilepsy: A study of an argentine population. *Epilepsy Behav* 2013;29:155-160.
- 80. Nichols DS. *Essentials of MMPI-2 assessment [electronic resource]*. 2nd ed. ed: Hoboken, NJ: Wiley; 2011.
- 81. Wilson. Practical meta-analysis effect size calculator. Available at <a href="http://www.campbellcollaboration.org/escalc/html/EffectSizeCalculator-OR4.php">http://www.campbellcollaboration.org/escalc/html/EffectSizeCalculator-OR4.php</a>. Accessed November 13, 2015

# **Figures**




Figure 1. Bodde et al.'s 18 model of NESs




Figure 2. Summary of process for identifying articles included in the review

# **Tables**

Table 1. Main terms in the final search

Terms related to NESs	Term related to subgroups
Psychogenic, pseudo epileptic, functional, stress related, hysterical, psychosomatic, somatic, somatoform, somatization, dissociative, non-organic, conversion disorder, psycho-physiological, PNES	Subcategories, subgroups, distinct groups, clusters

Table 2. Summary of key characteristics and quality scores of included studies

First author, year & reference	Country	Sample	Measures used	Total Quality Score	Range of significant relevant effect sizes reported/calculated	For details see
Baillés (2004) <sup>44</sup>	Spain	30 NESs, comorbid ESs/ other neurological disorders excluded	MMPI, SCID	48%	d=0.66 to 1.4 (medium to large)	Appendix N and personality disorder section of results
Bakvis (2010) <sup>39</sup>	Netherlands	18 NESs, 19 healthy controls	TEC, cortisol and a- amylase levels	73%	Insufficient data to calculate relevant effect sizes.	
Baslet (2010) <sup>40</sup>	USA	44 NES patients split into 3 groups	BDI-II, Seizure characteristics and semiology, DFI, DES, medical/ neurological/ psychiatric history, PHQ- 15	76%	OR 6 to ∞ <sup>a</sup> (medium to large)	Mental health section of results
Bodde (2012) <sup>27</sup>	Netherlands	90 NESs included from age 12 years	History, seizure semiology	48%	Insufficient data to calculate relevant effect sizes.	

First author, year & reference	Country	Sample	Measures used	Total Quality Score	Range of significant relevant effect sizes reported/calculated	For details see
Bodde (2013) <sup>45</sup>	Netherlands?	40 NESs, excluded LD and major psychiatric comorbidity, appears to be from the same clinic as Bodde (2012) <sup>32</sup> , but unclear if there is any overlap in the samples.	CERQ, CVST, DIS-Q, EPCL, MMPI (short Dutch version), RPM, SDQ-20, TCI (short Dutch version), TMT, TEC, UCS,	62%	d=0.7 to 2 (medium to large) r=0.35 (medium)	Appendix N Appendix O
Brown (2013) <sup>51</sup>	UK	51 NESs, response rate of 18.7%, moderate/severe LD excluded	DERS, GAD-7, PHQ-9, RSQ, SDQ, TAS	67%	r= 0.49 to 0.67 (medium to large)	Appendix P, Table 0.2
Cragar (2005) <sup>50</sup>	USA	184 adults with NESs, 18 excluded due to comorbid epilepsy/ other diagnoses	Neuropsychological tests, medical history, MMPI-2, NEO-PI-R	62%	d=0.85 to 1.99 (large)	Appendix P, Table 0.2
Duncan (2008)a <sup>46</sup>	Scotland	288/289 NESs	Non-standard measures relating to history and characteristics	67%	OR 3.30 to 20.83 (small to large)	Appendix N, Appendix O
Duncan (2008)b <sup>41</sup>	Scotland	263 NESs without LD, 25 NESs with LD, appears to be same sample as Duncan (2008)a 40	Non-standard measures relating to history and characteristics	76%	OR 3.45 to 14.74 (small to large)	Appendix O
Harden (2009) <sup>53</sup>	USA	32 ESs, 16 NESs	SCID-II	57%	No statistical tests at subgroup level	

First author, year & reference	Country	Sample	Measures used	Total Quality Score	Range of significant relevant effect sizes reported/calculated	For details see
Magaudda (2011) <sup>52</sup>	Italy	20 NESs split into subgroups	Non-standard measures relating to cognitive function, seizure semiology and psychiatric co-morbidity	38%	No statistical tests at subgroup level	
Myers (2013) <sup>47</sup>	USA	61 NESs, IQ>70, Passed effort testing (TOMM)	Cognitive battery, MMPI- 2RF, TOMM	62%	OR 5.13 to 6.56 (medium to large) d= 0.78 to 3.6 (medium to large)	Appendix N
Myers (2014) <sup>42</sup>	USA	79 to 63 NESs, IQ>70, sample appears be largely comprised of same people as Myers (2013) 39	BNT, CVLT, CVMT, D- KEFS, MCI, TOMM, TSI-2, WASI, WMS-II	71%	d=0.57 to 1.75 (medium to large)	Appendix N
Reuber (2004) <sup>49</sup>	Germany	100 healthy controls, 64 ESs, 85 NESs	DAPP-BQ (German version)	71%	No statistical tests comparing subgroups to each other	
Selkirk (2008) <sup>43</sup>	Scotland	176 NESs, Comorbid ESs excluded	PNES severity scale	86%	OR 1.42 to 7.88 (small to large)	Appendix N
Uliaszek (2012) <sup>48</sup>	USA	70 NESs	History, DASS, DERS, DFI, PHQ-15, QOLIE-31, BDI- II, DES	81%	d=0.85 to 2.29 (large)	Appendix P, Table 0.2

d=Cohen's d,

BDI: Beck Depression Inventory,

BNT: Boston naming test,

CVLT: California verbal learning test, CVMT: continuous visual memory test, CVST: computerised visual searching task,

 $<sup>^{\</sup>rm a}$  Odds ratios calculated using 2 x 2 contingency tables

DAPP-BQ: Dimensional Assessment of Personality Pathology -

Basic Questionnaire,

DASS: depression, anxiety, and stress symptoms scale,

DERS: difficulties in emotion regulation scale,

DES: dissociative experiences scale,

DFI: disruption of functioning index,

DFI: disruption of functioning index,

DIS-Q: Dissociation Questionnaire,

D-KEFS: Delis-Kaplan executive function system,

EPCL: everyday problem checklist,

ESs: people who experience epileptic seizures,

GAD-7: generalised anxiety disorder,

LD: people who have a learning/intellectual disability,

MCI: memory complaint inventory,

MMPI: Minessota Multiphasic Personality Inventory,

NEO-PI-R: NEO Personality Inventory - Revised,

NESs: people who experience non-epileptic seizures,

PHQ: patient health questionnaire,

QOLIE-31: Quality of life in epilepsy inventory,

RPM: Raven's progressive matrices,

RSQ: relationship scales questionnaire,

SCID: structured clinical interview for DSM disorders,

SDQ: somatoform dissociation questionnaire,

TAS: Toronto alexithymia scale,

TCI: temperament and character inventory,

TEC: traumatic experiences checklist, BDI-II:

TMT: trail making test, UCS: Utrecht coping scale,

TOMM: test of memory malingering,

TSI: trauma symptom inventory,

UCS: Utrecht coping scale,

WAIS-R: revised Wechsler adult intelligence scale,

WASI: Wechsler abbreviated scale of intelligence,

WMS: Wechsler memory scale.

Table 3. Summary of subgroups described in the articles

Article first author and reference	Number of subgroups	Labels given to subgroups by the article authors
Baillés (2004)	2 in 3 different ways	Presence vs. absence of traumatic experiences; Presence vs. absence of personality disorder; Presence vs. absence of dissociative disorders
Bakvis (2010) <sup>39</sup>	2	PNES without sexual trauma vs. PNES with sexual trauma
Baslet (2010)	3	Psychiatric burden vs. neurological burden vs. no burden
Bodde (2012)	2	Active high-speed referral group vs. the rest of the group
Bodde (2013) <sub>45</sub>	2 in 5 different ways	Patients with no trauma vs. patients with trauma; Higher vs. lower dissociation tendency; Extremely high number of complaints on daily hassles vs. the remaining patients; Average of higher on RPM vs. below average; Psychopathology <0 vs. >0 on subscale psychopathology of the short MMPI; Psychotrauma subgroup vs. high vulnerability
	analysis	somatization subgroup vs. high vulnerability sensitive personality problem subgroup vs. high vulnerability somatization subgroup with a low cognitive level
Brown (2013)	2 by cluster analysis	High levels of emotional dysregulation and alexithymia vs. relatively normal dysregulation and alexithymia
Cragar (2005)	3 by cluster analysis	Depressed neurotic vs. somatic defender vs. activated neurotic
Duncan (2008)a <sup>46</sup>	3 suggested	Patients with sexual abuse vs. patients with LD vs. patients with health-related trauma
Duncan (2008)b <sup>41</sup>	2	Patients with LD vs. patients without LD
Harden (2009) <sup>53</sup>	6	Personality disorders types A, B, C in different combinations
Magaudda (2011) <sup>52</sup>	3 unclear how formed	Group 1 pharmacoresistant epilepsy, normal cognition, and comorbid anxiety and vs. or depressive disorders vs. group 2 patients, the epilepsy is associated with mental retardation and dependent personality traits vs. Group 3 patients have epilepsy, normal cognition, comorbid cluster B personality disorders and anxiety disorders, and psychic trauma

Article first author and reference	Number of subgroups	Labels given to subgroups by the article authors
Myers (2013) 47	2 in 2 different ways	With trauma history vs. without trauma history, PTSD likely vs. PTSD not likely
Myers (2014)	3	PTSD vs. trauma but not PTSD vs. no trauma or PTSD
Reuber (2004) <sup>49</sup>	4 by cluster analysis	Cluster 1, similar to borderline personality disorder vs. cluster 2, over controlled vs. cluster 3 similar to avoidant personality disorder vs. cluster 4, outlier
Selkirk (2008)	2	Sexual abuse history reported vs. no sexual abuse history reported
Uliaszek (2012) <sup>48</sup>	2 by cluster analysis	Highly emotion dysregulated vs. low emotion dysregulated

LD: Learning disability, PTSD: Post traumatic stress disorder

Table 4. Psychological characteristics showing a significant difference between subgroups, comparing people with NESs who have reported trauma with those who have not reported trauma experiences

Psychological characteristic	Baillés (2004) <sup>38</sup>	Bakvis (2010) <sup>30</sup>	Bodde (2013) <sup>37</sup>	Duncan (2008)a <sup>40</sup>	Myers (2013) <sup>39</sup>	Myers (2014) <sup>35</sup>	Selkirk (2008) <sup>36</sup>
Avoidant behaviour +			٧		٧		
Coping strategies involving blame +			٧				
Demoralisation, sense of guilt, being a failure and helplessness +					٧		
Shyness or interpersonal difficulties +			٧				
Self-directedness -			٧				
Self-harm +				٧			٧
Health related trauma -				٧			
Incidence of bipolar or mood disorders or symptoms +	٧				٧		٧
Incidence of PTSD or symptoms of trauma +					٧		
Incidence of personality disorder diagnosis +							٧
History of engaging in psychotherapy or referral to mental health services +					٧		٧
Processing speed -			٧				
Delayed verbal semantic memory function -						٧	
Self-reported memory difficulties +						٧	
Presence of learning disability -				٧			

<sup>+:</sup> factor is increased with experience of trauma, -: factor is decreased with experience of trauma, √: study found a significant difference

1-61

Table 5. Summary of psychological factors upon which differences between clusters were indicated in each article using cluster or factor analysis

	Bodde (2013) <sup>37</sup>	Cragar (2005) <sup>44</sup>	Reuber (2004) <sup>42</sup>	Brown (2013) <sup>43</sup>	Uliaszek (2012) <sup>41</sup>
Experiences of trauma	٧				
Reporting of everyday problems	٧				٧
Self-blame	٧				
Somatization	٧				
Emotional dysregulation or alexithymia			٧	٧	٧
Interpersonal difficulties or avoidance			٧		
Mental health (depression, paranoia, obsessive compulsive, mania, psychosis)		٧	٧		٧
Cognitive abilities (processing speed, memory, IQ,)	٧	٧			



### SEIZURE - EUROPEAN JOURNAL OF EPILEPSY

**AUTHOR INFORMATION PACK** 

#### **TABLE OF CONTENTS**

•	Description	p.1
•	Audience	p.1
•	Impact Factor	p.1
•	Abstracting and Indexing	p.2
•	<b>Editorial Board</b>	p.2
•	Guide for Authors	p.4

**ISSN:** 1059-1311

#### **DESCRIPTION**

Seizure - European Journal of Epilepsy is an international journal owned by Epilepsy Action (the largest member led epilepsy organisation in the UK). It provides a forum for papers on all topics related to **epilepsy** and **seizure disorders**.

Seizure focuses especially on **clinical** and **psychosocial** aspects, but will publish papers on the basic sciences related to the condition itself, the differential diagnosis, natural history and epidemiology of **seizures**, as well as the investigation and practical management of seizure disorders (including drug treatment, neurosurgery and non-medical or behavioural treatments).

The journal reflects the social and psychological burden and impact of the condition on people with epilepsy, their families and society at large, and the methods and ideas that may help to alleviate the disability and stigma, which the condition may cause. The journal aims to share and disseminate knowledge between all disciplines that work in the field of epilepsy.

#### **AUDIENCE**

Epileptologists, neurologists, epilepsy specialist nurses, clinical neurophysiologists, pharmacologists, psychiatrists.

#### **IMPACT FACTOR**

2013: 2.059 © Thomson Reuters Journal Citation Reports 2014

#### ABSTRACTING AND INDEXING

CINAHL

Current Contents / Clinical Medicine MEDLINE® EMBASE

Neuroscience Citation Index

Psych INFO, SciSearch, MEDLARS Psychology Abstracts

Research Alert E-psyche Scopus

#### **EDITORIAL BOARD**

#### Editor-in-Chief:

M. Reuber, MD PhD FRCP, Adult Neurologist, Sheffield, UK

Improving the differential diagnosis of epilepsy and other seizure disorders

#### Associate Editors:

C.A. Helmstaedter, Neuropsychologist, Bonn, Germany

Cognition, behaviour, personality, and psychosocial aspects in epilepsy (children and adults)

W.P. Liao, Adult Neurologist, Guangzhou, China

Genetics of epilepsy

T. Loddenkemper, Paediatric Neurologist, Boston, MA, USA

Comparative effectiveness and interventional clinical trials in pediatric status epilepticus and epileptic encephalopathies

#### Social Media Editor:

R. Thomas, Adult Neurologist, Cardiff, UK

The genetic basis of the epilepsies

#### Editorial Board:

N.S. Abend, Pediatric Neurologist, Philadelphia PA USA

G. Baker, Liverpool, UK

S. Beyenburg, Adult neurologist, Luxembourg, Luxembourg

M. Brodie, General physician and clinical pharmacologist, Glasgow, UK

J. Carrizosa Moog, Child Neurologist, Medellin, Colombia

J.J. Craig, Belfast, UK

**B. Diehl**, London, England, UK

O. Dulac, Paris, France

J.S. Duncan, Professor of Neurology, UCL Institute of Neurology

Consultant Neurologist, National Hospital for Neurology and Neurosurgery

Divisional Clinical Director, Queen Square Division, UCLH NHS Foundation Trust, London, UK

C.E. Elger, Bonn, Germany

A. Gil-Nagel, Neurologist. Adult and pediatric epilepsy, Madrid, Spain

R. Guerrini, Firenze, Italy

**L. Gueye**, Dakar, Senegal

L.M.F.F. Guilhoto, San Paulo, Brazil

M. Johnson, London, UK

P. Kwan, Shatin, Hong Kong

K. Malmgren, Adult neurologist, Gothenburg, Sweden

Biological markers for treatment and outcomes of epilepsy

A. Martins da Silva, Professor, Adult Neurologist and Neurophysiologist, Porto, Portugal

R. Matsumoto, Kyoto, Japan

A. Mazarati, Los Angeles, California, USA

```
D.R. Nordli, Chicago, Illinois, USA
M. Oto, Glassgow, Scotland, UK
Ç. Özkara, İstanbul, Turkey
E. Perucca, Adult neurologist, Pavia, Italy
M. Privitera, MD, Professor of Neurology, Cincinnati, Ohio, USA
S.C. Schachter, Adult neurologist, Boston, Massachusetts
D. Schmidt, Berlin, Germany
A. Schulze-Bonhage, Professor of Neurology and Neurophysiology and head of the Epilepsy
Center at the
University Hospital Freiburg, Germany
J.M. Serratosa, Madrid, Spain
M.L. Sillanpää, Turku, Finland
H. Stefan, Adult neurologist, Erlangen, Germany
T. Syed, Cleveland, Ohio, USA
P. Tinuper, Adult neurologist, Bologna, Italy
J. Wilmshurst, Paediatric Neurologist, Cape Town, South Africa
(related to epilepsy):
P. Wolf, Neurologist consultant at Danish Epilepsy Centre Filadelfia, Dianalund, Denmark
Guest researcher, Federal University of Santa Catarina, Florianópolis, Brasil
Peter & Jytte Wolf Foundation for Epilepsy, Bielefeld, Germany
E. M. T. Yacubian, Adult and Pediatric Neurologist, São Paulo, Brazil
D. Zhou, Chengdu Sichuan, China
```

#### GUIDE FOR AUTHORS

#### Your Paper Your Way

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

To find out more, please visit the Preparation section below.

#### INTRODUCTION

#### Types of articles

Seizure - European Journal of Epilepsy publishes the following types of article:

#### 1.1 Peer-reviewed articles a. Full reviews.

Seizure welcomes comprehensive reviews on all subjects relating to epilepsy and other seizure disorders. Authors planning/proposing are invited to discuss their ideas with Editor-in-Chief prior to submission. Full reviews should be preceded by an abstract. Full reviews should not exceed 7,000 words, include no more than 6 figures or tables and 150 references.

#### b. Focused reviews.

Seizure is keen to publish focused reviews, especially on the latest developments in particular fields or on topics which are currently debated by clinicians and researchers. Authors are welcome to approach the Editor-in-Chief with their idea for a focused review prior to submission. Focused reviews should be preceded by an abstract. Focused reviews should be 1,500-2,500 words, and include no more than 3 figures or tables and 50 references.

#### c. Full-length original research articles.

The body of the text of these articles should be limited in length to 4,000 words, and there should be a maximum of 6 figures or tables. Additional figures, tables and other material (such as associated videos) can be submitted as online only Supporting Information (see section 'preparation of manuscripts' for further details). Full length research articles should be preceded by an abstract. The body of the text of the article should be clearly structured into 1) Introduction, 2) Methods 3) Discussion, 4) Conclusion and 5) References.

#### d. Short communications.

Comprise a number of different kinds of previously unpublished materials including short reports or small case series. Short communications should be preceded by an abstract. The body of the text is limited to 1,400 words. There are no more than 12 references, and 2 figures or tables (combined).

e. Case reports (Clinical Letters), see also Interactive Case Insights below Seizure will also publish particularly instructive case reports in the format of Clinical Letters. Clinical Letters will not be preceded by an abstract. The word count is limited to 1,000 words. Clinical Letters can only include a maximum of 4 references and 2 figures or tables (combined), authors may include additional reading as supplementary material.

#### f. Letters to the Editor

Letters containing critical assessment of papers recently published in the Seizure -European Journal of Epilepsy will be considered for publication in the correspondence section. Letters should not exceed

1,000 words including references as necessary, one table or one figure. Letters should be typed in double spacing, should have a heading and no abbreviations. If related to a previously published article, the article should be identified by title, author(s), and

volume/page numbers. All letters are subject to editorial review. At the Editor's discretion, a letter may be sent to authors of the original paper for comment, and both letter and reply may be published together.

#### 1.2 Editorially-reviewed material

Other contributions than original research or review articles will be published at the discretion of the Editor-in-Chief, with only editorial review. Such material includes: obituaries, workshop reports and conference summaries, letters/commentary to the Editors (500 word limit, exceptionally including figures or tables), special (brief) reports from ILAE Commissions or other working groups, book reviews and announcements.

#### 1.3 Supplements / Special Editions

The Editor-in-Chief invites ideas for supplements or special editions of Seizure including meeting abstracts. Such materials may be published, but only after prior arrangement with the Editor-in-Chief. Supplements will incur a charge. The page rate for proposed supplements can be negotiated with the Editor-in- Chief. Special editions are issues of Seizure wholly or partially dedicated to one particular topic. They may be edited or coedited by internationally recognised experts in their field. Such experts do not need to be members of the Editorial Board of Seizure and are welcome to approach the Editor- in-Chief with their ideas. Special editions of Seizure would be expected to contain the same kind of manuscripts which are published in normal editions.

#### Interactive Case Insights

The journal encourages authors to complement their Clinical Letters test questions that reinforce the key learning points. These author created questions are submitted along with the article (new or revised) and will be made available in ScienceDirect along with your paper. More information and examples are available at http://www.elsevier.com/about/content-innovation/interactivecase-insights. Test questions are created online at http://elsevierapps.sciverse.com/GadgetICRWeb/verification. Create the test questions, save them as a file to your desktop, and submit along with your (new or revised) manuscript through EES. That's it! For questions, please contact icihelp@elsevier.com.

#### **BEFORE YOU BEGIN**

#### Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journalauthors/ethics.

#### Conflict of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at:

http://help.elsevier.com/app/answers/detail/a\_id/286/p/7923.

#### Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see http://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of

the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <a href="http://www.elsevier.com/editors/plagdetect">http://www.elsevier.com/editors/plagdetect</a>.

#### Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author, will be forwarded by the Journal Manager to the corresponding author,

must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

#### Article transfer service

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information about this can be found here: http://www.elsevier.com/authors/article-transfer-service.

#### Copyright

This journal offers authors a choice in publishing their research: Open access and Subscription.

#### For subscription articles

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <a href="http://www.elsevier.com/copyright">http://www.elsevier.com/copyright</a>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <a href="http://www.elsevier.com/permissions">http://www.elsevier.com/permissions</a>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <a href="http://www.elsevier.com/permissions">http://www.elsevier.com/permissions</a>.

#### For open access articles

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see

http://www.elsevier.com/OAauthoragreement). Permitted reuse of open access articles is determined by the author's choice of user license (see http://www.elsevier.com/openaccesslicenses).

#### Retained author rights

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see http://www.elsevier.com/journal-authors/author-rights-and-responsibilities. Open access articles please see http://www.elsevier.com/OAauthoragreement.

#### Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

#### Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more existing agreements and policies please http://www.elsevier.com/fundingbodies.

This journal offers authors a choice in publishing their research:

#### Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (http://www.elsevier.com/access)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA): for non- commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non- commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Elsevier established funding has agreements with bodies, http://www.elsevier.com/fundingbodies. This ensures authors can comply with funding body open access requirements, including specific user licenses, such as CC BY. Some authors may also be reimbursed for associated publication fees. If you need to comply with your funding body policy, you can apply for the CC BY license after your manuscript is accepted for publication.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The open access publication fee for this journal is \$2,200, excluding taxes. Learn more about

Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.

#### Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language available Elsevier's WebShop Editina service from (http://webshop.elsevier.com/languageediting/) or visit our customer support site (http://support.elsevier.com) for more information.

#### Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals, http://www.elsevier.com/patient-consentpolicy. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

#### Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Please submit article via http://ees.elsevier.com/seizure/ your

#### Referees

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our Support site. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

#### **PREPARATION**

#### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or lay- out that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

#### References

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article

by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

#### Formatting requirements

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

#### Figures and tables embedded in text

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

#### REVISED SUBMISSIONS

#### Use of word processing software

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with http://www.elsevier.com/quidepublication). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

#### Article structure

#### Subdivision - unnumbered sections

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross- referencing text: refer to the subsection by heading as opposed to simply 'the text'.

#### Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

#### Material and methods

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

#### Theory/calculation

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

#### Results

Results should be clear and concise.

Only in case of short communications, the results and discussion sections may be combined. Results should usually be presented in graphic or tabular form, rather than discursively. There should be no duplication in text, tables and figures. Experimental conclusions should normally be based on adequate numbers of observations with statistical analysis of variance and the significance of differences. The number of individual values represented by a mean should be indicated.

#### Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Speculative discussion is not discouraged, but the speculation should be based on the data presented and identified as such.

In most cases a discussion of the limitations is appropriate and should be included in this section of the manuscript.

#### Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

#### **Appendices**

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

#### Essential title page information

- Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.
- Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

#### Correct author name format

To prevent confusion please ensure that all author names are listed in the following format; first (Christian) name first and the last name (Surname/Family) last. This is specified because Spain, China and some other countries often write them differently and this causes confusion with databases like MEDLINE.

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must defined their first mention the

Abstracts (when required) should be structured, using the subheadings purpose, methods, results, conclusion. They should be no longer than 250 words. Case reports (Clinical Letters) do not need to be preceded by an abstract.

#### Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531  $\times$  1328 pixels (h  $\times$  w) or proportionally more. The image should be readable at a size of 5  $\times$ 

13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See http://www.elsevier.com/graphicalabstracts for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: Illustration Service.

#### **Highlights**

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <a href="http://www.elsevier.com/highlights">http://www.elsevier.com/highlights</a> for examples.

Please note that the *Highlights* section above only applies to **Full Length Articles** and **Reviews**.

#### Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eliqible. These keywords will be used for indexing purposes.

#### **Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

#### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

#### Nomenclature and units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to consult IUPAC: Nomenclature of Organic Chemistry: <a href="http://www.iupac.org/">http://www.iupac.org/</a> for further information.

#### Database linking

Elsevier encourages authors to connect articles with external databases, giving their readers one- click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <a href="http://www.elsevier.com/databaselinking">http://www.elsevier.com/databaselinking</a> for more information and a full list of supported databases.

#### Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

#### **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

#### Artwork Electronic artwork General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files. A detailed guide on electronic artwork is available on our website: http://www.elsevier.com/artworkinstructions.

## You are urged to visit this site; some excerpts from the detailed information are given here.

#### **Formats**

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi. TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

#### Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

#### Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. For further information on the preparation of electronic artwork, please see

http://www.elsevier.com/artworkinstructions.

Please note: Because of technical complications that can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

#### Figure captions

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### Text graphics

Text graphics may be embedded in the text at the appropriate position. See further under Electronic artwork.

#### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

#### References

#### Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or

'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

#### Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

#### References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

#### Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

#### Reference style

*Text:* Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

*List:* Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

#### Examples:

Reference to a journal publication:

- [1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun
- 2010;163:51–9. Reference to a book:
- [2] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000. Reference to a chapter in an edited book:
- [3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith
- RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304.

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first

6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also http://www.nlm.nih.gov/bsd/uniform\_requirements.html).

#### Journal abbreviations source

Journal names should be abbreviated according to the List of Title Word Abbreviations:

http://www.issn.org/services/online-services/access-to-the-ltwa/.

#### Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version products. article Elsevier Web includina ScienceDirect: vour http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For please more detailed instructions visit our video instruction http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

#### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <a href="http://www.elsevier.com/audioslides">http://www.elsevier.com/audioslides</a>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

#### Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high- resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <a href="http://www.sciencedirect.com">http://www.sciencedirect.com</a>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <a href="http://www.elsevier.com/artworkinstructions">http://www.elsevier.com/artworkinstructions</a>.

#### 3D neuroimaging

You can enrich your online articles by providing 3D neuroimaging data in NIfTI format. This will be visualized for readers using the interactive viewer embedded within your article, and will enable them to: browse through available neuroimaging datasets; zoom, rotate and pan the 3D brain reconstruction; cut through the volume; change opacity and color mapping; switch between 3D and

2D projected views; and download the data. The viewer supports both single (.nii) and dual (.hdr and .img) NIfTI file formats. Recommended size of a single uncompressed dataset is 100 MB or less. Multiple datasets can be submitted. Each dataset will have to be zipped and uploaded to the online submission system via the '3D neuroimaging data' submission category. Please provide a short informative description for each dataset by filling in the 'Description' field when uploading a dataset. Note: all datasets will be available for downloading from the online article on ScienceDirect. If you have concerns about your data being downloadable, please provide a video instead. For more information see: http://www.elsevier.com/3DNeuroimaging.

#### Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes) Further considerations
- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge)

and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print

• If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at <a href="http://support.elsevier.com">http://support.elsevier.com</a>.

#### **AFTER ACCEPTANCE**

#### Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

http://dx.doi.org/10.1016/j.physletb.2010.09.059

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

#### Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less errorprone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

#### **Offprints**

The corresponding author, at no cost, will be provided with 25 free paper offprints, or, alternatively, a personalized link providing 50 days free access to the final published version of the article on ScienceDirect. This link can also be used for sharing via email and social networks. For an extra charge, more paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (http://webshop.elsevier.com/myarticleservices/booklets).

#### **AUTHOR INQUIRIES**

You can track your submitted article at

http://help.elsevier.com/app/answers/detail/a\_id/89/p/8045/. You can track your accepted article at http://www.elsevier.com/trackarticle. You are also welcome to contact Customer Support via http://support.elsevier.com.

© Copyright 2014 Elsevier | http://www.elsevier.com

### Appendix B. Journal Highlights

- Published empirical research has split NES patients into subgroups in nine ways
- Subgroups indicated behavioural, psychodynamic, and integrated models
- Individual psychological assessment and formulation is recommended
- Future research should take account of subgroups within the NES sample
- Measures of alexithymia, trauma, and attachment are likely to be useful

## Appendix C. Developing the research question

## Table C.1

<b>PICO</b>	anal	vsis

1 100 analysis	
Review Question	How have researchers split people who experience NESs into subgroups and what does this reveal about the psychological mechanisms of NES aetiology?
Population	Adults who experience NESs
Intervention	Measurement of psychological factors including trauma history
Comparator	Comparison between subgroups, or subgroups and overall group or controls
Outcomes	Psychological characteristics
Setting	Any setting
Study design	Primary quantitative research

## Appendix D. Search terms

#### Table D.1

#### **Final Search Terms**

Terms related to NESs

# Term related to subcategories

#### Part 1:

Psychogenic non-epileptic seizures, Psychogenic non epileptic seizures, psychogenic nonepileptic seizures, pseudoepileptic seizures, pseudo epileptic seizures, non-epileptic seizures, non epileptic seizures, nonepileptic seizures, functional seizures, pseudo seizures, stress related seizures, stress-related seizures, st

#### Part 2:

Psychogenic non-epileptic attacks, Psychogenic non epileptic attacks, psychogenic nonepileptic attacks, pseudoepileptic attacks, pseudoepileptic attacks, pseudo epileptic attacks, non-epileptic attacks, non epileptic attacks, nonepileptic attacks, functional attacks, pseudo attacks, stress related attacks, stress-related attacks, stress-related attacks, stress-related attacks, psychosomatic attacks, psychogenic attacks, hysterical attacks, psychosomatic attacks, somatic attacks, somaticattacks, somatization attacks, somatization attacks, non-organic attacks, non-organic attacks, nonorganic attacks, conversion disorder AND attacks, psycho-physiological attacks, psycho physiological attacks. Part 3:

Psychogenic non-epileptic convulsions, Psychogenic non epileptic convulsions, psychogenic nonepileptic convulsions, pseudoepileptic convulsions, pseudo epileptic convulsions, nonepileptic convulsions, nonepileptic convulsions, functional convulsions, pseudo convulsions, stress related convulsions, stress-related convulsions, stressrelated convulsions, psychogenic convulsions, hysterical convulsions, psychosomatic convulsions, somatic convulsions, somatoform convulsions, somatization AND convulsions, somatisation AND convulsion, dissociative convulsions, non-organic convulsions, non organic convulsions, psycho-physiological convulsions, psychophysiological convulsions, psychophysiological convulsions, psychophysiological convulsions, pseudoseizures, PNES

Subcategories, subcategories, sub categories, subgroups, sub-groups, distinct groups, sub groups, cluster, clusters, clustering

Where AND terms were nested within the search terms, these were placed in brackets then the search terms were combined into sets using 'OR'.

## Appendix E. Inclusion and exclusion criteria

### Table E.1

Inclusion and exclusion criteria

Inclusion Critoria	Doint applied
Inclusion Criteria	Point applied
Available in English	Search engine, abstract and full text
	reading
Peer reviewed	Search engine
Non-epileptic seizures as main topic	Abstract or full text if unclear
Relates to subgroups of people who	Abstract or full text if unclear
experience NESs based on psychological	
characteristics including trauma history	
Quantitative primary research	Abstract or full text if unclear
Exclusion Criteria	
Includes only secondary data	Abstract or full text if unclear
Relates to NESs in children only	Abstract or full text if unclear
Considers only demographic subgroups	Abstract or full text if unclear

# Appendix F. Included and excluded psychological characteristics Table F.1

Clarification of included and excluded characteristics

Included	Not included
All personality measures	Gender
Emotion processing	Seizure semiology (appearance and features)
Adult attachment style	Childhood attachment style
Intelligence	Comorbid diagnosis of Epilepsy
Measures of anxiety, depression or other distress	Medication
Current mental health diagnosis	Age of onset
Trauma history	

#### Appendix G. Downs & Black checklist

Checklist for measuring study quality

#### Reporting

1. Is the hypothesis/aim/objective of the study clearly described?

yes	1
no	0

 Are the main outcomes to be measured clearly described in the Introduction or Methods section?

If the main outcomes are ®rst mentioned in the Results section, the question should be answered no.

yes	1
no	0

3. Are the characteristics of the patients included in the study clearly described?
In cohort studies and trials, inclusion and/or exclusion criteria should be given. In casecontrol studies, a case-de®nition and the source for controls should be given.

yes	1
no	0

4. Are the interventions of interest clearly described?

Treatments and placebo (where relevant) that are to be compared should be clearly described.

yes	1
no	0

5. Are the distributions of principal confounders in each group of subjects to be compared clearly described?

A list of principal confounders is provided.

yes	2
partially	1
no	0

6. Are the main ®ndings of the study clearly described?

Simple outcome data (including denominators and numerators) should be reported for all major ®ndings so that the reader can check the major analyses and conclusions. (This question does not cover statistical tests which are considered below).

yes	1
no	0

7. Does the study provide estimates of the random variability in the data for the main outcomes? In non normally distributed data the interquartile range of results should be reported. In normally distributed data the standard error, standard deviation or con®-dence intervals should be reported. If the distribution of the data is not described, it must be assumed that the estimates used were appropriate and the question should be answered yes.

yes	1
no	0

8. Have all important adverse events that may be a consequence of the intervention been reported?

This should be answered yes if the study demonstrates that there was a comprehen-sive attempt to measure adverse events. (A list of possible adverse events is provided).

yes	1
no	0

9. Have the characteristics of patients lost to follow-up been described?

This should be answered yes where there were no losses to follow-up or where losses to follow-up were so small that ®ndings would be unaVected by their inclusion. This should be answered no where a study does not report the number of patients lost to follow-up.

yes	1
no	0

10. Have actual probability values been reported(e.g. 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001?

yes	1
no	0

#### External validity

All the following criteria attempt to address the representativeness of the ®ndings of the study and whether they may be generalised to the population from which the study subjects were derived.

11. Were the subjects asked to participate in the study representative of the entire population from which they were recruited?

The study must identify the source population for patients and describe how the patients were selected. Patients would be representative if they comprised the entire source population, an unselected sample of consecutive patients, or a random sample. Random sampling is only feasible where a list of all members of the relevant

population exists. Where a study does not report the proportion of the source population from which the patients are derived, the question should be answered as unable to determine.

yes	1
no	0
unable to determine	0

12. Were those subjects who were prepared to par-ticipate representative of the entire population from which they were recruited? The proportion of those asked who agreed should be stated. Validation that the sample was representative would include demonstrating that the distribution of the main confounding factors was the same in the study sample and the source popula-tion.

yes	1
no	0
unable to determine	0

13. Were the staV, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive?

For the question to be answered yes the study should demonstrate that the intervention was representative of that in use in the source population. The question should be answered no if, for example, the intervention was undertaken in a specialist centre unrepresentative of the hospitals most of the source population would attend.

yes	1
no	0
unable to determine	0

Internal validity - bias

14. Was an attempt made to blind study subjects to the intervention they have received?

For studies where the patients would have no way of knowing which intervention they received, this should be answered yes.

yes	1
no	0
unable to determine	0

15. Was an attempt made to blind those measuring the main outcomes of the intervention?

yes	1
no	0
unable to determine	0

16. If any of the results of the study were based on "data dredging", was this made clear?

Any analyses that had not been planned at the outset of the study should be clearly indicated. If no retrospective unplanned subgroup analyses were reported, then answer yes.

yes	1
no	0
unable to determine	0

17. In trials and cohort studies, do the analyses adjust for diVerent lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls?

Where follow-up was the same for all study patients the answer should yes. If diVerent lengths of follow-up were adjusted for by, for example, survival analysis the answer should be yes. Studies where diVerences in follow-up are ignored should be answered no.

yes	1
no	0
unable to determine	0

18. Were the statistical tests used to assess the main outcomes appropriate?

The statistical techniques used must be appropriate to the data. For example non-parametric methods should be used for small sample sizes. Where little statistical analysis has been undertaken but where there is no evidence of bias, the question should be answered yes. If the distribution of the data (normal or not) is not described it must be assumed that the estimates used were appropriate and the question should be answered yes.

yes	1
no	0
unable to determine	0

19. Was compliance with the intervention/s reliable?

Where there was non compliance with the allocated treatment or where there was contamination of one group, the question should be answered no. For studies where the eVect of any misclassi®cation was likely to bias any association to the null, the question should be answered yes.

yes	1
no	0
unable to determine	0

20. Were the main outcome measures used accurate (valid and reliable)?

For studies where the outcome measures are clearly described, the question should be answered yes. For studies which refer to other work or that demonstrates the outcome measures are accurate, the question should be answered as yes.

yes	1
no	0
unable to determine	0

Internal validity - confounding (selection bias)

21. Were the patients in diVerent intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population?

For example, patients for all comparison groups should be selected from the same hospital. The question should be answered unable to determine for cohort and case-control studies where there is no information concerning the source of patients included in the study.

yes	1
no	0
unable to determine	0

22. Were study subjects in diVerent intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time? For a study which does not specify the time period over which patients were recruited, the question should be answered as unable to determine.

yes	1
no	0
unable to determine	0

23. Were study subjects randomised to intervention groups?

Studies which state that subjects wereran-

studies which state that subjects wererandomised should be answered yes except where method of randomisation would not ensure random allocation. For example alternate allocation would score no be-cause it is predictable.

yes	1
no	0
unable to determine	0

24. Was the randomised intervention assignment concealed from both patients and health care staV until recruitment was complete and irrevocable?

All non-randomised studies should be answered no. If assignment was concealed from patients but not from staV, it should be answered no.

yes	1
no	0
unable to determine	0

25. Was there adequate adjustment for confound-ing in the analyses from which the main @nd-ings were drawn?

This question should be answered no for trials if: the main conclusions of the study were based on analyses of treatment rather than intention to treat; the distribution of known confounders in the diVerent treatment groups was not described; or the distribution of known confounders diVered between the treatment groups but was not taken into account in the analyses. In nonrandomised studies if the eVect of the main confounders was not investigated or confounding was demonstrated but no adjustment was made in the ®nal analyses the question should be answered as no.

yes	1
no	0
unable to determine	0

26. Were losses of patients to follow-up taken into account?

If the numbers of patients lost to follow-up are not reported, the question should be answered as unable to determine. If the proportion lost to follow-up was too small to aVect the main ®ndings, the question should be answered yes.

yes	1
no	0
unable to determine	0

#### Power

27. Did the study have suYcient power to detect a clinically important eVect where the probabil-ity value for a diVerence being due to chance is less than 5%?

Sample sizes have been calculated to detect a diVerence of x% and y%.

	Size of smallest intervention group	
A	<n<sub>1</n<sub>	0
В	$n_1 \pm n_2$	1
С	n <sub>3</sub> ±n <sub>4</sub>	2
D	$n_5\pm n_6$	3
Е	n7±n8	4
F	n <sub>8</sub> +	5

Appendix H. Table H.1. Article quality scores on the Downs and Black checklist  $^{\rm 31}$ 

Question no.	Article	Baillés (2004) <sup>44</sup>	Bakvis (2010) <sup>39</sup>	Baslet (2010) <sup>40</sup>	Bodde (2012) <sup>27</sup>	Bodde (2013) <sup>45</sup>	Brown (2013) <sup>51</sup>	Cragar (2005) <sup>50</sup>	Duncan (2008) a <sup>46</sup>	Duncan (2008) b <sup>41</sup>	Harden (2009) <sup>53</sup>	Magaudd a (2011) <sup>52</sup>	Myers (2013) <sup>47</sup>	Myers (2014) <sup>42</sup>	Reuber (2004) <sup>49</sup>	Selkirk (2008) <sup>43</sup>	Uliaszek (2012) <sup>48</sup>
1		1	1	1	1	1	1	1	0	1	0	1	1	1	0	1	1
2		1	1	1	0	1	1	1	1	1	0	0	1	1	1	1	1
3		1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1
4		1	1	1	0	1	1	1	0	1	1	0	1	1	1	1	1
5		0	1	1	0	0	1	1	1	1	0	1	0	1	1	0	0
6		1	1	1	0	1	1	0	1	1	1	1	1	1	1	1	1
7   8   9   10		1 n/a 0 0	1 n/a 1 1	1 n/a 1 1	0 n/a 1 1	0 n/a 1 1	1 n/a 0 0	11 n/a 0 0	1 n/a 0 1	1 n/a 1 1	1 n/a 1 1	1 n/a 0 0	1 n/a 0 1	11 n/a 0 1	1 n/a 1	1 n/a 1 1	1 n/a 1 0
Reporting score		6	9	9	4	7	7	5	6	9	6	5	7	8	7	8	7
Percentage		67%	100%	100%	44%	78%	78%	56%	67%	100%	67%	56%	78%	89%	78%	89%	78%
11 12 13		0 0 0	0 0 1	0 0 0	0 0 0	0 0 0	1 0 1	1 0 1	1 1 0	0 0 0	0 1 0	0 0 0	0 0 0	0 0 0	1 1 1	1 1 1	1 1 0
External validity		0	1	0	0	0	2	2	2	0	1	0	0	0	3	3	2
Percentage		0%	33%	0%	0%	0%	67%	67%	67%	0%	33%	0%	0%	0%	100%	100%	67%
14		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
15		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
16 17		1 n/a	1	1 n/a	1	1 n/a	1 n/a	1	1 n/a	1 n/a	1 n/a	1	1 n/a	1 n/a	1 n/a	1 n/a	1 n/a

Question no.	Article	Baillés (2004) <sup>44</sup>	Bakvis (2010) <sup>39</sup>	Baslet (2010) <sup>40</sup>	Bodde (2012) <sup>27</sup>	Bodde (2013) <sup>45</sup>	Brown (2013) <sup>51</sup>	Cragar (2005) <sup>50</sup>	Duncan (2008) a <sup>46</sup>	Duncan (2008) b <sup>41</sup>	Harden (2009) <sup>53</sup>	Magaudd a (2011) <sup>52</sup>	Myers (2013) <sup>47</sup>	Myers (2014) <sup>42</sup>	Reuber (2004) <sup>49</sup>	Selkirk (2008) <sup>43</sup>	Uliaszek (2012) <sup>48</sup>
18		0	1	1	1	1	1	1	1	1	1	0	1	1	0	1	1
19		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
20		1	1	1	0	1	1	1	0	0	1	0	1	1	1	0	1
Internal validity -	bias	2	3	3	2	3	3	3	2	2	3	1	3	3	2	2	3
Percentage		67%	100%	100%	67%	100%	100%	100%	67%	67%	100%	33%	100%	100%	67%	67%	100%
21		1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1
22		1	0	1	1	1	1	1	1	1	1	1	1	1	0	1	1
23		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
24		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
25		0	1	1	0	0	1	1	0	0	0	0	0	1	0	0	1
26		0	1	1	1	1	0	0	0	1	0	0	0	0	0	1	1
Internal validity	· <b>-</b>																
confounding		2	3	4	3	3	2	3	2	3	2	2	2	3	1	3	4
Percentage		50%	75%	100%	75%	75%	50%	75%	50%	75%	50%	50%	50%	75%	25%	75%	100%
27		0	0	0	1	0	0	0	2	2	0	0	1	1	2	2	1
Power		0	0	0	1	0	0	0	2	2	0	0	1	1	2	2	1
Percentage		0%	0%	0%	33%	0%	0%	0%	67%	67%	0%	0%	33%	33%	67%	67%	33%
Total Score		10	16	16	10	13	14	13	14	16	12	8	13	15	15	18	17
Percentage		45%	73%	73%	45%	59%	64%	59%	64%	73%	55%	36%	59%	68%	68%	82%	77%

## Appendix I. Quality scoring for question 27 (power)

Table I.1. Minimum sample sizes and quality scores for statistical tests

Test type	Detectable size 62	e effect	Minimum sample size <sup>63, 64</sup>	Quality score allocated
Difference between 2 means	d=0.2	small	788	3
(T-test)	d=0.5	medium	128	2
	d=0.8	large	52	1
	d>0.8		<52	0
Difference between 2 groups	d=0.2	small	824	3
(Mann-Whitney test)	d=0.5	medium	134	2
	d=0.8	large	54	1
	d>0.8		<54	0
ANOVA repeated measures (5	f=0.1	small	582	3
measurements) between	f=0.25	medium	96	2
factors (3 groups). Corr among rep measures 0.5.	f=0.4	large	42	1
rep measures 0.5.	f>0.4		<42	0
ANOVA one way (3 groups)	f=0.1	small	969	3
	f=0.25	medium	159	2
	f=0.4	large	66	1
	f>0.4		<66	0
Regression models (1, 2, 3, 4, 5, 6 predictors) <sup>a</sup>	$R^2 = 0.02$	small	387,476,539,590, 635, 667	3
	$R^2 = 0.13$	medium	55,68, 77, 85, 92, 98.	2
	R <sup>2</sup> =0.26	large	25, 31, 36, 40, 43, 46	1
	R <sup>2</sup> >0.26			0
$X^2$	w=0.10	small	785	3
	w=0.30	medium	88	2
	w=0.50	large	32	1
	w>0.50		<32	0
Fisher's exact test	OR=1.68	small	1.68	3
	OR= 3.47	medium	124	2
	OR= 6.71	large	68	1
2T-1 - C P'-1127 - 244	OR>6.71		<68	0

<sup>&</sup>lt;sup>a</sup> Taken from Field<sup>37</sup> p. 314

## Appendix J. Summary of reasons for article exclusion

**Table J.1**Reasons for article exclusion at each stage

Reason	No. excluded at abstract read	No. excluded at full text read
Related to children only	6	
Not available in English	2	3
Irrelevant topic	13	
Does not include subgroups	17	7
The subgroups were not based on psychological characteristics including trauma history	16	5
Not quantitative research	5	
Secondary data only	20	1
Total excluded	79	16

## Appendix K. Excluded articles

**Table K.1**List of articles excluded during full-text reading

List of articles e	xcluded during full-text reading	
1st Author,	Title	Reason(s) for exclusion after full
year &		text reading
reference		
Asadi-Pooya	Demographic and clinical	Sub categories related to
$(2013)^{65}$	manifestations of psychogenic	comorbid epilepsy/ family
	non-epileptic seizures: The impact	history of epilepsy not
	of co-existing epilepsy in patients	psychological characteristics
	or their family members.	
Asmussen	Differences in self-reported	Subgroups based on Male/female
$(2009)^{66}$	depressive symptoms between	not psychological characteristics.
	patients with epileptic and psychogenic nonepileptic seizures.	
Beghi (2015) <sup>67</sup>		Sacandary data only
begin (2015)	Psychogenic non-epileptic seizures: So-called psychiatric	Secondary data only
	comorbidity and underlying	
	defense mechanisms.	
Brown	Characteristics of patients with	The results do not include
$(1991)^{68}$	nonepileptic seizures.	analysis at subgroup level.
		Reference is made to
		heterogeneity in the discussion,
		but the analysis is qualitative
		only.
Duncan	Late onset psychogenic	Subgroups related to age of onset
$(2006)^{69}$	nonepileptic attacks.	not psychological characteristics
Grimaldi	Anxiety and depression in	Does not include any analysis at
$(2010)^{70}$	psychogenic movement disorder	sub-group level
	and non-epileptic seizures: A	
Develop	prospective comparative study.	De cometinale de come coloria et
Drake (1992) <sup>71</sup>	Neuropsychological and psychiatric correlates of	Does not include any analysis at sub-group level.
(1992)	intractable pseudoseizures.	sub-group level.
Hill (2011) <sup>72</sup>	Neuropsychological	Clusters are related to seizure
11111 (2011)	characteristics of nonepileptic	semiology not psychological
	seizure semiological subgroups.	characteristics
Hubsch	Psychogenic non-epileptic	Not a full article, insufficient
$(2010)^{73}$	seizures: clinical classification	information, abstract only, full
-	based on the video-EEG analysis of	text not available in English
	145 seizures.	-
-		

1st Author, year & reference	Title	Reason(s) for exclusion after full text reading
Locke (2006) <sup>74</sup>	Relationship of Indicators of Neuropathology, Psychopathology, and Effort to Neuropsychological Results in Patients with Epilepsy or Psychogenic Non-epileptic Seizures.	Regression analysis of relationship between cognitive functioning and various other measures including psychopathology. Not really subgroups as such, maybe useful for discussion
Martinović (2000) <sup>75</sup>	Diagnosis and classification of psychiatric disorders in patients with pharmacoresistant epilepsy.	Full text not available in English
Pintor Pérez (2002) <sup>76</sup>	Psychiatric disorders, personality and traumatic experiences in conversion non-epileptic seizure patients.	Not available in English
Ramchandani (1993) <sup>12</sup>	Evaluation of pseudoseizures: A psychiatric perspective.	Includes subgroups which are based on semiology not psychological factors
Reuber (2011) <sup>77</sup>	Psychogenic nonepileptic seizure manifestations reported by patients and witnesses.	Does not include any analysis at subgroup level
Rosenberg (2000) <sup>78</sup>	A comparative study of trauma and posttraumatic stress disorder prevalence in epilepsy patients and psychogenic nonepileptic seizure patients.	Does not include any analysis at sub-group level
Scévola (2013) <sup>79</sup>	Psychiatric disorders in patients with psychogenic nonepileptic seizures and drug-resistant epilepsy: A study of an Argentine population.	Does not include any analysis at sub-group level

## Appendix L. Data extraction

Table L.1
Sample of summary data extraction during full text reading

1st	Title	ction during full text re Reasons/ summary	Country	Setting	Methodology	Sample type, number, and	Overall opinion
Author	1100	after full text read	Gournery	Setting	rictionalogy	comments	overam opinion
and year		arter run text read				comments	
and year							
Baillés	Psychiatric	Range of comorbid	Spain		comparison of mean	30 PNES confirmed via	Results need to be
$(2004)^{44}$	disorders, trauma,	psychiatric diagnosis			MMPI scores	video-	interpreted cautiously
	and MMPI profile in	found. Heterogeneity			between groups	electroencephalography,	as p values were not
	a Spanish sample of	of personality				comorbid epilepsy/ other	reported, the sample
	non-epileptic seizure	profiles on the				neurological disorders	was small, and the
	patients.	Minnesota				excluded	data analysis appears
		Multiphasic					to have been
		Personality					exploratory.
		Inventory (MMPI).					
		Elevated mania					
		scores associated					
		with presence of					
		trauma and					
		personality disorder,					
		elevated paranoia					
		with presence of					
		personality disorder					

1st Author and year	Title	Reasons/ summary after full text read	Country	Setting	Methodology	Sample type, number, and comments	Overall opinion
Bakvis (2010) <sup>39</sup>	Basal hypercortisolism and trauma in patients with psychogenic non-epileptic seizures		Netherlands	Tertiary epilepsy centre	Comparisons of mean levels of cortisol in saliva between groups and within participants at different times. Also after administering a drug. Mixed design experiment	18 PNES, 19 Healthy controls advertised though newspaper	A well-written article, experiment seems well designed, sample size small but analysis seems reliable. Out of my area of expertise, as it was a neurological article, but it was written in a way that was easy to understand.

## Appendix M. PRISMA 2009 checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1.1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	1.3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	1.5-1.9
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	1.9-1.10
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	n/a
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	1.10-1.14
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	1.12
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	1.80
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	1.16-1.17
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	1.16-1.17
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	1.16-1.17

Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	1.14-1.15
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	1.16 - 1.17
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	n/a

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	1.16
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	n/a
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	1.13
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	1.17-1.29
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	1.20
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	1.17-1.29
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	n/a
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	1.36-1.37
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	n/a
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	1.30-1.41
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	1.36-1.39

## NON-EPILEPTIC SEIZURE SUBGROUPS

### 1-96

Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	1.39-1.41
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	n/a

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

# Appendix N. Subgroups based on trauma experience

Table N.1

Details of significant differences reported between subgroups with and without trauma experiences

rticle	Item	Item description	Direction	Effect size (confidence interval)	P value
aillés 1004) <sup>44</sup>	MMPI Mania sub-scale	Indicating elated unstable mood, excitement, restlessness and inflated self-esteem <sup>80</sup>	Greater with trauma	d=0.86a	<0.05
odde 013) <sup>45</sup>	CERQ blaming others	Emotion regulation strategy of cognitively putting the blame onto others	Greater with trauma	d=0.8b	0.018
	Short MMPI negativism	Items that indicate passive avoidant behaviour, bearing grudges and feeling dissatisfied	Greater with trauma	d=2 <sup>b</sup>	0.049
	Short MMPI shyness	Indicates feelings of shyness and interpersonal difficulties	Greater with trauma	d=1.5 b	0.006
	DISQ-1	Subscale of the Dissociation Questionnaire relating to identity confusion and depersonalization	Greater with trauma	d=1 <sup>b</sup>	0.019
	Short TCI harm avoidance	A dimension of personality based on the psychobiological theory of personality	Greater with trauma	d=0.7 b	0.027
	Short TCI self- directednesss	As above	Less with trauma	d=0.8 b	0.024
	CVST rt	Processing speed	Slower with trauma	d=2 b	0.011
ıncan 008)a <sup>46</sup>	Predictors of reporting sexual abuse	Female gender	More likely with reported sexual abuse	OR 6.02 (2.50-14.49)	<0.001
		Learning disability	Less likely with reported sexual abuse	OR 0.15 (0.03-0.73) 1/OR=6.67	0.019
		self-harm	More likely with reported sexual abuse	OR 3.30 (1.73-6.33)	<0.001

Article	Item	Item description	Direction	Effect size (confidence interval)	P value
		health related trauma	Less likely with reported sexual abuse	0.09 (0.01-0.71) 1/0R=11.11	0.023
Myers (2013) <sup>47</sup>	Psychotherapy engagement	Engaged in psychotherapy presently or in the past	More likely with trauma	OR= 5.13°	0.009
	Mood/bipolar disorder	Diagnosis of comorbid mood/bipolar disorder	More likely with trauma	Insufficient information to calculate	0.005
	PTSD	Diagnosis of comorbid post-traumatic stress syndrome	More likely with trauma	OR=6.56	0.04
	TSI-2	The trauma symptom inventory, includes anxious arousal, depression, anger, intrusive experiences, defensive avoidance, dissociation, somatic concerns, dysfunctional sex behaviour, impaired self-reference, & tension reduction behaviours	All scales higher with trauma	d=3.6° for dysfunctional sexual behaviour to d=0.78° for anxious arousal	0.000 for defensive avoidance, to 0.045 for dysfunctional sex behaviour
	MMPI RCd Demoralization subscale of the Minnesota Multiphasic Personality Inventory-2RF	Higher scores indicate a person functioning with reduced efficiency and competence; a sense of guilt, failure, helplessness and desperation, distraction and being overwhelmed; (who may avoid or collapse under everyday stresses. <sup>80</sup> )	Higher with trauma	d=0.80 <sup>a</sup>	0.028
Myers (2014) <sup>42</sup>	Welscher Memory Scale- III logical memory II	A test of delayed verbal semantic memory administered by a professional, higher scores indicate better functioning	Lowest scores with PTSD, then with trauma but no PTSD, highest scores with no trauma	No trauma – trauma without PTSD d=0.57 <sup>a</sup> No trauma – trauma with PTSD d=1.10 <sup>a</sup>	0.032

Article	Item	Item description	Direction	Effect size (confidence interval)	P value
	Memory Complaints Inventory total	A self-report measure with broad range, relating to verbal and visual memory, higher scores indicate worse functioning	PTSD group significantly higher than: Trauma no PTSD, and group without trauma	d=1.56 <sup>a</sup> d=1.75 <sup>a</sup>	0.0001
Selkirk (2008) <sup>43</sup>	Indicators of mental ill health	Previous referral to mental health services	Higher with reported sexual abuse	OR 2.03 (1.56-2.63)	<0.0001
		History of any mental health problem	Higher with reported sexual abuse	OR 1.42 (1.24-1.64)	<0.0001
		History of depression	Higher with reported sexual abuse	OR 1.79 (1.36-2.35)	0.0001
		History of deliberate self-harm	Higher with reported sexual abuse	OR 4.25 (2.47-7.30)	<0.0001
		Diagnosis of personality disorder	Higher with reported sexual abuse	OR 7.88 (1.76-35.33)	0.0012

<sup>&</sup>lt;sup>a</sup> Effect size calculated from stated means and standard deviations, using the standard deviation for no trauma subgroup; <sup>b</sup>Cohen's d effect size estimated from graph of Z scores, as figures were not reported; <sup>c</sup>Odds ratio determined using Wilson's 'Practical meta-analysis effect size calculator'<sup>81</sup>. OR: odds ratio with 95% confidence interval in brackets.

# Appendix O. subgroups based on cognitive functioning

**Table 0.1**Psychological factors showing significant differences between subgroups based on level of cognitive functioning

Study	Factor subgroups are	Significant differences between subgroups	Effect size (confidence interval)	p
	determined by	between subgroups	intervary	
Bodde (2013) <sup>45</sup>	Global cognitive level (RPM)	Those scoring below average on the RPM scored significantly: lower on 'persistence' higher on 'positive refocusing' on the TCI	r=0.35 r=0.35	0.03 0.043
Duncan (2008)a 46	Predictors of learning disability	Male gender Comorbid epilepsy Environmental triggers Pseudostatus	OR 3.40 (1.22-9.49) OR 5.61 (1.71-18.87) OR 20.83 (5.35-83.33) OR 3.77 (1.35-10.35)	0.019 0.005 <0.001 0.012
Duncan (2008)b <sup>41</sup>	Presence or absence of learning disability (LD)	Likelihood of having comorbid epilepsy 36% compared to 8.7% for those without LD	OR 5.87 (2.33-14.76) OR 3.85 (1.40-10.57)	<0.001
		More likely to be on anti- epileptic medication Less likely to have reported sexual abuse More likely to have identified environmental triggers for the seizures	OR 0.29 (0.08 – 1.00) 1/OR=3.45 OR 14.74 (4.83-43.31)	0.038 < 0.001
Magaudda (2011) <sup>52</sup>	Presence of mild learning disability	No statistical tests done, but case data seems to indicate aetiology of NESs more likely to be associated with a reduction in epileptic seizures		Not available

OR: odds ratio; CI: 95% confidence interval

# Appendix P. Subgroups based on factor and cluster analysis

**Table P.1** Factor loadings above 0.4 for subgroups identified by factor analysis

Article	Factor	Factor loadings
Bodde (2013) <sup>45</sup>	Factor 1, Psychotrauma subgroup	TEC 0.586, SDQ-20 0.800, EPCL total complaints 0.661, CERQ self blame 0.511
	Factor 2, high vulnerability somatization subgroup	TEC -0.650, Short MMPI somatization 0.663, CVST - 0.417, EPCL total complaints 0.569
	Factor 3, high vulnerability sensitive personality problem subgroup	Short TCI novelty seeking 0.746, CVST 0.401, CERQ self blame 0.693
	Factor 4, high vulnerability somatization subgroup with a low cognitive level	Short MMPI somatization 0.654, CVST 0.639

See Table 4 in results for abbreviations

**Table P.2**Psychological characteristics upon which significant differences between groups were found following cluster analysis

Article	Clusters	Measures upon which significant differences were found between clusters	Effect sizes
Cragar (2005) <sup>50</sup>	Depressed neurotic/ somatic defender/ activated neurotic	MMPI-2 (scales F, K, 2, 6, 7, 8, 9, 0), intellectual ability, memory ability, language ability, visual spatial ability	d=0.85 to 2.47
Reuber (2004) <sup>49</sup>	Cluster 1, similar to borderline personality disorder/ cluster 2, over controlled/ cluster 3 similar to avoidant personality disorder/ cluster 4, outlier	No statistics on differences between clusters, only comparisons with healthy controls	n/a
Brown (2013) <sup>51</sup>	Cluster 1, high levels of emotional dysregulation and alexithymia/Cluster 2, relatively normal emotional dysregulation and alexithymia	All subscales of DERS other than awareness, TAS difficulty identifying and described feelings subscales	r= 0.49 to 0.67
Uliaszek (2012) <sup>48</sup>	Highly emotion dysregulated/ low emotion dysregulated	DERS total score DASS (anxiety, depression, stress), BDI-II, DES, PHQ-15, QOLIE-31	d=0.85 to 2.29 <sup>a</sup>

<sup>&</sup>lt;sup>a</sup>Cohen's d effect sizes calculated using the f or t statistic and cluster n<sup>81</sup>.

Section Two: Emp	irical Paper
Relationships bety seizures	ween early life events, individual differences, and
Liz Tallentire	
Doctorate in Clinical Ps Division of Health Resec	ychology arch, Lancaster University
Word Counts:	7,979 excluding title page, tables, figures, references, and Appendices
	15,273 in total excluding author guidance of 7,370 words
Presented in the style o	of the journal Epilepsia, see Appendix A for author guidelines

## Summary

**Objectives:** To identify subgroups of people who experience non-epileptic seizures (NESs) and examine their psychological characteristics in comparison to each other and those people who experience epileptic seizures (ESs).

**Methods:** 316 people who reported experiencing ES, NES, or both epileptic and non-epileptic seizures (ES+NES) consented to take part via an online survey. Following initial exploratory data analysis (n=278), a cluster analyses (n=114) was implemented to split those who experienced NESs into subgroups based on their trauma and alexithymia scores. Further exploratory analysis then compared the NES subgroups (n=49, 21, 44) to each other and to the ES group (n=119) by testing for differences between group means and correlations.

Results: Consistent with previous research, the overall NES group compared to the ES group, had a significantly higher mean trauma score and seizure frequency, and seizures had a greater impact on their quality of life. Clustering of the NES group identified three clusters which differed significantly on trauma, attachment, and alexithymia measures. There were also significant differences when comparing correlations between psychological characteristics for each cluster and the epilepsy data.

**Significance:** This research emphasises the importance of assessment and formulation of individual differences in both ES and NES presentations. Assessing experiences of trauma, attachment, and alexithymia is likely to be helpful, in future research and in clinical settings. Further research to test whether the subgroup characteristics in this research are supported and to assess the efficacy of therapeutic interventions informed by the psychological characteristics of each subgroup is suggested. If further research is congruent with this study, it may form the basis of a means of allocating people who experience seizures to appropriate psychological assessment and therapeutic pathways.

# **Key words**

Epilepsy, non-epileptic, attachment, alexithymia, childhood trauma, subgroups

Epilepsy or epileptic seizures (ES) are caused by abnormal bursts of electrical impulses in the neurons of the brain; these bursts alter the functioning of the brain and body. Symptoms vary; they may include, altered perception, being unresponsive, losing consciousness, and convulsions<sup>1</sup>. The unusual electrical activity in the brain associated with ES can usually be detected using an electroencephalogram (EEG)<sup>1</sup>. Non-epileptic seizures (NES) have similar symptoms and appearance to ES, but they are not associated with unusual electrical activity in the brain or with other somatic causes, such as acute infections<sup>2-5</sup>. Alternative names for NES include, non-epileptic attack disorder (NEAD), psychogenic non-epileptic seizures (PNES), and dissociative episodes<sup>3</sup>, 6. A meta-analysis of the incidence of epilepsy internationally reported a median incidence of 50.4 per 100,000 people per year (interquartile range 33.6-75.6)<sup>7</sup>. Estimates of the prevalence of NES have varied between 1.5 and 4.9 per 100,000 people in the general population and 25 to 30 in every 100 people referred to tertiary epilepsy centres<sup>6</sup>. Some people experience ESs and NESs; comorbidity has been reported at a prevalence of 5 to 40 in every 100 people in samples of people who have experienced NESs<sup>3, 8</sup>.

Both ES and NES can be very distressing for people who experience them; they are associated with a poorer quality of life and increased risk of psychological difficulties, such as, depression, anxiety, and personality disorders<sup>4, 9-15</sup>. Financial costs are large; one study estimated the direct and indirect cost of epilepsy across the European Union's 25 member countries to be €15.5 billion (€33 per capita) in 2004<sup>16</sup>. The main treatment for epilepsy is anti-epileptic medication, and in severe cases, surgery is considered. However, several studies have reported success in reducing ES frequency using psychological therapies, such as CBT<sup>41-43</sup>. Treatments for NES have focussed on psychological therapy, such as cognitive behavioural therapy (CBT), and

psycho-education; a Cochrane review found little reliable evidence to support choice of treatment for NES<sup>6</sup>. Despite treatments for ESs focusing on medical intervention and NESs psychological intervention a study indicated that patients perceived ES and NES as both psychological and physical<sup>44</sup>.

NES that are unrecognised or mistaken for epilepsy present a significant issue because of the risk of potentially severe side-effects of unnecessary anti-epileptic medication or other inappropriate intervention, such as surgery, and the neglect of the actual psychological difficulties that may be causing the seizures <sup>15</sup>. Unrecognised NESs also presents a significant cost to health services; for example, one hospital in Ireland estimated the cost of to be €20,995.30 per year per patient <sup>17</sup>. Differentiating between ES and NES is difficult and costly <sup>18-20</sup> and is further complicated by comorbidity and the heterogeneity of NES aetiologies <sup>19,21-24</sup>.

This heterogeneity has been explored by those such as Brown et al. <sup>25</sup> and Reuber et al. <sup>22</sup>. They used cluster analysis and were successful in identifying NES subgroups. For example, Brown et al. identified a subgroup with elevated levels of psychopathology, somatisation and alexithymia, and a subgroup with relatively normal levels of alexithymia, but high somatisation and depression scores <sup>25</sup>. Reuber identified three subgroups that differed on measures of personality and emotion dysregulation <sup>22</sup>. Differences have been identified between subgroups on a variety of psychological characteristics; for example, personality difficulties <sup>26, 27</sup>, mood disorders <sup>10, 28</sup>, reporting of everyday problems <sup>23, 27</sup> and cognitive abilities <sup>21, 27</sup>. Trauma reporting and emotion regulation have been identified frequently as variables that can differentiate subgroups <sup>22, 23, 25-27</sup>.

Understanding the psychological characteristics typical of different seizure types and clusters is important, as they may help clinicians to be alert to unmet psychological

needs and prompt further exploration of seizure types, where atypical characteristics are present. It may also inform interventions upon which further research is based. This study investigated trauma experience, seizure frequency, quality of life, adult attachment style, and alexithymia. Their relevance to NESs and ESs will be discussed below.

Literature reviews have frequently reported that having a history of trauma is more common for people who experience NES than for those who experience ES<sup>2, 19, 29</sup>. Lally et al.<sup>30</sup>reported that the number of categories of reported trauma correlated significantly and positively with seizure frequency for people who experienced NES. This evidence suggests that trauma history and seizure frequency will be worthy of further investigation. Corrallo et al.<sup>31</sup> suggested that quality of life (QoL) is also important to consider in relation to seizure patients.

Bowlby's<sup>32</sup> attachment theory proposed that the way a child relates to their main caregiver shapes the way they relate to others throughout life, through the process of forming an internal working model of that relationship. This develops into an attachment style, which Bowlby<sup>32</sup> described categorically as secure, anxious resistant or anxious avoidant. Later, in social psychology, Brennan, Clark and Shaver<sup>33</sup> developed this categorical understanding, and conceptualised adult attachment style as consisting of two major dimensions, attachment anxiety and attachment avoidance. People scoring high on attachment anxiety would be expected to fear others abandoning them and to need approval from others. Those scoring high on attachment avoidance would be expected to avoid getting close to others and be very self-reliant. People scoring low on both dimensions would correspond to Bowlby's secure category and Brennan, Clark and Shaver<sup>33</sup> suggested they would be able to easily form supportive adult relationships.

Quinn, Schofield, and Middleton<sup>34</sup> proposed the theory that experiences of trauma, in the context of an attachment relationship that is not validating, form the basis of one aetiology of NES. This suggests that a child who experiences trauma and is cared for by parents who do not recognise, acknowledge and cope with the child's thoughts and feelings, would be more likely to develop NES than a child who experiences the same trauma but is emotionally supported by their parents. However, adult attachment styles have not been widely studied in relation to NES. Only one study, with a small sample size, has found that people who experienced NES (n=17) were significantly more likely to have a fearful adult attachment style than those who had epilepsy alone (n=26)<sup>35</sup>. In the same study the results were not significant for secure, dismissing, or preoccupied attachment categories<sup>35</sup>. Another study found no significant differences in attachment styles for those experiencing ES and NES<sup>36</sup>. However, the investigators reported reliability issues with the particular attachment measure employed in the study.

The personality characteristic, alexithymia, relates to recognising and describing feelings, as well as interacting with others<sup>37</sup>. The concept is related to the broader concept of emotion regulation<sup>38</sup>. High levels of alexithymia indicate a person has difficulties with identifying, describing and sharing their emotions. Research has reported mixed results in relation to alexithymia and seizures; Kaplan et al.<sup>39</sup> reported that people who experienced NES had higher levels of alexithymia than those who experienced ES, whereas, Bewley et al.<sup>40</sup> reported similar levels of alexithymia in people with ES and NES, both being significantly higher than controls. In addition to Bewley et al.'s<sup>40</sup> research, other indicators suggest a relationship between psychological characteristics and ES. For example, Harden et al.<sup>9</sup> reported that 75% of their sample of

people diagnosed with epilepsy (n=16) met criteria for a diagnosis of personality disorder (n=12).

Theoretically, the concept of emotion regulation is closely linked to childhood attachment style. Cassidy<sup>45</sup> proposed that emotion regulation style is an adaptive response, which the child develops in order to manage and maintain the attachment relationship with their caregiver. Cassidy<sup>45</sup> suggested that when a caregiver repeatedly rejects a child, the child develops an avoidant attachment style and minimises their emotions in order to avoid further rejection. When a caregiver is unavailable or inconsistently available, the child develops an anxious attachment style and maximises their feelings in order to increase the chances of getting a response from the caregiver. Research, consistent with this theory, has identified a link between adult attachment style and alexithymia. For example, low levels of alexithymia, indicating no problems with emotion processing have been associated with secure adult attachment style in a student sample<sup>46</sup>. Fearful or anxious adult attachment style has been linked to high levels of alexithymia in young men with mood disorders<sup>47</sup>. A combination of both anxious and avoidant attachment strategies, and over and under regulation of emotion has been reported in a study subgroup of people who were diagnosed with both somatoform disorder and personality disorder<sup>48</sup>. The authors proposed that this was consistent with a disorganized attachment style, which has been associated with childhood adversity<sup>48, 49</sup>.

In relation to NES, a comprehensive review in 2009 identified a lack of studies that obtained sufficiently large sample sizes to achieve an appropriate level of power<sup>3</sup>. Five studies have considered psychological characteristics and used cluster or factor analysis to account for NES heterogeneity<sup>21-23, 25, 27</sup>. None of these studies considered alexithymia, attachment, and trauma together.

Consequently, in order to address the gaps in the current literature, this study aimed to collect data from a relatively large sample of NES and ES participants on their trauma experience, seizure frequency, quality of life, adult attachment style, and level of alexithymia. In order to achieve the desired sample size it used a cross sectional survey design and online recruitment. It was hoped that this study would increase understanding of the differences in psychological characteristics of people who experience ESs and those subgroups that experience NESs. This understanding may help clinicians differentiate between seizure presentations and identify psychological therapies that may be appropriate in further clinical research.

#### Research aims

In order to achieve a larger sample size this study used self-reporting of seizure type, which has not been used in previous research. Therefore, it was important to check the data against hypotheses based on previous research before completing the main analysis. It was hypothesised that people who experienced NESs compared to people who experienced ESs would on average, (H1) report more episodes of childhood trauma, (H2) report higher levels of seizure frequency, and (H3) report lower quality of life.

Following this initial assessment of the data to ensure they matched hypotheses from previous research, the aims of the main analyses were (1) to identify NES subgroups and (2) to compare mean scores and correlations of psychological characteristics between NES subgroups and those people who have experienced ESs using exploratory analysis.

#### Method

#### Design

The study used a cross sectional survey design.

#### **Ethics**

The study gained ethical approval via NHS ethics proportionate review, Research Ethics Service reference number 15/NW/0110; details of the application are included in section four.

## **Participants**

Participants were over 18 years of age and identified themselves as experiencing ES and/or NES. Inability to understand the instructions and measures in English language was an exclusion criterion, because not all measures were available in alternative languages.

#### Measures

Participants were asked to self-report their demographic details, seizure type (ES and/or NES) and seizure frequency, followed by the measures (Appendix B) presented in the order below.

## Impact of Seizures

The revised Liverpool impact of epilepsy scale (RLIOES) was used to assess quality of life. It has 12-items and asks participants about the impact of seizures on aspects of life, such as health and relationships. Responses are on a 5-point Likert scale from 'very much for the better' to 'very much for the worse'. The RLIOES was scored

according to the method outlined by Crossley, Jacoby, & Baker  $^{50}$ . The measure has possible scores ranging from -24 to +24, with negative scores indicating a detrimental effect on quality of life and positive scores indicating a positive effect on quality of life. It was chosen over other more general measures of quality of life because it asks specifically about the impact of seizures on quality of life. It was reported to have good reliability and acceptable validity  $^{50}$  with Cronbach's  $\alpha$  of 0.83.

#### Attachment

The experiences in close relationships short form (ECR-SF)<sup>51</sup> was used to measure adult attachment anxiety and avoidance, based on Brennan, Clark and Shaver's dimensional model of attachment<sup>33</sup>. The ECR-SF contains 12 statements about how a person generally feels in relationships. Six items form the attachment anxiety dimension and six items the attachment avoidance dimension. The participant rates their level of agreement on a 7-point scale, from 'strongly agree' (1), to 'strongly disagree' (7). The presentation order of the ECR items was randomised as recommended by the authors and it was scored in accordance with the methods used in its development and validation<sup>51</sup>. Possible scores ranged from 6 to 42 for each dimension; higher scores indicated increased levels of attachment anxiety or avoidance. The ECR short form has been reported to have good reliability and validity with Cronbach's alpha values between 0.77 and 0.86 for the anxiety scale and 0.78 and 0.88 for the avoidance scale<sup>52, 53</sup>.

### Alexithymia

The Toronto Alexithymia scale (TAS-20) was used to assess levels of alexithymia<sup>54</sup>. The TAS-20 consists of 20 statements about emotions, sensations, and

interpersonal interactions. The measure has a three-factor structure, labelled as difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking. Responses are on a five-point Likert scale from strongly disagree (1) to strongly agree (5). Scoring was completed according to instructions provided by the author; scoring involved reverse scoring five items before adding up the score for each subscale and the total score. Missing items, up to a maximum of 3 in the total score and 1 in each subscale, were replaced by the mean of the other items. Possible total scores range from 20 to 100, with greater than or equal to 61 described as high alexithymia and lower than or equal to 51 described as low alexithymia $^{55}$ . The TAS-20 has been used with clinical and non-clinical populations $^{56,57}$ ; it has been validated using internet administration and found to have good cross-cultural validity for the difficulty identifying feelings and difficulty describing feelings factors $^{58,59}$ . The TAS-20 is reported to be reliable and to have factorial validity, with a Cronbach's  $\alpha$  of  $0.86^{60}$ . This measure was chosen in preference to other measures of alexithymia because it has a comprehensive evidence base, including online presentation and international samples.

## Childhood Trauma

The Early Trauma Inventory Self Report- Short Form (ETISR-SF)<sup>61, 62</sup> was used to enquire about experiences of trauma prior to the age of 18 years. It has 29 items, asking about experiences of different traumas, arranged into four domains of physical, emotional, sexual abuse, and general trauma. Responses are, yes or no. Scoring was completed by summing the number of yes responses in each domain, and calculating the overall sum, as recommended by Bremner, Bolus, and Mayer<sup>61</sup>. The possible range for the total score was from 0 to 29, with higher scores indicating more different types of childhood trauma were reported. An overall score was calculated for those with no

more than 4 items missing, the score for each subscale was calculated if no more than 1 item in the scale was missed, with the exception of the dissociation sub-scale which has two items. The dissociation subscale was only scored if both items were completed. Bremner<sup>61</sup> tested the ETISR-SF using a sample of healthy controls and people with psychiatric disorders, including abuse history. Bremner<sup>61</sup> reported acceptable validity and internal consistency with Cronbach's  $\alpha$  of 0.95; another study reported excellent reliability<sup>63</sup>. This scale was chosen because it includes a range of trauma types, including emotional abuse, and it has been used with clinical populations.

#### **Procedures**

The study was promoted to potential participants through online forums and health clinics that were likely to be accessed by people who experience ES and/or NES, between the dates of 2<sup>nd</sup> February 2015 and 13<sup>th</sup> March 2015 (Appendix C). The online data collection closed on 16<sup>th</sup> March 2015. Participants were asked to pass on information about the study to others who may be interested.

Participants accessed information about the study and completed the questionnaires via an online survey hosted by Lancaster University (see Appendix D for examples of information presented to participants). Data were collected anonymously: anonymity was important as previous research has indicated that it increased the likelihood of reporting childhood traumas<sup>64</sup>.

#### Statistical Analysis

The analysis was completed using IBM SPSS statistics 22.0.01 and the R: language and environment for statistical computing<sup>65</sup>. Figure 1 reports details of the numbers of participants with missing data who were excluded or included in score

calculations; Appendix E includes this data for the subscales of the TAS-20 and ETISR-SF. The stages of analysis are described below. Details of the specific tests used are in Appendix F. Tests were administered using pairwise exclusion for missing data. The analysis was exploratory therefore; a Bonferroni correction was not applied.

<<INSERT FIGURE 1>>

Exploratory data analyses (EDA) included three groups: (1) those who experienced ES only (n=119), (2) those who experienced NES only (n=131), and (3) those who experienced both ES and NES (ES+NES, n=28). The cluster analyses were applied to group 2, NESs only. Consistent with the research aim of contrasting differences in psychological characteristics NES subgroups and the ES group, subsequent analyses focussed on the subgroups, formed from group 2, and group 1.

#### Exploratory data analysis (EDA)

EDA involved considering exclusion of outliers and small n categories. Outliers were examined for unusual patterns of responses, but none were removed from the analyses at this stage. Group means and frequencies for demographics and total scores on all the measures were compared across the ES, NES, and ES+NES groups. Due to non-normal distributions, comparisons were checked using permutation tests for the seizure frequency and trauma data. Effect sizes for differences between group means were calculated using the mean and standard deviation for the epilepsy group.

### Cluster analysis

The NES group was clustered on the childhood trauma (total score) and alexithymia (total score) measures as these variables have been found to differentiate subgroups of NES patients in previous research (see part 1). The clustering method used was agglomerative hierarchical cluster analysis, using Ward's method and the squared Euclidean distance measure. Cluster analysis<sup>66</sup> was chosen because it allowed the clustering to incorporate more than one variable at once and negated the need for the researcher to set arbitrary cut off values. Hierarchical methods were chosen because the number of clusters was unknown.

Clustering is sensitive to differences in scale<sup>66</sup>; therefore, the trauma and alexithymia scores were standardised using Z-scores. As Ward's method is sensitive to outliers<sup>67</sup>, nearest neighbour cluster analysis was used to identify them<sup>68</sup> by examination of the dendrogram (appendix G). Case numbers 150 and 220 were removed prior to Ward's method clustering. The cluster analysis was then repeated, using average linkage within groups, and the results compared.

### Comparison of cluster and epilepsy data means

Mean age and total scores on all measures were compared across the three NES clusters, obtained from the cluster analysis, and the ES only group, using the same methods as the EDA.

### Comparison of correlations within clusters and epilepsy data

In order to investigate the relationships between variables and how these differed between the NES clusters and ES group, correlations within NES clusters were examined and compared to those for the ES group.

#### Power calculation

The power calculation was based on the ability to detect differences in mean scores when comparing the NES subgroups and ES group, post clustering. Based on there being a maximum of three NES subgroups, therefore a total of four groups, of equal size, assuming a medium effect size (f=0.25), alpha error probability of 0.05 and a power of 0.8 the minimum sample size was 180<sup>65</sup>.

#### Results

All participants completed the survey online; no paper copies were received. A total of 313 participants consented to take part. Figure 1 illustrates the numbers of

participants providing a full data set for each section of the survey. The 60 included with missing data on the trauma measure relate mainly to the last two questions, which read 'If you responded "YES" for any of the above events, answer the following...' It appears that most participants had interpreted this as relating to the section immediately before this question about sexual abuse, as 59 out of 60 of the people who did not answer the dissociation questions had answered no to all the sexual abuse questions. Seven out of 60 had responded negatively on the whole trauma survey.

Participants who had not entered any data on the first survey were excluded leaving an initial sample size of 288. From this initial sample (n=288), the highest dropout was between the revised Liverpool impact of epilepsy scale (RLIOES) (survey 1) and the experiences in close relationships short form (ECR-SF) (survey 2), at this point n=25 (9%) provided a complete data set for the RILOES but not for the ECR-SF.

Cronbach's alpha values were 0.88 for the RLIOES, 0.73 for ECR-SF anxiety, 0.83 for ECR-SF avoidance, 0.87 for the TAS-20, and 0.90 for the ETISR-SF; indicating that internal reliability was at least acceptable for all measures.

### Exploratory data analysis

*Gender, country, and seizure occurrence* 

In the sample (n=288), 119 (41.3%) of the participants indicated they experienced ES only; 131 (45.5%) NES only; 28 (9.7%) ES+NES; and 10 (3.5%) were unsure about one or both seizure types. The data from the 10 participants who were unsure about their seizure type was excluded from further analyses. Table 1 summarises the categorical variables for the participants included in the exploratory data analysis (n=278).



The distributions of gender ( $\chi^2(2)$ =7.18 p=0.03) and whether or not seizures were reported in the last year (p<0.001, Fisher's exact test) were significantly different across the ES, NES and ES+NES groups. The percentage of males in the ES (16.0%) and ES+NES (17.9%) groups were similar. The NES group had a smaller proportion of males (6.1%) than the ES group ( $\chi^2(1)$  = 6.29, p=0.01) and the ES+NES group (p=0.055, Fisher's exact test). The odds ratio indicated that the odds of being male were 2.9 times greater in the ES group than the NES group. The percentage of people experiencing seizures in the last year in the ES group (72.3%) was significantly smaller than the NES group (93.1%,  $\chi^2(1)$  = 19.41, p<0.001) and smaller (approaching significance) than the ES+NES group (85.7%,  $\chi^2(1)$  = 3.27, p=0.053). The odds of having seizures in the last year were 5.20 times greater in the NES group than the ES group.

Clinically it was expected that people with ESs may not currently experience seizures, due to antiepileptic medication. However, it was more unusual for people with NESs not to have experienced seizures in the last year. Therefore, this NES group were investigated to assess any possible bias they may introduce. The group was relatively small (n=9) and their mean scores were not significantly different to the rest of the NES group on any of the measure total scores or their age (p>0.25). Therefore, they were included in the analysis as it seemed unlikely they would have a significant impact on the results.

Age, seizure frequency, childhood trauma, adult attachment, alexithymia, and impact of seizures

Table 2 provides the descriptive statistics for each group of participants. Subscale data are provided in Appendix H, Table H.1, and Appendix I.

<<INSERT TABLE 2>>

The differences between the groups' mean ages were statistically significant (F=6.01, p=0.003). However, the mean (32.43, 36.85, 38.04) and median (30, 36, 38.5) ages of the three groups all fell within 30 and 40 years, and their ranges were similar (18-66, 18-61, & 19-62). Therefore the groups were, to all intents, comparable. Post hoc tests (Appendix J) indicated that the epilepsy group had a significantly lower mean total childhood trauma score (5.48) than the NES group (9.78, d=0.85, p<0.001) or the ES+NES group (12.57, d=1.40, p<0.001). The NES and ES+NES groups did not differ significantly (p=0.06). The epilepsy group also had significantly lower mean seizure frequency (15.21 per month, d=0.33, p=0.02) and less impact of seizures (-8.69, d=0.98, p<0.001) when compared to the NES only group who had mean seizure frequency of 41.05 per month and mean impact of seizures score of -14.58.

#### Summary of seizure type groups

The EDA considered three groups of participants; those who experienced ESs only, NESs only, and both types of seizures (ESs+NESs). The ES+NES group was much smaller (n=28) and not all of them provided sufficient data to include in analyses, therefore they were excluded from subsequent analyses.

#### Cluster analysis

The graph of the agglomeration schedule (n=114) showed a relatively sharp increase on step 111 (Appendix K) indicating a three cluster solution. Clustering based on Ward's method and within groups average linkage, produced a similar pattern of results, the main difference being the boundary between clusters 1 and 2, which was at a lower level of alexithymia using Ward's method (Appendix L). However post-hoc tests

showed that the solution under Ward's method gave subgroups that were both more distinct and theoretically more sensible.

With reference to the whole NES group, cluster 1 included those with low to medium childhood trauma and medium to high alexithymia, cluster 2 low to medium childhood trauma and low to medium alexithymia, cluster 3 medium to high childhood trauma and medium to high alexithymia. The clusters are illustrated in Figure 2.

<<INSERT FIGURE 2 >>

### Comparison of NES clusters and the ES group

Categorical data is provided in table 3, the only significant categorical difference between clusters was gender (p=0.04, Fisher's exact test). The differences between means across the three NES clusters and ES group were significant for all variables in Table 4 (p<0.001 to 0.004). The means are illustrated in Figure 3, subscale data is in Appendix H, Table H.2. Post hoc test results are provided in Table 5. Differences between the groups' mean ages were only significant (p=0.01) for the difference between cluster 3, mean 38.25 (standard deviation 10.46) and epilepsy data, 32.45 (10.68), and all means were between 30 and 40 years. With reference to tables 4 and 5, and figure 2 it can be seen that cluster three is characterised by significantly higher scores than some or all of the other groups in childhood trauma reporting, alexithymia, and attachment anxiety. All the NES groups have significantly greater negative impact of seizures than the ES group. With the exception of impact of seizures, cluster 1 is quite similar to the epilepsy group. Cluster 2 is characterised by significantly lower scores than some or all of the other groups in attachment anxiety, attachment avoidance, and alexithymia.

<<INSERT TABLE 3>>

<<INSERT TABLE 4>>

<<INSERT FIGURE 3>>

<<INSERT TABLE 5>>

# Comparison of correlations within clusters and epilepsy data

Results of the correlation analyses are given in Table 6. Notable points were that attachment anxiety and avoidance were correlated significantly and positively with each other in all groups (range r=0.25 to 0.51). Correlations between attachment avoidance and alexithymia were also similar across the groups and were close to medium effect size, although those in clusters 2 and 3 were not significant. It was also notable that in cluster 3 there was only one significant correlation, and for many comparisons r was close to 0, whereas in the ES group the correlations between, alexithymia and impact of seizures (r=-0.38, p<0.001), alexithymia and attachment anxiety (r=0.28, p=0.004), alexithymia and attachment avoidance (r=0.34, p<0.001), were significant and close to a medium effect size. Permutation tests for significance of differences between correlations are located in Appendix M.

Cluster 2 had several large significant correlations and several medium correlations that were insignificant. Insignificance of medium correlations is likely to be related to the sample size (n=22).

<<INSERT TABLE 6>>

# **Discussion**

# Summary of results

The EDA results showed significant differences between the three groups of people who experienced seizures (ESs only, NESs only, or ESs+NESs) in terms of their age, gender, seizure occurrence, seizure frequency, impact of seizures score, and childhood trauma total score. As hypothesised, when the whole group with NESs were compared to those with ESs, childhood trauma reporting was greater (H1), seizure frequency was higher (H2), and impact of seizures was greater (scores more negative) (H3). These results support the viability of this dataset, which is also examined in the following demographics section.

The cluster analysis, comparisons of means, and correlation analyses provide information relating to the research aim of comparing the psychological characteristics of NES subgroups and the ES group, which will be explored in subsequent sections.

# **Demographics**

In this study 17.6% of the people who reported experiencing NES reported also having ES; other studies have reported 5 to 40%<sup>3,8</sup>. The reported mean age (36.85 years) of the NES group was similar to that reported in other studies<sup>29</sup> (mean 33.1 years, range 25-38.7 years, n=15, for studies relating to adults). The percentage of females (93.9%) in the NES only group was towards the higher end of the range (64-100%) reported in previous studies<sup>19,29</sup>. The percentage of females in the ES only group (84.0%) was higher than expected (around 50%)<sup>69</sup>; this may be due to the method of recruitment, which was largely through online support groups, as Mo, Malik, and Coulson<sup>70</sup> reported females make more use of online discussion forums than males.

# Epilepsy group

The mean alexithymia score for the epilepsy data (57.31) is approximately 1 standard deviation higher than the mean reported from a community sample in previous research using the same measure (n=1933)<sup>60</sup>. It is possible that levels of alexithymia have been inflated in this group due to inaccurate self-reporting of seizure type i.e. people who are experiencing NESs reporting they have ESs only. However, elevated levels of alexithymia in an ES group have been previously reported in research that did not rely on self-reporting of seizure type<sup>40</sup>. A medium negative correlation was found between total alexithymia score and impact of seizures for the ES group (r=-0.38, p<0.001), indicating that if they have more problems with emotion regulation, their epilepsy has a greater impact on their quality of life. One possible explanation for both these observations could be that epilepsy has an impact on the brain's ability to process emotions, so more severe epilepsy, which results in a greater impact on quality of life, also increases alexithymia. This would be consistent with previous research linking seizure control with emotion processing<sup>71</sup>. However, alexithymia did not correlate significantly with seizure frequency in the epilepsy group; this may indicate that at least part of the difference in impact of epilepsy scores is due to levels of alexithymia that are not the result of epilepsy but of other factors. From a psychological perspective the correlation between alexithymia and impact of epilepsy could mean that for those people who have epilepsy and have emotion processing difficulties, coping with the emotions that arise as a result of having seizures, e.g. anxiety, embarrassment, and sadness, may be more difficult, which then means the seizures have a greater impact on quality of life. Whatever the cause of elevated alexithymia levels in some people with ESs; intervention to improve emotion-processing skills could help improve their quality of life, which is consistent with research that has found psychological interventions

helpful for people with ES<sup>41-43</sup>.

# Cluster one

Cluster 1 had a mean trauma score (5.39) slightly above that reported previously for a non-clinical sample (mean 3.4, SD 3.1, n=83)<sup>61</sup>. This cluster seems similar in many ways to the epilepsy group. For example the mean scores on Figure 3, the correlation between seizure frequency and total childhood trauma score, and the pattern of correlations between the adult attachment and alexithymia variables in Table 6. They did differ significantly (p=0.006) on the correlation between childhood trauma and adult attachment anxiety, which was medium (0.42) for cluster 1 and virtually zero (-0.02) for the epilepsy group.

Cluster 1's mean total scores were quite similar to cluster 3. The only significant difference was childhood trauma (d=2.12, p<0.001), which was lower in cluster 1. However, there were more differences in the correlations, notably those between adult attachment anxiety, alexithymia, and childhood trauma total score, which were medium (or close to) and significant (or close to) in cluster 1 but near to zero in cluster 3. The differences between these correlations were significant except for alexithymia and childhood trauma (p=0.34, Table M.3).

Given the similarity of cluster 1 to epilepsy data and cluster 3 one possible explanation is that the aetiology is similar to cluster 3 but the childhood trauma scores are lower as they have experienced traumas not identified by the ETI-SF. The ETI-SF only asks about trauma before age 18 and therefore may miss traumas occurring in adulthood, which may to include health related traumas. However, the childhood trauma measure in cluster 1 does seem to be important as it correlates with adult

attachment anxiety, alexithymia, and seizure frequency. Perhaps in this cluster the childhood trauma was key to the development of NESs, hence its association with other characteristics, whereas in cluster 3 traumas happened within the context of already disrupted attachment relationships. This cluster appears consistent with Bodde et al.'s<sup>3</sup> model of NES aetiology, which suggests that psychogenic causation, such as trauma, combines with emotional 'make up', in this case alexithymia and attachment anxiety to produce NESs.

#### Cluster two

Cluster 2 seems distinct from the other two clusters and the epilepsy data, with mean alexithymia total score approximately 0.7 standard deviations below that reported from a community sample (n=1933)<sup>60</sup>. Cluster 2's adult attachment anxiety (d=1.19, p<0.001), adult attachment avoidance (d=0.77, p=0.004), and total alexithymia (d=2.09, p<0.001) scores were significantly lower than cluster 3's. Cluster 2's adult attachment avoidance and total alexithymia scores were also significantly lower than cluster 1's or the epilepsy data. This cluster had a mean trauma score (5.71) slightly above that reported in previous research for a healthy sample (3.5, SD 3.3, n=83). These scores may lead us to think that this group was similar to a non-clinical population in terms of attachment and alexithymia. As identified in the introduction, low levels of alexithymia have been associated with secure attachment styles<sup>46</sup>. However, this group is clearly distressed by seizures, as indicated by an impact of seizures average score higher than that of cluster 1 and significantly higher (d=1.13, p<0.001) than that of the epilepsy group.

This cluster appears consistent with clusters found in other research<sup>22, 23</sup>, which have been described as over-controlled. Reuber et al.<sup>22</sup> suggested such groups could

represent people who separate themselves from their feelings to the point that they are unaware of their distress. This would be consistent with the psychodynamic theory that NESs are connected to repression of emotions. It is not consistent however, with Cassidy's theory described in the introduction that links minimisation of emotions with rejection and avoidant attachment style, as this group scored lower than the other groups on adult attachment avoidance. Perhaps, instead of becoming avoidant of attachment, this group have become indifferent to it, and do not value attachments with others, therefore having lower adult attachment anxiety and avoidance than would be expected. This idea would need to be explored with further research.

The large correlation between adult attachment avoidance and adult attachment anxiety (d=0.51, p=0.02) in cluster 2 was notable. We need to be cautious about interpretation due to the small sample size (n=21) and exploratory nature of the correlation analysis. A meta-analysis of the correlations between ECR attachment avoidance and anxiety reported that the dimensions were correlated, with a range of -0.22 to 0.6872. This was based on the longer version of the measure used in this study and the revised version (ECR-R). They also reported that older and non-university samples had higher correlations. For the ECR-SF, Wei et al. <sup>51</sup>reported correlations of 0.25, 0.19, and 0.28 in the validation research studies. The correlations in this study seem larger, especially for cluster 2. However, other studies using clinical samples have reported higher correlations, such as 0.97 (n=82, p<0.01) in a group with obsessive compulsive disorder symptoms<sup>73</sup>. This could indicate that in clinical samples adult attachment avoidance and anxiety are more likely to be correlated, perhaps due to both being associated with abuse and trauma.

#### Cluster three

Cluster 3 was characterised by a similar pattern of means to the epilepsy data and cluster 1; most were elevated slightly further, and the childhood trauma score was significantly elevated (2.1 standard deviations above epilepsy data). This cluster with higher adult attachment anxiety, alexithymia, and childhood trauma scores than the other groups could be consistent with the NES aetiology proposed by Quinn, Schofield, and Middleton described in the introduction. They suggested that NESs might develop due to a child experiencing trauma, in the context of attachment relationships that do not provide emotional support. Experiences of trauma and alexithymia<sup>74,75</sup> are also common in those diagnosed with borderline personality disorder. A related finding in borderline personality disorder (BPD) and somatoform disorder research was that potentially traumatizing experiences, instigated by a primary care giver, were associated with alexithymia (under regulation of affect) and severity of BPD symptoms<sup>75</sup>.

Cluster 3 also had a higher attachment avoidance (mean 18.8) than that reported in a sample of undergraduate students (15.0, SD 6.4, n=65) in the measure validation research<sup>51</sup>. Dijke and Ford<sup>48</sup> reported a similar finding of elevated adult attachment avoidance and anxiety for a subgroup of their study who were diagnosed as having somatoform disorder and borderline personality disorder.

Due to the similarities identified in the previous two paragraphs, it may be useful to explore further evidence-based therapeutic approaches for treatment of personality disorders for people in this cluster, an idea also suggested by Reuber<sup>22</sup>. These techniques include mentalization-based therapy; and mindfulness, and emotion regulation training, such as dialectical behavioural therapy (DBT) <sup>76-79</sup>.

Cluster 3 showed a distinct lack of significant correlations of seizure frequency, impact of seizures, and total childhood trauma scores with the adult attachment and alexithymia variables, despite being one of the larger clusters (n=44). This may be because once a certain amount of childhood trauma has been experienced, further trauma does not increase difficulties, or perhaps as suggested above, the high levels of childhood trauma, attachment anxiety and alexithymia indicate disrupted attachment relationships, where children are not protected from experiencing traumas or supported emotionally. This attachment relationship context could be the key factor in developing NESs rather than the childhood trauma, which could be thought of as secondary.

# Cluster summary

Clusters 1 and 3 have some similarities. However, it is suggested that trauma may have a pivotal role in NES development in cluster 1 whereas disrupted attachment relationships may be key in cluster 3 and trauma secondary. Cluster 2 warrants further research and its aetiology may be linked to psychodynamic theories regarding repression of emotions. Alexithymia was an issue for all groups except cluster 2.

# Clinical implications

The results are consistent with previous research indicating increased mean levels of alexithymia in groups of people with ESs and subgroups with NESs. This suggests that interventions, such as DBT that have been reported to reduce alexithymia in BPD<sup>80</sup> and transdiagnostic<sup>81</sup> research could be explored in clinical research for those with ESs and/or NESs. Mindfulness, which is one aspect of DBT has been investigated in a small (n=12) pilot of NES patients and found to be feasible and warrant further

studies<sup>82</sup>. A randomised controlled study found that in the mindfulness treatment group compared to the social support controls, significantly more people showed clinical improvement in quality of life, they also had a significant reduction in seizure frequency, and depression and anxiety symptoms<sup>83</sup>. Techniques, such as DBT and mindfulness may help people to learn to express and manage difficult emotions. For people who have NESs that may be related to trauma this may be a useful starting point enabling them to go on to explore, with a therapist, their emotions surrounding their traumatic experiences. However, given the heterogeneity of the NES population, for example the existence of a subgroup with low alexithymia, it would be important to assess individual differences, to aid formulation, before recommending such treatment. The ETI-SF, TAS-20, and ECR-SF are short easily administered scales that could be useful in differentiating NES clusters and identifying people with ESs who have emotion regulation difficulties. The low number of incomplete responses to these surveys (n=1, n=4, n=4 respectively) indicated that they are acceptable to participants.

These measures could also help identify the pattern of high childhood trauma, alexithymia, and adult attachment difficulties characteristic of cluster 3. For this group, the possible impact of adult attachment issues on treatment should be considered, as this is known to affect treatment effectiveness<sup>84</sup>. Therapeutic approaches that incorporate attachment could be useful, such as mentalization-based therapy or cognitive analytic therapy<sup>85-87</sup>. People who score slightly lower on childhood trauma measures, with elevated alexithymia scores, could be consistent with cluster 1. This may indicate a presentation in which trauma is key to the development of NESs. This possibility could be explored with psychological assessment and formulation. People with this presentation may benefit from interventions to address the psychological

difficulties associated with the traumatic event(s), such as cognitive behavioural therapy (CBT) for trauma or eye movement desensitisation reprocessing (EMDR)<sup>88, 89</sup>.

The above points emphasise the importance of assessing individual differences for both NES and ES patients. The identified measures could be used alongside psychological assessment and formulation for all NES patients and ES patients where emotion regulation and/or attachment difficulties are indicated. This would increase the likelihood of identifying appropriate treatments.

#### Further research

In order to explore the hypothesised differences in NES aetiology it would be useful to conduct mixed methods research, using the measures to identify people with characteristics similar to each subgroup and then explore their experiences, perhaps through formulation with a clinical psychologist, using a qualitative methodology to gain greater understanding of their NES aetiology from a psychological perspective. It would be particularly useful to explore the subgroup which has low alexithymia and attachment scores in order to investigate the possibility of repression of emotions being a factor in their NES aetiology.

It is suggested that future research relating to treatments for NESs and ESs considers the individual differences in adult attachment and alexithymia, and the possible impact on appropriate treatment. As well as different types of trauma, such as health related trauma, trauma in adulthood, and whether or not the primary care giver is involved in the trauma.

Given the exploratory nature of the data analysis in this study, researchers may like to use the findings to formulate hypotheses that can be tested. For example, by collecting a sample of data and clustering it based on alexithymia and childhood trauma

scores to assess if the same pattern of means is reproduced.

# Strengths and weaknesses

A potential weakness of this research is the use of self-reporting of seizure type, and self-report measures. Self-report measures have been widely used in previous studies relating to ESs and NESs, but no other published studies appear to have relied on self-reporting of seizure type. Scrag, Brown, and Trimble<sup>90</sup> found that people who experience medically unexplained symptoms were less accurate in their reporting of their past diagnoses than others. This could be a reason for some of the outliers in the data. From a clinical perspective, related to a desire for medical explanations, it seems the most likely that ESs would be reported when in fact the person has NESs. Therefore the group most likely to be affected would be the ES group and it is unlikely this issue has affected the NES data. While the use of self-reporting may have introduced some inaccuracy, the similarities of findings in this research to previous data, e.g. the association of trauma, higher seizure frequency, and poorer quality of life with NES, supports that this is a viable way to collect data for this population. The use of selfreporting allowed the deployment of online recruitment. This had advantages in terms of access to a relatively large worldwide sample and ease and efficiency of data collection for both participants and researchers. A disadvantage was that the sample was biased towards a greater proportion of females, which could have implications for generalisability.

The sampling procedures were convenience/snowballing, most of the data analysis was exploratory, and the sample consisted of mostly British and American people. The necessary ability to understand the questions is likely to have excluded some people with intellectual disabilities. Therefore, a high degree of caution is

indicated in applying these results to other populations, especially to males, and people with intellectual disabilities.

This research uses the epilepsy group as reference group, for example when displaying means in Figure 2 and for calculation of effect sizes. The epilepsy group, however, is not truly a control group, as, due to the effects of ESs on the brain discussed above, they are not representative of the general population. Due to relevant scale norms not being available for all the measures, future research may wish to consider recruiting a control group, representative of the general population, in order to estimate effect sizes when comparing to a non-clinical population.

#### Conclusion

Comparison with previous research indicates that alexithymia (emotion processing) was a difficulty for many people in the sample; this suggests that further research, regarding activities aimed at reducing alexithymia would be useful. It will be important to assess individuals, both in research and clinical treatment, as cluster analysis indicates NES subgroups differ on childhood trauma, alexithymia, and adult attachment and one NES subgroup had lower alexithymia scores than was previously reported in a community sample<sup>60</sup>. The measures used in this research could be useful, and acceptable, to use alongside psychological formulation in clinical and research settings. In clinical settings, it is suggested that psychological formulation will be useful for those with NESs and those with ESs who have elevated alexithymia and/or adult attachment scores. This will help consider the individual differences and identify appropriate diagnosis, treatments, and support. Further clinical research is recommended to explore the effectiveness of treatments, such as DBT, for people with ESs or NESs who have elevated alexithymia. For those with elevated attachment anxiety

and/or avoidance, alexithymia and childhood trauma scores (cluster 3), especially if psychological formulation indicates that attachment relationships may be key to the development of NESs, it may be useful to explore therapies with an attachment focus, such as mentalization based therapy and cognitive analytical therapy. For those people with lower childhood trauma scores who are experiencing alexithymia difficulties (cluster 2), especially if psychological formulation indicates trauma is key to the development of NESs, therapy specifically addressing the trauma, such as CBT or EMDR may be useful to investigate.

This research alongside further academic and clinical research could lead to the development of therapeutic pathways appropriate for subgroups of people who experience NESs and ESs taking into account their individual differences.

#### References

- NHS Choices. Epilepsy 2014. Available at http://www.nhs.uk/conditions/Epilepsy.
   Accessed January 26, 2015
- 2. Cragar D, Berry D, Fakhoury T, et al. A review of diagnostic techniques in the differential diagnosis of epileptic and nonepileptic seizures. Neuropsychol Rev 2002;12:31-64.
- 3. Bodde NMG, Brooks JL, Baker GA, et al. Psychogenic non-epileptic seizures—definition, etiology, treatment and prognostic issues: A critical review. Seizure 2009;18:543-553.
- 4. Fiest KM, Dykeman J, Patten SB, et al. Depression in epilepsy: A systematic review and meta-analysis. Neurology 2013;80:590-599.
- 5. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia 2010;51:676-685.
- 6. Martlew J, Pulman J, Marson AG. Psychological and behavioural treatments for adults with non-epileptic attack disorder. Cochrane Database of Systematic Reviews 2014.
- 7. Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: A systematic review and meta- analysis. Neurology 2011;77:1005.
- 8. Hoepner R, Labudda K, May TW, et al. Distinguishing between patients with pure psychogenic nonepileptic seizures and those with comorbid epilepsy by means of clinical data. Epilepsy Behav 2014;35:54-58.
- 9. Harden CL, Jovine L, Burgut FT, et al. A comparison of personality disorder characteristics of patients with nonepileptic psychogenic pseudoseizures with those of patients with epilepsy. Epilepsy Behav 2009;14:481-483.

- 10. Baillés E, Pintor L, Fernandez-Egea E, et al. Psychiatric disorders, trauma, and MMPI profile in a Spanish sample of nonepileptic seizure patients. Gen Hosp Psychiatry 2004;26:310-315.
- 11. Kimiskidis V, Valeta T. Epilepsy and anxiety: Epidemiology, classification, aetiology, and treatment. Epileptic Disord 2012;14:248-256.
- 12. Moore PM, Baker GA. Non- epileptic attack disorder: A psychological perspective. Seizure-Eur J Epilep 1997;6:429-434.
- 13. Quintas R, Raggi A, Giovannetti AM, et al. Psychosocial difficulties in people with epilepsy: A systematic review of literature from 2005 until 2010. Epilepsy Behav 2012;25:60-67.
- 14. Jones R, Rickards H, Cavanna AE. The prevalence of psychiatric disorders in epilepsy: A critical review of the evidence. Funct Neurol 2010;25:191.
- 15. Francis P, Baker GA. Non-epileptic attack disorder (NEAD): A comprehensive review. Seizure 1999;8:53-61.
- 16. Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in europe: A review with economic modeling. Epilepsia 2007;48:2224-2233.
- 17. Magee JA, Burke T, Delanty N, et al. The economic cost of nonepileptic attack disorder in Ireland. Epilepsy Behav 2014;33:45-48.
- 18. Ahmedani BK, Osborne J, Nerenz DR, et al. Diagnosis, costs, and utilization for psychogenic non-epileptic seizures in a US health care setting. Psychosomatics 2013;54:28-34.
- 19. Bodde NMG, Brooks JL, Baker GA, et al. Psychogenic non-epileptic seizures—diagnostic issues: A critical review. Clin Neurol Neurosurg 2009;111:1-9.

- 20. MacDonald T, Hill A, Phan T, et al. Psychiatry versus general physicians: Who is better at differentiating epileptic from psychogenic non-epileptic seizures?

  Australasian Psychiatry 2012;20:379-383.
- 21. Cragar DE, Berry DTR, Schmitt FA, et al. Cluster analysis of normal personality traits in patients with psychogenic nonepileptic seizures. Epilepsy Behav 2005;6:593-600.
- 22. Reuber M, Pukrop R, Bauer J, et al. Multidimensional assessment of personality in patients with psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry 2004;75:743-748.
- 23. Uliaszek AA, Prensky E, Baslet G. Emotion regulation profiles in psychogenic nonepileptic seizures. Epilepsy Behav 2012;23:364-369.
- 24. Reuber M, Mayor R. Recent progress in the understanding and treatment of nonepileptic seizures. Curr Opin Psychiatry 2012;25:244-250.
- 25. Brown RJ, Bouska JF, Frow A, et al. Emotional dysregulation, alexithymia, and attachment in psychogenic nonepileptic seizures. Epilepsy Behav 2013;29:178-183.
- 26. Myers L, Perrine K, Lancman M, et al. Psychological trauma in patients with psychogenic nonepileptic seizures: Trauma characteristics and those who develop PTSD. Epilepsy Behav 2013;28:121-126.
- 27. Bodde NMG, van der Kruijs SJM, Ijff DM, et al. Subgroup classification in patients with psychogenic non-epileptic seizures. Epilepsy Behav 2013;26:279-289.
- 28. Selkirk M, Duncan R, Oto M, et al. Clinical differences between patients with nonepileptic seizures who report antecedent sexual abuse and those who do not. Epilepsia 2008;49:1446-1450.
- 29. Fiszman A, Alves-Leon SV, Nunes RG, et al. Traumatic events and posttraumatic stress disorder in patients with psychogenic nonepileptic seizures: A critical review. Epilepsy Behav 2004;5:818-825.

- 30. Lally N, Spence W, McCusker C, et al. Psychological processes and histories associated with nonepileptic versus epileptic seizure presentations. Epilepsy Behav 2010;17:360-365.
- 31. Corallo F, De Luca R, Leonardi R, et al. The clinical use of quality-of-life scales in neurological disorders. Acta Neuropsychiatrica 2013;25:193-205.
- 32. Bowlby J. A secure base: Clinical implications of attachment theory. London: Routledge; 1988.
- 33. Brennan KA, Clark CL, Shaver PR. Self-report measurement of adult attachment: An integrative overview. In: Simpson JA, Rholes WS, editors. Attachment theory and close relationships. New York: The Guilford Press; 1998. p. 46-76.
- 34. Quinn M, Schofield M, Middleton W. Conceptualization and treatment of psychogenic non-epileptic seizures. Journal of Trauma & Dissociation 2008;9:63-84.
- 35. Holman N, Kirkby A, Duncan S, et al. Adult attachment style and childhood interpersonal trauma in non-epileptic attack disorder. Epilepsy Res 2008;79:84-89.
- 36. Brown RJ, Bouska JF, Frow A, et al. Emotional dysregulation, alexithymia, and attachment in psychogenic nonepileptic seizures. Epilepsy Behav 2013;29:178-183.
- 37. Bagby RM, Parker JDA, Taylor GJ. The twenty- item Toronto alexithymia scale—Item selection and cross- validation of the factor structure. J Psychosom Res 1994;38:23-32.
- 38. Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behav Assess 2004;26:41-54.
- 39. Kaplan MJ, Dwivedi AK, Privitera MD, et al. Comparisons of childhood trauma, alexithymia, and defensive styles in patients with psychogenic non-epileptic seizures

- vs. Epilepsy: Implications for the etiology of conversion disorder. J Psychosom Res 2013;75:142-146.
- 40. Bewley J, Murphy PN, Mallows J, et al. Does alexithymia differentiate between patients with nonepileptic seizures, patients with epilepsy, and nonpatient controls? Epilepsy Behav 2005;7:430-437.
- 41. Charyton C, Elliott JO, Moore JL, et al. Is it time to consider cognitive behavioral therapy for persons with epilepsy? Clues from pathophysiology, treatment and functional neuroimaging. Expert Rev Neurother 2010;10:1911-1927.
- 42. Fenwick PB. Behavioural treatment of epilepsy. Int Rev Psychiatry 1989;1:297-306.
- 43. McLaughlin D, McFarland K. A randomized trial of a group based cognitive behavior therapy program for older adults with epilepsy: The impact on seizure frequency, depression and psychosocial well-being. J Behav Med 2011;34:201-207.
- 44. Whitehead K, Kandler R, Reuber M. Patients' and neurologists' perception of epilepsy and psychogenic nonepileptic seizures. Epilepsia 2013;54:708-717.
- 45. Cassidy J. Emotion regulation: Influences of attachment relationships. Monogr Soc Res Child Dev 1994;59:228-249.
- 46. Hexel M. Alexithymia and attachment style in relation to locus of control. Pers Individ Dif 2003;35:1261-1270.
- 47. Troisi A, Argenio A, Peracchio F, et al. Insecure attachment and alexithymia in young men with mood symptoms. J Nerv Ment Dis 2001;189:311.
- 48. van Dijke A, Ford JD. Adult attachment and emotion dysregulation in borderline personality and somatoform disorders. Borderline Personal Disord Emot Dysregul 2015;2:6.

- 49. Fonagy P, Luyten P. A developmental, mentalization- based approach to the understanding and treatment of borderline personality disorder. Dev Psychopathol 2009;21:1355-1381.
- 50. Crossley J, Jacoby A, Baker GA. The reliability and validity of the revised Liverpool impact of epilepsy scale for use in people with new-onset epilepsy. Epilepsy Behav 2012;26:175-181.
- 51. Wei M, Russell D, Mallinckrodt B, et al. The experiences in close relationship scale ( ECR)-short form: Reliability, validity, and factor structure. J Pers Assess 2007;88:187-204.
- 52. Alessandri G, Fagnani C, Di Gennaro G, et al. Measurement invariance of the experiences in close relationships questionnaire across different populations. Span J Psychol 2014;17.
- 53. Wongpakaran T, Wongpakaran N. A short version of the revised 'experience of close relationships questionnaire': Investigating non-clinical and clinical samples. Clin Pract Epidemiol Ment Health 2012;8:36-42.
- 54. Taylor GJ. Twenty-item Toronto alexithymia scale (TAS-20) 2014. Available at http://www.gtaylorpsychiatry.org/tas.htm. Accessed March 11, 2016
- 55. Hale KE. Validity of the Toronto alexithymia scale (TAS-20) in an inpatient population. US: ProQuest Information & Learning; 2013.
- 56. Caretti V, Porcelli P, Solano L, et al. Reliability and validity of the Toronto structured interview for alexithymia in a mixed clinical and nonclinical sample from Italy.

  Psychiatry Res 2011;187:432-436.
- 57. Bach M, Bach D. Alexithymia in somatoform disorder and somatic disease: A comparative study. Psychother Psychosom 1996;65:150-152.

- 58. Bagby RM, Ayearst LE, Morariu RA, et al. The internet administration version of the 20- item Toronto alexithymia scale. Psychol Assess 2014;26:16-22.
- 59. Taylor GJ, Bagby RM, Parker JDA. The 20- item Toronto alexithymia scale: IV.

  Reliability and factorial validity in different languages and cultures. J Psychosom Res
  2003;55:277-283.
- 60. Parker JDA, Taylor GJ, Bagby RM. The 20-item Toronto alexithymia scale: III. Reliability and factorial validity in a community population. J Psychosom Res 2003;55:269-275.
- 61. Bremner JD, Bolus R, Mayer EA. Psychometric properties of the early trauma inventory- self report. J Nerv Ment Dis 2007;195:211.
- 62. Bremner D. Early trauma inventory self report-short form (ETISR-SF) 2009.


  Available at http://www.psychiatry.emory.edu/documents/research/ETISR-SF.pdf.

  Accessed March 11, 2016
- 63. Osório FL, Salum GA, Donadon MF, et al. Psychometrics properties of early trauma inventory self report--short form (ETISR-SF) for the Brazilian context. PLoS One 2013;8.
- 64. Chase S, Beatty, Jr., Ondersma SJ. A randomized trial of the effects of anonymity and quasi anonymity on disclosure of child maltreatment- related outcomes among postpartum women. Child Maltreatment 2011;16:33-40.
- 65. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.
- 66. Afifi A, Clark VA, May S. Cluster analysis. Computer-aided multivariate analysis. 4th ed. London: Chapman & Hall/CRC; 2004. p. 417-444.
- 67. Milligan G. An examination of the effect of six types of error perturbation on fifteen clustering algorithms. Psychometrika 1980;45:325-342.

- 68. Statistic Solutions. Conduct and interpret a cluster analysis 2016. Available at http://www.statisticssolutions.com/cluster-analysis-2/. Accessed February 28, 2016
  69. Savic I. Sex differences in human epilepsy. Exp Neurol 2014;259:38-43.
- 70. Mo PKH, Malik SH, Coulson NS. Gender differences in computer-mediated communication: A systematic literature review of online health-related support groups. Patient Educ Couns 2009;75:16-24.
- 71. Szaflarski JP, Allendorfer JB, Heyse H, et al. Functional MRI of facial emotion processing in left temporal lobe epilepsy. Epilepsy & Behavior 2014;32:92-99.
- 72. Cameron JJ, Finnegan H, Morry MM. Orthogonal dreams in an oblique world: A metaanalysis of the association between attachment anxiety and avoidance. Journal of Research in Personality 2012;46:472-476.
- 73. Carpenter L, Chung MC. Childhood trauma in obsessive compulsive disorder: The roles of alexithymia and attachment. Psychology and Psychotherapy: Theory, Research and Practice 2011;84:367-388.
- 74. Weaver TL, Clum GA. Early family environments and traumatic experiences associated with borderline personality-disorder. J Consult Clin Psychol 1993;61:1068-1075.
- 75. van Dijke A, Ford JD, van Son M, et al. Association of childhood-trauma-by-primary caregiver and affect dysregulation with borderline personality disorder symptoms in adulthood. Psychological Trauma-Theory Research Practice and Policy 2013;5:217-224.
- 76. Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. The American Journal of Psychiatry 2009;166:1355-1364.

- 77. Haskayne D, Hirschfeld R, Larkin M. The outcome of psychodynamic psychotherapies with individuals diagnosed with personality disorders: A systematic review. Psychoanalytic Psychotherapy 2014;28:115-138.
- 78. Lynch TR, Trost WT, Salsman N, et al. Dialectical behavior therapy for borderline personality disorder. Annu Rev Clin Psychol 2007;3:181.
- 79. Trull TJ, Stepp SD, Durrett CA. Research on borderline personality disorder: An update. Curr Opin Psychiatry 2003;16:77-82.
- 80. Goodman M, Carpenter D, Tang CY, et al. Dialectical behavior therapy alters emotion regulation and amygdala activity in patients with borderline personality disorder. J Psychiatr Res 2014.
- 81. Neacsiu AD, Eberle JW, Kramer R, et al. Dialectical behavior therapy skills for transdiagnostic emotion dysregulation: A pilot randomized controlled trial. Behav Res Ther 2014;59:40-51.
- 82. Baslet G, Dworetzky BA, Perez DL, et al. Treatment of psychogenic nonepileptic seizures. Clin EEG Neurosci 2015;46:54-64.
- 83. Tang V, Poon WS, Kwan P. Mindfulness-based therapy for drug-resistant epilepsy:
  An assessor-blinded randomized trial. Neurology 2015;85:1100-1107 1108p.
- 84. Jellema A. Insecure attachment states: Their relationship to borderline and narcissistic personality disorders and treatment process in cognitive analytic therapy. Clin Psychol Psychother 2000;7:138-154.
- 85. Bateman A, Fonagy P. Mentalization-based treatment for borderline personality disorder. Oxford: Oxford University Press; 2006.
- 86. Agrawal HR, Gunderson J, Holmes BM, et al. Attachment studies with borderline patients: A review. Harvard Review of Psychiatry (Taylor & Francis Ltd) 2004;12:94-104.

- 87. Levy KN, Meehan KB, Weber M, et al. Attachment and borderline personality disorder: Implications for psychotherapy. Psychopathology 2005;38:64-74.
- 88. Kar N. Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: A review. Neuropsychiatr Dis Treat 2011;7.
- 89. Shapiro F, Maxfield L. Eye movement desensitization and reprocessing (EMDR): Information processing in the treatment of trauma. J Clin Psychol 2002;58:933-946.
- 90. Schrag A, Brown RJ, Trimble MR. Reliability of self-reported diagnoses in patients with neurologically unexplained symptoms. J Neurol Neurosurg Psychiatry 2004;75:608.
- 91. Hothorn T, Hornik K, van de Wiel MA, et al. Implementing a class of permutation tests: The coin package. Journal of Statistical Software 2008;28.
- 92. Mangiafico SS. One-way analysis with permutation test 2015. Available at http://rcompanion.org/rcompanion/d\_06a.html. Accessed 10 April, 2016
- 93. Everitt B. Cluster analysis [electronic resource]. 5th ed. Chichester, West Sussex, U.K. : Wiley; 2011.
- 94. Cohen J. A power primer. Psychol Bull 1992;112:155-159.



<sup>&</sup>lt;sup>a</sup>Exited by survey logic; <sup>b</sup>Excluded due to missing data

Figure 1. Numbers of participants; providing a full data set for each question or scale, exited or excluded, and included with missing data




Figure 2. Illustration of NES clusters




Figure 3. Chart illustrating means for each NES cluster expressed in standard deviations of difference from epilepsy data means

**Tables** 

Table 1. Numbers of participants reporting ES only, NES only, or ES+NES within each category

	Gender*:		Country:			Seizure occurrence***:		
Group	Male	Female	UK and NI	USA	Other	In the last year	Over a year ago	Not sure
ES only (n=119)	19 (16.0%)	100 (84.0%)	104 (87.4%)	10 (8.4%)	5 (4.2%)	86 (72.3%)	33 (27.7%)	
<b>NES only (n=131)</b>	8 (6.1%)	123 (93.9%)	94 (71.8%)	28 (21.4%)	9 (6.8%)	122 (93.1%)	9 (6.9%)	
ES+NES (n=28)a	5 (17.9%)	23 (82.1%)	22 (78.6%)	5 (17.9%)	1 (3.6%)	24 (85.7%)	3 (10.7%)	1 (3.6%)

<sup>\*</sup> Differences between the three groups significant at p<0.05; \*\* significant at p<0.01; \*\*\* significant at p<0.001.

Table 2. Descriptive statistics for each seizure type group in the study

	Demographics:		Childhood trauma:	Adult attachment:		Alexithymia:	Seizures:	Impact of seizures:
Age in years**		Total score***	Attachment anxiety	Attachment avoidance	Total score	Seizure frequency*	Total score***	
ES only	32.43 (10.68) <sup>a</sup>	n=119 <sup>b</sup>	5.48 (5.06)	22.57 (6.82)	18.35 (8.19)	57.31(13.14)	15.21(77.53) n=86	-8.69 (6.04)
NES only	36.85 (11.01)	n=131	9.78 (6.35)	22.37 (8.23)	17.43 (7.26)	58.79 (14.43)	41.05(76.18)	-14.58(6.42)
ES + NES	38.04 (12.77)	n=28	12.57 (7.02)	23.46 (5.44)	20.67 (7.23)	61.36 (14.02)	20.88 (24.37 )	-11.11(9.16)

<sup>&</sup>lt;sup>a</sup> Values given are sample mean (sample standard deviation); <sup>b</sup> n varied slightly due to missing data, where there was a large variation from the stated n this is reported next to the data; \* Differences between the three group means significant at p<0.05, \*\* differences significant at p<0.01; \*\*\* significant at p<0.001.

Table 3. Numbers of participants in each cluster within each category

	Gender*:		Country:			Seizure occurrence:	
Group	Male	Female	UK and NI	USA	Other	In the last year	Over a year ago
NES cluster 1 (n=49)	7(14.3%)	42(85.7%)	40(81.6%)	5(10.2%)	4(8.2%)	44(89.8%)	5(10.2%)
NES cluster 2 (n=21)	0	21(100%)	14(66.7)	7(33.3%)		21(100%)	
NES cluster 3 (n=44)	1(2.3%)	43(97.7%)	30(68.2%)	13(29.5%)	1(2.3%)	41(93.2%)	3(6.8%)

<sup>\*</sup> Differences between the three groups significant at p<0.05;

Table 4. Descriptive statistics for each NES cluster, and the ES group

8 1		Childhood trauma:			Alexithymia:	Seizures:	Impact of seizures:	
	Age in years**	Total score***	Attachment anxiety**	Attachment avoidance**	Total score***	Seizure frequency	Total score***	
Cluster 1	35.63(11.48) <sup>a</sup> n=49 <sup>b</sup>	5.39 (3.41)	22.00(8.32)	18.47(7.65)	61.77(9.41)	33.28(64.14)	-13.06(7.22)	
Cluster 2	39.38 (10.51) n=21	5.71 (4.47)	17.52(6.93)	12.43(6.49)	37.43(5.90)	63.43(79.31)	-15.52(5.14)	
Cluster 3	38.25 (10.46) n=44	16.09(2.99)	25.64(7.60)	18.77(6.56)	66.81(10.43)	39.29(93.43)	-16.26(5.93)	
Epilepsy only (0)	32.45 (10.68) n=119	5.48 (5.06)	22.57 (6.82)	18.35 (8.19)	57.31(13.14)	15.21(77.53) n=86	-8.69 (6.04)	

<sup>&</sup>lt;sup>a</sup>Data displayed, sample mean (sample standard deviation); <sup>b</sup>n varied slightly due to missing data, where there was a large variation from the stated n this is reported next to the data; \*differences between the group means significant at p<0.05, \*\*significant at p<0.01; \*\*\* significant at p<0.001.

Table 5. Effect sizes and confidence intervals of post hoc tests comparing means of the NES clusters, and the ES group

Age in years	3		
	Cluster 2	Cluster 3	Epilepsy
Cluster 1	0.35 (-1.06, 0.36)a	0.24 (-0.80, 0.31)	0.30 (-0.17, 0.77)
Cluster 2		0.11 (-0.59, 0.80)	0.65 (0.01, 1.29)
Cluster 3			0.54 (0.09, 1.00)*
Childhood t	rauma total score		
	Cluster 2	Cluster 3	Epilepsy
Cluster 1	0.06 (-0.65, 0.52)	2.12 (2.46, 1.77)***	0.02 (-0.38, 0.34)
Cluster 2		2.05 (2.63, 1.47)***	0.05 (-0.54, 0.64)
Cluster 3			2.10 (1.75, 2.45)***
Attachment	anxiety		
	Cluster 2	Cluster 3	Epilepsy
Cluster 1	0.66 (-0.10, 1.41)	0.53 (-1.17, 0.10)	0.08 (-0.61, 0.44)
Cluster 2		1.19 (1.93, 0.45)***	0.74 (1.40, 0.08)*
Cluster 3			0.45 (-0.06, 0.96)
Attachment	avoidance		
	Cluster 2	Cluster 3	Epilepsy
Cluster 1	0.74 (0.15, 1.32)*	0.04 (-0.51, 0.43)	0.01 (-0.42, 0.45)
Cluster 2		0.77 (1.34, 0.21)**	0.72 (1.26, 0.19)**
Cluster 3			0.05 (-0.35, 0.46)
Alexithymia	total score		
	Cluster 2	Cluster 3	Epilepsy
Cluster 1	1.73 (1.38, 2.08)***	0.36 (-0.74, 0.03)	0.32 (-0.03, 0.66)
Cluster 2		2.09 (2.47, 1.71)***	1.41 (1.75, 1.07)***
Cluster 3			0.67 (0.30, 1.05)***
Impact of se	eizures		
	Cluster 2	Cluster 3	Epilepsy
Cluster 1	0.41 (-0.26, 1.08)	0.53 (-0.07, 1.12)	0.72 (1.23, 0.22)***
Cluster 2		0.12 (-0.52, 0.76)	1.13 (1.70, 0.57)***
Cluster 3			1.25 (1.72, 0.79)***

<sup>&</sup>lt;sup>a</sup>Data given for all entries is Cohen's d effect size based on standard deviation of epilepsy only data (95% confidence interval).

Table 6. Correlations of childhood trauma, adult attachment, impact of seizures and seizure frequency in each NES cluster and the ES group

		Alexithymia total score	Childhood trauma total score	Adult attachment anxiety	Adult attachment avoidance	Impact of seizures
d tal	Cluster 1	0.26 (-0.02, 0.50) <sup>a</sup>				
ildhoo ıma tot score	Cluster 2	0.28 (-0.24, 0.74)				
Childhood trauma total score	Cluster 3	0.07 (-0.20, 0.36)				
C	Epilepsy	0.11 (-0.08, 0.29)				
nt —	Cluster 1	0.40 (0.13, 0.62)**	0.42 (0.18, 0.61)**			
Adult attachment anxiety	Cluster 2	0.36 (-0.06, 0.70)	0.22 (-0.29, 0.66)			
Ad tach anx	Cluster 3	-0.06 (-0.38, 0.30)	0.02 (-0.27, 0.30)			
at	Epilepsy	0.28 (0.10, 0.43)**	-0.02 (-0.24, 0.17)			
nt	Cluster 1	0.38 (0.15, 0.57)**	-0.10 (-0.40, 0.24)	0.37 (0.11, 0.60)**		
Adult attachment avoidance	Cluster 2	0.30 (-0.11, 0.68)	-0.19 (-0.62, 0.31)	0.51 (0.11, 0.79)*		
Ad tack void	Cluster 3	0.28 (-0.01, 0.55)	-0.16 (-0.46, 0.18)	0.30 (0.03, 0.53)*		
= at	Epilepsy	0.34(0.16, 0.51)***	0.10 (-0.09, 0.31)	0.25 (0.07, 0.42)**		
<del>_</del>	Cluster 1	-0.13 (-0.37, 0.18)	-0.29 (-0.54, 0.02)*	-0.16 (-0.42, 0.14)	-0.12 (-0.40, 0.19)	
Impact of seizures	Cluster 2	0.00 (-0.48, 0.41)	0.59 (0.17, 0.8.)**	-0.30 (-0.63, 0.09)	-0.40 (-0.76, 0.11)	
mpa seiz	Cluster 3	-0.03 (-0.35, 0.33)	-0.21 (-0.50, 0.07)	0.13 (-0.24, 0.49)	-0.06 (-0.38, 0.28)	
	Epilepsy	-0.38(-0.55, -0.16)***	-0.02 (-0.20, 0.16)	-0.28 (-0.48, -0.07)**	-0.19 (-0.34, -0.03)	
zure uency	Cluster 1	0.03 (-0.28, 0.37)	0.32 (-0.01, 0.58)*	0.05 (-0.26, 0.37)	-0.13 (-0.45, 0.22)	-0.45 (-0.69, -0.11)**
	Cluster 2	-0.05 (-0.45, 0.39)	0.27 (-0.28, 0.66)	-0.22 (-0.65, 0.22)	-0.24 (-0.65, 0.28)	-0.07 (-0.54, 0.40)
	Cluster 3	-0.06 (-0.38, 0.25)	0.04 (-0.29, 0.37)	-0.15 (-0.43, 0.14)	-0.03 (-0.31, 0.24)	-0.19 (-0.51, 0.16)
fī	Epilepsy	0.17 (-0.05, 0.37)	0.23 (-0.02, 0.45)*	-0.07 (-0.28, 0.13)	0.05 (-0.18, 0.27)	-0.36 (-0.55, -0.15)**

<sup>&</sup>lt;sup>a</sup>Data given for each item are: Spearman's rho (bootstrap BCa 95% confidence interval); \* Correlation significant at p<0.05; \*\* significant at p<0.01; \*\*\* significant at p<0.001.



# Appendix A

Journal guidance

# **Epilepsia**

© The International League Against Epilepsy

# Instructions for Authors

*Epilepsia* is the official journal of the **International League Against Epilepsy (ILAE)**. The Journal publishes original articles on all aspects of epilepsy, clinical and experimental, especially of an International importance. Manuscripts should be the work of the author(s), must not have been previously published elsewhere, and must not be under consideration by another journal.

If you have a question not addressed in these pages then contact the journal at epilepsia@epilepsia.com.

# EDITORIAL POLICIES

(1) The Editors-in-Chief of *Epilepsia* invite manuscripts in all areas of epilepsy-related research, especially if useful for an international audience. Manuscript submission is free. As a general guide, manuscripts will be considered for publication if they contribute significant new findings to the field. The primary aim of *Epilepsia* is to publish innovative and high quality papers that provide clinical and/or basic science insights.

The Editors will make an initial evaluation of all manuscripts to determine whether they are appropriate for the Journal (editorial review). Reports are unlikely to be accepted for publication if they are not based in sound science and/or they provide only incremental knowledge of limited general usefulness. To assist authors in deciding whether to submit a manuscript to *Epilepsia*, we provide the following commonly encountered examples of reports which we are unlikely to publish:

- (a) Papers that describe clinical features or epidemiology in a given region of the world that do not provide new insights into epilepsy not already published;
- (b) Correlative studies where the sample size is too low to provide statistically sound findings;
- (c) Genetic association studies in which the association has already been confirmed;
- (d) Investigatory articles describing the application of a new technical variation which is not likely to have clinical utility or impact;
- (e) Correlative clinical studies, which are conceived with- out clear hypotheses and the results of which are of little clinical utility;

- (f) Basic research studies that are not grounded in epilepsy relevant hypotheses;
- (g) Single group, before-after evaluations of therapeutic interventions and programs that do not include a con-trol group;
- (h) Small case series which largely replicate what is already known;
- (i) Case reports (highly unlikely to be accepted unless they provide novel findings of theoretical or clinical importance).

*Epilepsia* will accept, review, and publish studies with negative results, provided that appropriate controls have been used, the study is adequately powered, and the results are important and or useful to others in the research community.

- (2) Manuscripts describing original research, and passing the initial editorial screen, will be subject to external peer review. Acceptance of these manuscripts is never guaranteed. At least two reviews are generally obtained for these submissions; additional reviews maybe sought at the discretion of the Editors. Appeals of rejection decisions will be considered by the Editors-in-Chief; decisions of the Editors-in-Chief are final.
- (3) In the cover letter, authors should indicate that the material described in the manuscript is the work of the author(s), has not been previously published, except in abstract form, and that it is not simultaneously under consideration by any other journal.
- (4) As a condition of publication, *Epilepsia* requires authors to transfer copyright to the ILAE. Authors will be asked to login into Author Services and complete the appropriate license agreement via Wiley Author Licensing Service.
- (5) *Epilepsia* complies with recommendations of the International Committee of Medical Journal Editors (<a href="http://www.icmje.org">http://www.icmje.org</a>). Authors are required to include a statement at the end of their manuscript affirming that the work described is consistent with the Journal's guidelines for ethical publication (see below). *Epilepsia* is a member of the Committee on Publication Ethics (COPE), and we adhere to its principles (<a href="http://publicationethics.org/">http://publicationethics.org/</a>).



(6) Data reporting should follow appropriate checklists and guidelines (e.g., STROBE for observational trials; CONSORT for clinical trials), and other checklists should be consulted for other reports including diagnostic accuracy (STARD) or meta-analyses (PRISMA). A completed checklist should be submitted with their protocols as a supporting document. Checklists can be downloaded from the following: STROBE – http://strobe-statement.org

CONSORT - http://www.consort-statement.org/consort-statement/

STARD – http://www.stard-statement.org/PRIMSA – http://www.prisma-statement.org/

- (7) For animal experiments, the authors need to state that the experiments have been performed in accordance with all applicable national and/or international guidelines/laws. The authors should also provide their allowance number for performing animal experiments when available and should add a statement indicating that the principles outlined in the ARRIVE guidelines and the Basel declaration (<a href="http://www.basel.declaration.org">http://www.basel.declaration.org</a>) including the 3R concept have been considered when planning the experiments.
- (8) Authors are also required to provide full disclosure of any conflict of interest as a part of the submitted manuscript (see Disclosure of Conflicts of Interest in the Manuscript Format section under Manuscript Preparation). Manuscripts that do not conform to these guidelines will not be considered for publication. Discovery of or failure to comply will result in rejection of the manuscript, retraction of the published article, and/or a ban on future submissions by the author(s).
- (9) In submitting a manuscript, the submitting/corresponding author must acknowledge that: a) all co-authors have been substantively involved in the study and/or the preparation of the manuscript; b) no undisclosed groups or persons have had a primary role in the study and/or in manuscript preparation (i.e., there are no "ghost-writers"); and c) all co-authors have seen and approved the submitted version of the paper and accept responsibility for its content. The Editors reserve the right to require authors to submit their original data for comparison with the manuscript's illustrations, tables, and results.
- (10) Sometimes editors make mistakes. If an author believes an editor has made a decision in error we welcome an appeal. Please contact the editor and in your appeal letter, clearly state why you think the decision is a mistake and set out specific responses to any comments related to the rejection. An appeal does not guarantee a re-review.

#### Types of Manuscripts

The following types of material may be considered for publication:

- (1) Peer-reviewed papers (to be submitted by upload- ing online via Scholar One Manuscript Central http://mc.manuscriptcentral.com/Epilepsia)
- a. Critical reviews and commentaries. The Editors-in-Chief encourage submission of reviews and commentaries on topical and controversial issues. Authors planning/proposing such papers should consult with the Editors-in-Chief before submitting the manuscripts. Authors can also approach one of Epilepsia's Associate Editors about possible reviews. While there are no strict length limits on this type of paper, manuscripts generally should be around 4000 words and no longer than 6000 words, with no more than 5 to 7 figures/tables (combined). Longer manuscripts will be considered at the discretion of the Editors-in-Chief.
- b. Full-length original research articles. These articles should be limited in length to 4000 words and no more than 6 figures and tables. Additional figures and tables can be submitted as online only Supporting Information (which will be linked to the online version of the published article). Authors should aim for presenting material clearly and completely, in the most concise and direct form possible; the Introduction should be brief (typically less than 600 words), and the Discussion should be restricted to issues directly relevant to the Results (typically less than 1500 words).
- c. Brief communications. These articles including short studies, small series, case reports, etc. should describe previously unpublished material, including original research and/or clinical observations. The papers are limited generally to 1800 words (excluding the summary), 15 references (unless more are approved by the Editors-in-Chief prior to manuscript acceptance), and no more than 2 figures and tables (combined). Please note that the Editors may use their discretion to request that brief communications be shortened to a length that they feel is appropriate.

Brief Communications may be published online only (not in the print version of the journal) depending on their impact. They will appear in a specific issue in the electronic (online) version, and will be identified and described (Short Summary) in the Table of Contents of the printed version of that issue. The online versions will be dealt with by PubMed/Medline and other indexing/citation systems, exactly the same way as print articles; they will be referenced by their DOI number and date of online publication (which will continue to be approximately 35 working days following acceptance).

(2) Editorially-reviewed material (to be submitted by email to the Editors-in-Chief at epilepsia@epilepsia.com, except letters and commentaries which should be submit- ted online at http://mc.manuscriptcentral.com/Epilepsia)



Other contributions that do not report original research will be published at the discretion of the Editors-in-Chief, with only editorial review. Such material includes: workshop reports and conference summaries, obituaries, letters/commentary to the Editors (500 word limit, and only exceptionally figures or tables), special (brief) reports from ILAE Commissions or other working groups, and announcements. Such material will usually be published in **Gray Matters**.

(3) Supplements (to be submitted as directed by the

Editors-in-Chief)

Supplements, including meeting abstracts, will be published only after advance arrangements are made with the Editors-in-Chief. Guidelines for preparing supplements are given below. Proposal for, and questions about supplements should be directed to one of the Editors-in-Chief (epilepsia@epilepsia.com). Such proposals must be explicitly approved by the Editors-in-Chief, who will also confirm the page rate charge for the proposed supplement.

(4) <u>Special reports</u> In some cases, special reports from ILAE Commissions or other broadly constituted working groups will be published after peer review. The corresponding author of such papers should confer with the Editors-in-Chief to determine if the full manuscript will be peer-reviewed, or whether only a short version will be considered for publication in *Epilepsia*'s Gray Matters (see below).

#### MANUSCRIPT PREPARATION

## **General Style Guidelines**

Manuscripts are to be submitted (and will be published) in English. Writers not fluent in English should seek assistance to ensure proper grammar and syntax, and to help generate a manuscript organization that facilitates reader understanding. Authors for whom English is a second language may choose to have their manuscript professionally edited before submission, to improve the English. A list of independent suppliers of editing services can be found at http://author services.wiley.com/bauthor/english\_language.asp. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication. The Editors will not re-write papers submitted in unacceptable English, and will return such manuscripts for revision before sending them out for review.

Use international non-proprietary (generic) names when referring to drugs; avoid proprietary (brand) names. All acronyms should be spelled out at first men-

tion. Spell out s below 10 and all numbers that are used to begin a sentence; use Arabic numerals for numbers above 10 and for units of measure. Manuscript text should be double spaced with at least 1 inch margin on all sides using 12 fonts. Word limits for each type of submission will generally be enforced unless there are good reasons not to do so. If manuscripts exceed these guidelines, authors should submit a covering letter explaining why the additional length is necessary.

Authors are encouraged to use the most recent terminology of seizure and epilepsy classification of the ILAE (Berg et al., 2010). Studies involving treatments should adhere to ILAE's classification of medically refractory epilepsy (Kwan et al., 2011).

#### **Manuscript Format**

- a. Critical Reviews and Invited Commentaries
- ☐ **Title Page** (see Full-Length Original Research below)
- Summary and Key Words

Reviews and commentaries should generally begin with a summary (less than 300 words) of the content. The summary (structured) should provide the reader with the main points of the paper, and be divided into Objective, Methods, Results, and Significance. The Summary should be followed by a list of 3–6 Key Words; please provide Key Words that will assist in the indexing of your article (i.e., make it easy for individuals who are searching PubMed to find your paper). Do not use words already incorporated into your title (those words are picked up automatically by the indexing service).

#### □ Body of review

There is no designated structure for the body of Reviews or Commentaries. Authors are encouraged, however, to use sub-headings to separate major sections and to facilitate clarity.

Tables, figures, figure legends, references, acknowledgements, statement of compliance with the Journal's guidelines for ethical standards in publishing, disclosure of conflicts of interest, and Supplementary material – as for *Full-Length Original Research* (see below).

#### b. Full-Length Original Research, Special Reports, and

#### **Brief Communications**

#### □ Title Page

Include the following information: Full title of the manuscript which generally should be as concise and precise as possible; authors' names (first and last names, middle initial when commonly used by that author); institutional affiliation for each author (use superscripted numbers after each author's name, and a corresponding superscripted number before each institutional affiliation); contact information for the corresponding author (name, address, telephone number, fax number, e-mail address); running title (no more than 40 characters and spaces in length);



Key Words for use by abstracting services (same as following summary); number of text pages; number of words; number of figures; number of tables.

#### □ Summary and Key Words

Provide a summary of no more than 300 words (200 words for Brief Communications). The summary of Full-Length Original Research reports should consist of four sections, labeled: Objective; Methods; Results; Significance. This structured summary should concisely and specifically describe why and how the study was performed, the essential results, and what the authors conclude from the results. To promote brevity, authors may use phrases rather than complete sentences. The summary for Special Reports, Invited Commentaries, and Brief Communications is not structured, but should cover the same topics as the structured summary. The summary (structured or unstructured) should be followed by 3-6 Key Words (see above). A second short summary (less than 100 words) is required for Brief Communications that can be used in the print issue Table of Contents. Submit the second short summary as a Supporting Document.

#### □ Introduction

State the objectives of the study clearly and concisely, and provide a context for the study by referring judiciously to previous work in the area. Do not attempt to present a comprehensive review of the field. Provide a statement about the significance of this research for understanding and/or treating epilepsy.

#### □ Methods

Describe the research methods in sufficient detail that the work can be duplicated; alternatively, give references (if they are readily accessible) to previous comprehensive descriptions. Identify the statistical procedures that were used and the rationale for choosing a particular method, especially if it is not standard.

Reports of experimental studies on humans must explicitly certify that the research received prior approval by the appropriate institutional review body and that informed consent was obtained from each volunteer or patient. Studies involving animals must include an explicit statement that animal care and use conformed to institutional policies and guidelines. When animals are subjected to invasive procedures, details must be provided regarding the steps taken to eliminate/minimize pain and suffering, including the specific anesthetics, analgesics, or other drugs used for that purpose (amounts, mode of delivery, frequency of administration).

If extensive descriptions of methods are needed, provide basic information within the text and submit supplementary information for online Supporting Information.

#### □ Results

Results should be reported fully and concisely, in a logical order. Do not repeat methodological details from the Methods section. Where possible, use figures and/or tables to present the data in a clear and concise format. Do not repeat data in the text that are given in a table, but refer to the table. Provide textual explanations for all figures, with clear reference to the figure(s) under discussion. Descriptive information provided in figure legends need not be repeated in the text; use the text, however, to describe key features of the figures. When appropriate, give sample numbers, the range and standard deviation (or mean error) of measurements, and significance values for compared populations.

#### **□** Discussion

Provide an interpretation of the results and assess their significance in relation to previous work in the field. Do not repeat the results. Do not engage in general discussion beyond the scope of the experimental results. Conclusions should be supported by the data obtained in the reported study; avoid speculation not warranted by experimental results, and label speculation clearly. Discuss the significance of the data for understanding and/or treating epilepsy.

#### **□** Statistical Methods

The following guidelines assume familiarity with common statistical terminology and methods. We recommend that authors consult a biostatistician during the planning stages of their study, with further consultations during the analytical and interpretational stages.

#### 1. Analysis guidelines:

- Use robust analytic methods when data are skewed.
- Use Kaplan Meier methods, Cox Proportional Hazards, and mixed models analyses for longitudinal data.
- · Account properly for statistical outliers.
  - Use exact methods as much as possible in analy- ses of categorical data.
- Use appropriate correction procedures to account for multiple comparisons, and conduct post- hoc comparisons with statistically appropriate methods.

#### 2. Presentation guidelines:

- Report means accompanied by standard deviations; standard errors should not be used.
- Present results with only as much precision as is appropriate.
- Present confidence intervals, whenever possible, including in figures.
- Describe quantity of missingness and methods used for handling such missingness.



- In general, present two-sided p-values. P-values larger than 0.01 should be reported to two deci—mal places, those between 0.01 and 0.001 to three decimal places, and those smaller than 0.001 should be reported as p<0.001.
- In reporting clinical trials, include a flow diagram, a completed trial checklist, and trial registration information. The CONSORT flow diagram and checklist are recommended (http://www.consort-statement.org/).

#### □ Acknowledgements

Acknowledge sources of support (grants from government agencies, private foundations, etc.); including funds obtained from private industry. Also acknowledge (consistent with requirements of courtesy and disclosure) participation of contributors to the study who are not included in the author list.

#### **□** Disclosure of Conflicts of Interest

In addition, each author should provide full disclosure of any conflicts of interest. One of the following sentences must be included at the end of the paper: either "Author A has received support from, and/or has served as a paid consultant for .... Author B has received support from .... The remaining authors have no conflicts of interest." Or "None of the authors has any conflict of interest to disclose." Note: Disclosure is needed for financial income/payment from commercial sources, the interests of which are relevant to this research activity. Please identify sources from which financial assistance/income was obtained during the period of the research activity and generation of the current report. Grants from government and/ or private agencies should be identified in the Acknowledgements section. All papers must include the following statement to indicate that the authors have read the Journal's position on issues involved in ethical publication (see below) and affirm that their report is consistent with those guidelines: "We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines."

#### □ References

Authors are responsible for the accuracy of their references. References should follow a modified Vancouver style format. Citation of references in the text should be in superscript numbers (including those in figure legends and tables). Cite the end references in numerical order. The first three authors should be listed and followed by et al. Use journals' PubMed abbreviations in the reference list at the end of the paper (as opposed to the journals' names being written out in full).

Number of references is limited to the following: Full Length Original Research – 40
Brief communications – 15
Reviews – 80
Special Reports – 80
Sample References:

#### Journal article

Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. *Epilepsia* 2010;51: 676–685.

# Journal article published electronically ahead of print version

Faure JB, Akimana G, Carneiro JE, et al. A comprehensive behavioral evaluation in the lithium-pilocarpine model in rats: Effects of carisbamate administration during status epilepticus. *Epilepsia* Epub 2013 May 11.

#### Journal article In Press

Battino D, Tomson T, Bonizzoni E,et. al. Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry. *Epilepsia* (in press 2013)

#### Letter

Marucci, G. Commentary on the new ILAE classification system for focal cortical dysplasias. *Epilepsia* 2012; 1:219–220. Letter

#### Published Abstract

Noe, K, Drazkowski, J. Safety of Long-Term Video EEG Monitoring. *Epilepsia* 2008; 59 (Suppl. 7):1.125. Abstract

#### Book

Shorvon, S. Handbook of the treatment of epilepsy. Oxford: Blackwell Publishing; 2005

#### Chapter in a Book

Fraser RT, Gumnit RJ, Thorbecke R, et al. Psychosocial rehabilitation: A pre- and postoperative perspective. In Engel J (Ed) Surgical treatment of the epilepsies. 2nd Ed. New York: Raven, 1993:669–667

#### Online

Russo CA, Elixhauser A. Hospitalizations for Epilepsy and Convulsions, 2005: Statistical Brief #46. Available at: <a href="http://www.hcup-us.ahrq.gov/reports/statbriefs/sb46.">http://www.hcup-us.ahrq.gov/reports/statbriefs/sb46.</a> jsp. Accessed February 12, 2011.

#### □ Figure legends

Number each legend sequentially to conform to the figure number (e.g., Figure 1, Figure 2...). The legend should provide a brief description of the figure, with explanation of all symbols and abbreviations. Written permission to use non-original material must be



obtained (from the original authors (where possible) and publishers) by the authors. Credit for previously published material (author(s), date, journal/book title, and publisher) must be included in the legend.

#### □ Tables

Tables should be formatted as the authors wish the table to appear in print. Present all tables together at the end of the manuscript, with each table on a separate manuscript page. Each table should be given a number and a descriptive title. Provide notes and explanations of abbreviations below the table, and provide clear headings for each column and row. Do not duplicate data given in the text and/or in figures. Written permission to use non-original material must be obtained (from the original authors (where possible) and publishers) by the authors. Credit for previously-published material (author(s), date, journal/book title, and publisher) must be included in the table notes.

#### □ Figures

All figures should be prepared with care and professionalism. Submissions that do not comply with the following formatting requirements will be returned for correction and re-submission. Figures should be submitted as TIFF files in the size expected for final publication-approximately 3 inches for half column and 6 to 7 inches for double columns. Submit black and white figures with a minimum of 300 dpi (MRI scans) and for line drawings or figures that included imbedded text (bar graphs with numbers) at least 600 dpi. Complex figures (including photographs, micrographs, and MR-related images), either in color, in half-tones, or in black and white, should also be submitted in TIF format with a resolution of at least 600 dpi. We recommend saving the TIF files with LZW compression (an option when you 'save as' in packages like Photoshop), which will make the files smaller and quicker to upload without reducing the resolution/quality. Save each TIF file with a name that includes the first author's last name and the figure number as referenced in the text (e.g., Smith-fig1.tif). Provide clear labels on the ordinate and abscissa. Figures with more than one part should be combined by the authors in the correct orientation and labeled with A, B, C etc. When relevant, include calibration information. Scale bars should be applied to photomicrographs of histology and relevant figures. Label figures using Calibri font and be sure that all labels are large enough to be clearly legible. The maximum size of any figure is  $17 \times 22.5$ cm and 40 megapixels; the total number of pixels for each figure (i.e., height × width) must be less than 40 megapixels otherwise the image will not convert to PDF for review. There is no charge for color figures. We strongly encourage authors to generate figures in

color (to enhance clarity of presentation and aesthetic appeal), using the following color palette:

	<b>CMYK</b>	<b>RGB</b>
Color	<b>Definition</b>	<b>Definition</b>
Yellow	0/11/65/0	255/222/117
Orange	0/58/100/8	227/124/29
Red	0/100/60/37	163/1/52
Green	27/0/95/55	103/119/24
Green-blue	100/0/28/65	0/83/94
Blue	100/46/0/0	0/118/192

Photographs or videos of patients should not reveal patient identity; masking eyes and/or other identifiers is compulsory unless the eyes are essential to the meaning of the photograph or video. In addition, such photographs and videos must be accompanied by a letter saying that signed consent forms authorizing publication have been obtained for all identifiable patients, and that the consents will be maintained by the author for seven years or until the patient reaches 21 years of age, whichever is longer. Do not send *Epilepsia* the consent forms; U.S. Federal privacy rules prohibit sending signed consent forms to *Epilepsia* or Wiley-Blackwell Publishing without written permission from the patient to do so.

#### **□** Supporting Information

Supporting information, to be published online only, can be submitted for review. Such material may include: additional figures, large tables, videos, etc. that cannot be accommodated within the normal printed space allocation for an article - but provide important complementary information for the reader. As determined by the reviewers and Editors, supporting information will be posted on the Wiley Online Library Epilepsia server and directly integrated into the full-text HTML article. Explicit reference to the supporting information in the main body of the text of the article is recommended, and the material must be captioned at the foot of the text, below the reference list. Supporting information will be published as submitted and will not be corrected or checked for scientific content, typographical errors or functionality. Although hosted on Wiley Online Library, the responsibility for scientific accuracy and file functionality remains entirely with the authors. A disclaimer will be displayed to this effect with any supporting information published.

Supporting Information files should be accompanied by detailed information (if relevant) about what they are and how they were created (e.g., a native dataset from a specific piece of apparatus). Acceptable formats for supporting information include:

General – Standard MS Office format (Word, Excel, PowerPoint, Project, Access, etc.); PDF



Graphics – GIF; TIF (or TIFF); EPS; PNG; JPG (or JPEG); BMP; PS (postscript); embedded graphics (e.g. a GIF pasted into a Word file) are also acceptable.

Video-QuickTime; MPEG; AVI. All video clips must be created with commonly-used codecs, and the codec used should be noted in the supplementary material leg-

end. Video files should be tested for playback before submission, preferably on computers not used for its creation, to check for any compatibility issues. Video clips are likely to be large; try to limit their size to less than 10 MB.

#### c. Gray Matters

#### □ Title

Letters, workshop reports, etc. should be given a brief title. Letters should start with the opening *To the Editors:* 

#### □ Authors and affiliations

Provide authors' names (first and last names, middle initial when commonly used by that author); institutional affiliation for each author (use superscripted numbers after each author's name, and a corresponding superscripted number for each institutional affiliation); e-mail contact address for the corresponding author.

#### □ Body of submission

Letters and commentaries should be restricted to 500 words or less, unless otherwise allowed by the Editors. Figures and tables will be included only in exceptional cases. Gray Matters will not be used to publish case reports. Tables, figures, figure legends, references, acknowledgements, disclosure of conflicts of interest, and Supporting Information – as for *Full Length Original Research* (see above).

### (3) Details of Preparation

Detailed instructions for all aspects of electronic manuscript submission (including useful information on image files) is available on the *Epilepsia* Scholar One Manuscripts website (<a href="http://mc.manuscriptcentral.com/Epilepsia">http://mc.manuscriptcentral.com/Epilepsia</a>); please click 'Get Help Now' at the top right-hand corner of the homepage; then click on the link 'Author and Reviewer Guides'.

#### a. Text

Manuscripts should be prepared using a word processing program. Save text and tables as a Microsoft Word document. Place the lead author's name and the page number in the upper right hand corner of each page. Begin numbering with the Title Page as #1, and number pages consecutively including references, figure legends, and tables. Text (including acknowledgements, disclosure statement, and figure legends) and references should be double-spaced, and be composed in 12 point font (preferably Times New Roman). When generating a revised manuscript, identify the altered portions of the manuscript with highlighted

text, underlined, colored or bold font to indicate where changes to the original version of the text have been made.

#### b. Tables, Figures, and Supporting Information

See above.

# - Manuscript Submission

#### (1) Online submission via Manuscript

Central Manuscripts should be submitted via the Journal's website on Scholar One Manuscripts at <a href="http://mc.manuscriptcentral.com/Epilepsia">http://mc.manuscriptcentral.com/Epilepsia</a>. Instructions at the site will guide the author through the submission process. Separate files should be submitted for: Cover letter to editors, manuscript text, tables, each figure, supplemental material, permissions to use previously-published material, patient consent declaration.

#### (2) Cover letter

All manuscripts should be submitted with a cover letter, addressed to the Editors-in-Chief, which explains why the manuscript should be published in *Epilepsia*. In particular, authors should identify novel findings, innovative approaches, and important insights that would make the manuscript of particular value to the broad readership of *Epilepsia*.

## (3) <u>Text, table and figure files</u>

All files should be given a label that includes the first author's last name and the nature of the file (e.g., Smith-manuscripttext.doc; Smith-Fig1.tif).

#### (4) Other materials/forms

At the time of submission, all other materials (e.g., permission forms, supplemental material, patient consent) must be uploaded onto Manuscript Central, faxed to the editorial office (Fax: +1-702-548-0706) or emailed to epilepsia@epilepsia.com.

#### (5) **Questions/Contacts**

Questions and request for assistance should be addressed to the Journal at epilepsia@epilepsia.com. The Managing Editor, Ms. Laurie Beninsig will in most cases be able to provide direction, or will contact the Editors-in-Chief for further assistance.

# Manuscript Publication

(1) Once accepted for publication, authors are required to provide a portrait color photograph of the first au- thor (1.25 inches × 1.25 inches, 300 dpi light colored background) along with a one sentence line describing who they are (limited to 100 characters with spaces) to be included in the title page, findings presented as a



figure for presentation on the ILAE website and to be used in promotion of the article.

(2) The Editors may approach authors to provide one or two of their figures as possible cover material for the printed journal. These figures will need to be large enough and with the appropriate dpi.

#### (3) Online tracking of your article

Online production tracking of your article is available through Blackwell's Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive an e-mail with a unique link that enables him/her to register and have the article automatically added to the system. To facilitate this service, please ensure that you provide a complete e-mail address when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor/ for more details on online production tracking and for other publication resources (including FAQs and tips on article preparation, submission and more).

#### (4) Proofs

Proofs are sent electronically in PDF format, and must be returned within 48 hours of receipt. Late returns of proofs will cause substantial delay in article publication. It is the corresponding author's responsibility to see that the proof is accurately checked and corrected, and to return the proofs promptly to avoid publication delays. Please check the spelling of coauthors' names, text, tables, legends, and references carefully. It is the authors' responsibility to make sure that the information is accurate. Indicate corrections either using the PDF editor function or with clear hard-copy indications which should be faxed to +1508-586-4024. The proof corrections stage is not the time for fine-tuning language or making any other substantive changes. Confine corrections to errors in printing; authors may be charged for major authorinitiated changes.

#### (5) Early View

The publication-ready PDF of an article will be published initially online. Early View publication will precede print publication by a variable time period. The online publication date will be considered the official

publication date. Early View published material will be indexed by PubMed, and can be cited by DOI number. In general, manuscripts will be published on Early View within 35 working days of the publisher's receipt of the complete accepted manuscript (including CAF and permission forms).

# Appendix A Author Guidance 2.64

#### (6) Print issue publication

Publication of an article in a print issue will typically occur after Early View publication. Print issue articles carry their electronic publication date.

#### (7) Public access of accepted/published articles

Prior to acceptance, articles may be shared (print or electronic copies) with colleagues; at this time the article may be posted on the author's personal website, on his/ her employer's website, and/or on free public servers in the author's subject area – with the acknowledgement that the article has been submitted to Epilepsia. After an article has been accepted, authors may share print or electronic copies of the article (accepted and revised to address peer review) with colleagues, and may use the material in personal compilations, other publications of his/her own work, and for educational/research purposes. Articles published in Epilepsia are freely accessible to the public via the Wiley Online Library website - one year after publication. Epilepsia will automatically upload NIH-supported studies to PubMed Central after a 12 month moratorium (provided the appropriate funding acknowledgement has been provided). Similarly, at this time authors may post an electronic version of the article on their own personal websites, on their employer's website/repository, and on free public servers in the relevant subject area. Electronic versions of the accepted (or published) article must include a link to the published version of the article, together with the following text: "The definitive version is at http://www3.interscience.wiley.com/ journal/117957420/home." Authors can also choose to make their articles open access and available free for all readers through the payment of an author fee. This facility allows authors to fulfill the requirements for studies supported by agencies requiring open access before 12 months for full details visit http:// authorservices.wiley.com/bauthor/onlineopen.asp

#### (8) Reprints

An order form for reprints will be included with the electronic transmission of initial proofs. For pricing of quantities in excess of 500 copies, please contact Brooke Maynard at Wiley-Blackwell Publishing (bmaynard@wiley.com).

#### — Supplement Publication

#### (1) Policy

A decision to publish a supplement is based on the topic, Guest Editor, proposed table of contents and contributing authors, and availability of necessary



funding. Supplement topics must be of importance to *Epilepsia* readers, and supplements will be published only if there is scientific or educational rationale for combining papers on a given theme within one publication. The number and quality of the articles must be sufficient to constitute a body of important information. Each supplement will have a Guest Editor who is an expert on the theme of the supplement. The Guest Editor is responsible for compiling articles and assisting with the editorial process, and is responsible for the overall quality and integrity of the supplement. The publication of a supplement usually incurs charges, payable to Wiley-Blackwell Publishing.

#### (2) Publishing guidelines

Articles in a supplement are subject to the same copyright regulations and ethical publishing guidelines that apply to articles published in regular issues of *Epilepsia*. All supplement articles are peer-reviewed; the first level of review is carried out by the Guest Editor and his/her designates, and the second level of review is overseen by the Editors-in-Chief.

#### (3) Online-only and print supplements

Abstract supplements, from meetings or congresses sponsored by the ILAE or its chapters, will generally be published online only. Longer articles will be published in print supplements (these articles will also appear online). Print supplements may be generated from proceedings of symposia organized by an independent body of professionals in which the funding organization does not have a controlling voice on scientific content. The Guest Editor and/or organizers of such symposia should be members of ILAE chapters. Supplements from other sources including invited supplements initiated by the Editors-in-Chief will also are considered.

#### (4) Supplement content

The content of supplements must not be biased in the interest of any sponsor. *Epilepsia* does not permit presentations that extol a commercial product, and supplements should not be perceived as endorsing a particular product. Publication of supplements does not constitute product or sponsor endorsement by *Epilepsia* or ILAE. In most cases, supplements should not focus on a single product; however, when a new product is introduced, a single product focus will be

considered by the Editors-in-Chief. In all cases, the content of a supplement must be determined by a body of professionals working independently of the sponsor. The Guest Editor is charged with assuring that the material presented in the supplement is not biased toward the interests of the product manufacturer.

#### (5) Supplement sponsorship

Most supplements require external sponsorship. When a supplement proposal is presented to the Editors-in-Chief, they will fix appropriate fees. Supplement costs may be negotiated with the Editors-in-Chief and the publisher's supplement representative. The Editors-in-Chief may choose to publish a supplement of particular academic and clinical value without external sponsorship.

#### (6) <u>Instructions for submitting supplements</u>

Agreement to publish a supplement must be obtained from the Editors-in-Chief prior to submission. Proposals for supplements should be submitted to the Editors-in-Chief (epilepsia@epilepsia.com) well in advance of desired publication date, so that the proposal can be evaluated and discussed. Timing is especially critical if the supplement is linked to a symposium or congress, since rapid publication is often important to assure that the information is current. The proposals should identify the Guest Editor and, include a list of topics and potential authors. The proposal should include an estimate of supplement length so that the Editors-in-Chief can provide reasonable information about the cost of publication. The cost of any supplement, and related financial issues, should be discussed with Chris Breslin at Wiley-Blackwell Publishing (cbreslin@ wiley.com). Collection of manuscripts, as well as initial editing and reviewing should be carried out by the Guest Editor on a schedule predetermined in discussion with the Editors-in-Chief. The Guest Editor is responsible for timely submission of articles, and should expect to assist the Editors-in-Chief in collecting final revised manuscripts (including any required permissions).

#### (7) Format of supplement articles

In general, articles should follow the format described above for Critical Reviews (in regular issues of the Journal). Contact the Editors-in-Chief for additional information and special instructions.

# Epilepsia's Position on Issues Involved in Ethical Publication

#### (1) Authorship/Credit

*Epilepsia* follows the guidelines of the International Committee of Medical Journal Editors regarding criteria for authorship (<a href="http://www.icmje.org/">http://www.icmje.org/</a>). The author list should include those who have made

substantial intellectual/conceptual contributions to the work. Such contributions should include participation in: (a) experimental design, data acquisition, and analysis and interpretation of data; (Continued on next page)



# Epilepsia's Position on Issues Involved in Ethical Publication (cont.)

(b) drafting and/or critically revising the article with respect to intellectual content; and (c) final approval of the manuscript version to be published. We strongly discourage the inclusion of "honorary" authors (individuals who are listed as authors but have not contributed to the work/manuscript - e.g., heads of departments) and "ghost" authorship (individuals who have substantively contributed to the work and/or manuscript but are not listed as authors or contributors). In cases where writing support is necessary, the writer(s) should be acknowledged in the Acknowledgements section, and the source of funding for writing support should be provided under Disclosure of Conflicts of Interest. The corresponding/submitting author must, when submitting a manuscript, give assurance that all authors have read and approved the submitted manuscript. The corresponding/submitting author should also give assurance that all authors have seen and approved the final (accepted) manuscript, and that the manuscript includes all conflict of interest declarations. All individuals who have contributed to the work but do not meet criteria for authorship should be cited in the Acknowledgement section.

#### (2) Funding

Sources of funding (for the research, data analysis, and manuscript generation) should always be disclosed in the Acknowledgements section. Sources may include government funding agencies, institutions and departments, private industry, and charitable organizations and foundations. Funding for all authors should be acknowledged.

#### (3) Procedures involving Human and Animal Subjects

The authors should include within the manuscript an explicit statement indicating that the submitted study was approved by the relevant research ethics committee or institutional review board (IRB). When the study involves human participants (including material from human subjects), authors should also provide assurance that appropriate consent was obtained. When studies involve animal subjects, authors should provide methodological details about steps taken to minimize pain/discomfort. Such papers must contain a statement that affirms that the experimental protocols were approved by the institutional animal care and use committee (IACUC).

#### (4) Confidentiality

In all cases, information and images derived from individual patients must be presented with assurance of appropriate consent and with details removed that might reveal identity of the individual.

#### (5) Disclosure

All authors are required to disclose associations which might affect their ability to present and/ or interpret data objectively, particularly financial ties to funding sources for the work under review (e.g., membership on corporate scientific boards, stock ownership, consultant arrangements, patent ownership or application, etc.). Disclosure of such associations for the Editorial personnel of *Epilepsia* (Editors-in-Chief, Associate Editors, Editorial Board members) will be published each year. Reviewers will also be asked to affirm that they have no conflict of interest when critiquing a manuscript.

# (6) Research Misconduct (Data Fabrication/ Falsification)

*Epilepsia* will attempt to ensure that any allegations of misconduct are properly investigated. In the case of any allegations, authors will be given a right to respond. While the Journal is limited in its ability to investigate misconduct, we will seek COPE's advice and alert appropriate bodies and encourage them to investigate.

# (7) <u>Plagiarism, Duplication, and</u> <u>Redundant</u> <u>Publication</u>

Epilepsia requires that work submitted for publication is the authors' own work and has not been misappropriated. When previously published material is used, appropriate credit must be given and written permission obtained (for use of copyrighted material). Epilepsia also explicitly discourages duplication of published material and redundant publication.

# (8) <u>Corrections of Erroneous Information</u>

Authors are expected to proof-read their articles carefully before returning page proofs for publication. They should make needed corrections at this time. We recognize that it is only human to err occasionally, and the Journal is committed to correcting mistakes when those errors affect the interpretation of data or information presented in an article. (Continued on next page)



# Epilepsia's Position on Issues Involved in Ethical Publication (cont.)

Such corrections will be published in the form of an Erratum, and linked to the original article electronically. Errors that result from author oversight in the proofing process, and that do not affect data interpretation, will not be corrected.

#### (9) Peer Review

*Epilepsia* is committed to a peer-review system that is fair to the author and enhances the value of the articles published in the Journal. In order to encourage qualified reviewers too offer their time and efforts to the Journal, reviewer identity is kept confidential. Reviewers are chosen for their expertise in the

field; conflicts of interest are avoided whenever the Editors are aware of such issues, and reviewers are asked to affirm that they have no conflicts of interest in reviewing a given *Epilepsia* manuscript. Authors are encouraged to identify specific individuals who, they believe, cannot provide unbiased review. While the Editors-in-Chief reserve the right to make the final decision to accept or reject an article, appeals will be seriously considered. Address appeals to the Editors-in-Chief, who will examine the reviews and the author responses, consult the relevant Associate Editor, and seek additional reviewer input if deemed necessary.





# Appendix B. Questions and Measures

# Early life events, individual differences, and seizures

Survey	Questions				
How old are yo	ou?		year	rs	
What Country	do you live in?				
What gender a	re you? (Please o	circle one)			
mal	le female	transg	gender	other gender	prefer not to say
Have you expe	rienced seizures	, attacks, or fi	its?		
yes, in the last year	yes, over a year ago	never	not su	ıre	
IF yes, approxi	mately how ofter	n do you expe	erience th	iese seizures, attac	eks, or fits? Enter
the approxima	te number of tim	ıes per month	ı in the bo	ox:	
Do you have a	diagnosis of <b>epil</b>	l <b>epsy</b> ? If you	r doctor ł	nas told you your s	eizures are
<b>epileptic</b> answ	ver yes, see infor	mation sheet	for furth	er information.	
yes	no	not sure			
Do you have <b>n</b> o	on-epileptic seiz	zures? Non-e	pileptic s	eizures may be cal	lled PNES,
functional seiz	ures, non-epilep	tic attack disc	order (NE	(AD) or conversion	ı disorder. See
information sh	neet for further in	nformation.			
yes	no	not sure			
If you are unsu	ıre if you have ep	oilepsy or nor	ı-epilepti	c seizures, write in	the box below
any names you	ır seizures, fits, o	r attacks hav	e been giv	ven:	



# Revised Liverpool Impact of Epilepsy Scale

We would like to know how much you feel the attacks you have had affect your everyday life. For each item listed, please ring the number which shows <u>best</u> how you feel.

Thinking about the attacks you have had, do you feel they have affected for better or worse :

	Very much for the better	Somewhat for the better	No difference		Very much for the worse	Does not apply
a) Your relationship with your spouse/partner?	1	2	3	4	5	6
b) Your relationship with other close member of your family	1	2	3	4	5	6
c) Your social life and social activities?	1	2	3	4	5	6
d) Whether or not you are able to work in paid employment?.	1	2	3	4	5	6
e) The kind of paid work you can do?	1	2	3	4	5	6
f) Your health overall?	1	2	3	4	5	6
g) Your relationships with friends?	1	2	3	4	5	6
h) The way you feel about yourself?	1	2	3	4	5	6
i) Your plans and ambitions for the future?	1	2	3	4	5	6
j) Your standard of living?	1	2	3	4	5	6
k) Whether or not you are able to drive?	1	2	3	4	5	6
l) The level of your independence	1	2	3	4	5	6





# **Experiences in Close Relationship Scale-Short Form (ECR-S)**

**Instruction:** The following statements concern how you feel in romantic relationships. We are interested in how you generally experience relationships, not just in what is happening in a current relationship. Respond to each statement by indicating how much you agree or disagree with it. Mark your answer using the following rating scale:

1	2	3	4	5	6	7
Strongly	Disagree	Slightly	Neutral	Slightly	Agree	Strongly
Disagree		Disagree		Agree		Agree

1.	My desire to be very close sometimes scares people away.	
2.	I do not often worry about being abandoned.	
3.	I am nervous when partners get too close to me.	
4.	I want to get close to my partner, but I keep pulling back.	
5.	It helps to turn to my romantic partner in times of need.	
6.	I usually discuss my problems and concerns with my partner.	
7.	I find that my partner(s) don't want to get as close as I would like.	
8.	I worry that romantic partners won't care about me as much as I care about them.	
9.	I need a lot of reassurance that I am loved by my partner.	
10.	I turn to my partner for many things, including comfort and reassurance.	
11.	I try to avoid getting too close to my partner.	
12.	I get frustrated if romantic partners are not available when I need them.	

Wei, M., Russell, D. W., Mallinckrodt, B., & Vogel, D. L. (2007). The experiences in Close Relationship Scale (ECR)-Short Form: Reliability, validity, and factor structure. *Journal of Personality Assessment, 88,* 187-204.



According to the wishes of the author, the Toronto Alexithymia Scale is not reproduced here, however a small sample of questions are included as examples.

Using the scale provided as a guide, indicate how much you agree or disagree with each of the following statements by circling the corresponding number. Give only one answer for each statement.

Circle 1 if you STRONGLY DISAGREE
Circle 2 if you MODERATELY DISAGREE
Circle 3 if you NEITHER DISAGREE NOR AGREE
Circle 4 if you MODERATELY AGREE
Circle 5 if you STRONGLY AGREE

		Strongly Disagree	Moderately Disagree	Neither Agree nor Disagree	Moderately Agree	Strongly Agree
1.	I am often confused about what emotion I am feeling.	1	2	3	4	5
2.	It is difficult for me to find the right words for my feelings.	1	2	3	4	5
12.	People tell me to describe my feelings More.	1	2	3	4	5



# This questionnaire asks about childhood trauma, including sexual abuse. If you find this distressing, please feel free to leave out some or all of these questions.

# Early Trauma Inventory Self Report-Short Form (ETISR-SF) J. Douglas Bremner, Emory University School of Medicine, Atlanta GA

Part 1. General Traumas. <u>Before the age of 18</u>		
1. Were you ever exposed to a life-threatening natural disaster?	YES	NO
2. Were you involved in a serious accident?	YES	NO
3. Did you ever suffer a serious personal injury or illness?	YES	NO
4. Did you ever experience the death or serious illness of a parent or a primary		
caretaker?	YES	NO
5. Did you experience the divorce or separation of your parents?	YES	NO
6. Did you experience the death or serious injury of a sibling?	YES	NO
7. Did you ever experience the death or serious injury of a friend?	YES	NO
8. Did you ever witness violence towards others, including family members?	YES	NO
9. Did anyone in your family ever suffer from mental or psychiatric illness or have		
a "breakdown"?	YES	NO
10. Did your parents or primary caretaker have a problem with alcoholism or		
drug abuse?	YES	NO
11. Did you ever see someone murdered?	YES	NO
Part 2.Physical Punishment. <u>Before the age of 18</u>		
1. Were you ever slapped in the face with an open hand?		NO
Were you ever slapped in the face with an open hand?      Were you ever burned with hot water, a cigarette or something else?	.YES	NO NO
1. Were you ever slapped in the face with an open hand?	.YES	
Were you ever slapped in the face with an open hand?      Were you ever burned with hot water, a cigarette or something else?	.YES .YES	NO
Were you ever slapped in the face with an open hand?      Were you ever burned with hot water, a cigarette or something else?      Were you ever punched or kicked?	.YES .YES .YES	NO NO
<ol> <li>Were you ever slapped in the face with an open hand?</li> <li>Were you ever burned with hot water, a cigarette or something else?</li> <li>Were you ever punched or kicked?</li> <li>Were you ever hit with an object that was thrown at you?</li> <li>Were you ever pushed or shoved?</li> </ol>	.YES .YES .YES	NO NO NO
<ol> <li>Were you ever slapped in the face with an open hand?</li> <li>Were you ever burned with hot water, a cigarette or something else?</li> <li>Were you ever punched or kicked?</li> <li>Were you ever hit with an object that was thrown at you?</li> <li>Were you ever pushed or shoved?</li> </ol> Part 3.Emotional Abuse.Before the age of 18	.YES .YES .YES .YES	NO NO NO
1. Were you ever slapped in the face with an open hand? 2. Were you ever burned with hot water, a cigarette or something else? 3. Were you ever punched or kicked? 4. Were you ever hit with an object that was thrown at you? 5. Were you ever pushed or shoved?  Part 3.Emotional Abuse.Before the age of 18  1. Were you often put down or ridiculed?	.YES .YES .YES .YES	NO NO NO
1. Were you ever slapped in the face with an open hand?  2. Were you ever burned with hot water, a cigarette or something else?  3. Were you ever punched or kicked?  4. Were you ever hit with an object that was thrown at you?  5. Were you ever pushed or shoved?  Part 3.Emotional Abuse.Before the age of 18  1. Were you often put down or ridiculed?  2. Were you often ignored or made to feel that you didn't count?	. YES . YES . YES . YES . YES	NO NO NO
1. Were you ever slapped in the face with an open hand? 2. Were you ever burned with hot water, a cigarette or something else? 3. Were you ever punched or kicked? 4. Were you ever hit with an object that was thrown at you? 5. Were you ever pushed or shoved?  Part 3.Emotional Abuse.Before the age of 18  1. Were you often put down or ridiculed?	. YES . YES . YES . YES . YES	NO NO NO NO
1. Were you ever slapped in the face with an open hand?	. YES . YES . YES . YES . YES	NO NO NO NO
1. Were you ever slapped in the face with an open hand?  2. Were you ever burned with hot water, a cigarette or something else?  3. Were you ever punched or kicked?  4. Were you ever hit with an object that was thrown at you?  5. Were you ever pushed or shoved?  Part 3.Emotional Abuse.Before the age of 18  1. Were you often put down or ridiculed?  2. Were you often ignored or made to feel that you didn't count?  3. Were you often told you were no good?	YES YES YES YES YES	NO NO NO NO

# Continued on the next page



# Part 4.Sexual Events. Before the age of 18

1. Were you ever touched in an intimate or private part of your body (e.g. breast,		
thighs, genitals) in a way that surprised you or made you feel uncomfortable?	YES	NO
2. Did you ever experience someone rubbing their genitals against you?	YES	NO
3. Were you ever forced or coerced to touch another person in an intimate or		
private part of their body?	YES	NO
4. Did anyone ever have genital sex with you against your will?	YES	NO
5. Were you ever forced or coerced to perform oral sex on someone against your		
will?	YES	NO
6. Were you ever forced or coerced to kiss someone in a sexual rather than an		
affectionate way?	YES	NO
If you responded "YES" for any of the above events, answer the following for the	one th	at has had

If you responded "YES" for any of the above events, answer the following for the one that has had the greatest impact on your life. In answering consider how you felt at the time of the event.

1. Did you experience emotions of intense fear, horror or helplessness?YES	NO
2. Did you feel out-of-your-body or as if you were in a dream?YES	No

# **Appendix C**

Table C.1. List of organisations and sectors the study was promoted through

Contact Organisation	Sector
	NHS
	Facebook group
	Facebook page
	Charity
	Facebook group
	Facebook page
	Facebook group
	Facebook forum
	Facebook group
	NHS
	NHS



### Appendix D

# Participant information Sheet

# Relationships between early life events, individual differences, and seizures

#### Who are the researchers?

The main researcher is Liz Tallentire. She is training to be a clinical psychologist. This study is part of her doctoral thesis at Lancaster University.

Two people are supervising this study:

- Dr Ian Fletcher, Senior Lecturer, Lancaster University, and
- Dr Jayne Martlew, Consultant Clinical Neuropsychologist at the Walton Centre, Liverpool.

# What is the study about?

This study is investigating the relationship between early life events, individual differences, and seizures. It will consider seizure type, seizure frequency, and impact of seizures. The researchers hope this will increase understanding of the relationship between what happens to people in their early lives, the way they process emotions, how they relate to others, and their seizure experiences. In future, this may help professionals to identify people who are more likely to have different types of seizures.

# Why have I been approached?

You may be someone who experiences epileptic or non-epileptic seizures, or both. Seizures are also called fits, convulsions, or attacks. They may be given a name other than epileptic or non-epileptic, for example, epilepsy, NEAD, conversion disorder, or functional seizures. If you are unsure, please see the list below for full details of names of seizures that are relevant





Do I have to take part?

NO. You do not have to take part. This survey is not related to your health care. There will be no consequences if you choose not to take part.

# Who can take part?

To take part you must:

- Experience epileptic and/or non-epileptic seizures (see list below if unsure)
- Be over 18 years old
- Be able to understand the questions in English

#### How do I take part?

There are two ways to take part:

- 1. Complete the survey online
- 2. Complete the survey on paper and send it using the freepost address

Instructions for each way of taking part are below:

If you would like to take part online go to http://tinyurl.com/SeiRes15
 Or scan the QR code on the right, using your mobile phone



- 2. If you would like to complete the study on paper and do not already have a pack:
  - a. If you have seen the study advertised in a health clinic they may have packs available
  - b. If a member of your care team provided you with information about the study they may be able to give you a pack

#### Can I think about it?

Appendix D participant information sheet



Yes, please take some time to think about this. The planned close date for the study is 16<sup>th</sup>

#### **March 2015**

#### If I have any questions about the survey who do I contact?

You can contact Liz in any of the following ways

Emai

Email her at <u>l.tallentire@lancaster.ac.uk</u>

Liz Tallentire, DClinPsy,

Write to her at: Furness Building,

Lancaster University

LA1 4YG

,

60

Phone the 07508 375 657 (UK)

research mobile 0044 7508 375 657 (international)

#### What if I need help to take part

You can have someone help you to take part, but the answers must be your own. So for example, it is **OK** for someone to read the questions out to you, and you tell them what to put. You need to be able to understand the questions in English; it is **not OK** to translate questions, as this could affect the results.

#### What will taking part involve?

You will be asked to answer some basic questions about yourself e.g. age, how often you have seizures and the country you live in. Then you will be asked to complete some questionnaires about how your seizures affect your life, how you relate to other people, how you manage feelings, and your childhood experiences.

This may take 10 to 15 minutes.

# Will my data be confidential?



During the survey, the researchers will not ask you for any identifying information.

Therefore, your data will be anonymous to the researchers; they will not know who sent it. You have the option of providing an email or postal address to receive a summary of the study results. If you choose to do this, the researchers will not link your email or postal address to your questionnaire data.

#### How will my data be stored?

All data will be stored electronically using password protection on the Lancaster University Secure file store. The researchers will delete email and postal address lists once they have sent information about the results of the study. Lancaster University will store securely anonymous survey data for 10 years following the end of the study.

# What will happen to the results?

After Liz has used the results in her thesis, the researchers may also use them to write an article in a journal. Liz will do a presentation about the study to her colleagues at the university. She may also do other presentations, for example, at conferences. It will not be possible to identify you in the results.

#### Are there any risks?

It is possible that asking you about your experiences will remind you of difficult feelings or times in your life. If you think you will find the questions distressing, please do not participate. If you find that you become distressed when filling in the questionnaires please stop. In the pack, there will be information on sources of support.

## Can I change my mind?

Yes, up to the point when you send information to the researchers. At the end of each page on the electronic form, or when you post paper questionnaires, you are sending information.



It will not be possible to remove information you have already sent, because the information is anonymous, so the researchers will not know which your information is.

You can stop completing the questions at any point.

#### Do I have to answer all the questions?

You may miss out questions, for example if you find them too distressing or you do not understand them.

# Are there any benefits to taking part?

There is no direct benefit to taking part. However, you will be contributing to research that may help develop understanding and treatments for people who experience seizures.

# Who has approved this study?

An NHS Research Ethics Committee has approved this study.

## What if I have a complaint

If you have a complaint about this study, you would like to discuss informally, please contact Dr Jane Simpson, Research Director at Lancaster University.

You can contact Jane in any of the following ways



Email her at

j.simpson2@lancaster.ac.uk



Write to her at:

Dr Jane Simpson Furness Building

Lancaster University

LA1 4YG



Phone Jane on

0044 1524 592 858



If you would like to make a formal complaint, please contact:

Professor Roger Pickup by email <a href="mailto:r.pickup@lancaster.ac.uk">r.pickup@lancaster.ac.uk</a>

or by post

Prof R Pickup

**Biomedical Sciences** 

Lancaster University

LA1 4YG





# List of possible names for seizure types relevant to this study.

You only need to read this list if you are unsure whether your seizure type is relevant to this study.

In any of these names, the term seizure may be replaced with fit, attack, or convulsion. Please note that sometimes these terms may be used in relation to either epileptic or non-epileptic seizures. The use of one of these terms does not imply that your seizures are definitely of the associated type. Some of the terms are outdated, they are included here for reference, and not because the researchers think they are appropriate to use.

Terms usually associated with epileptic	Terms usually associated with non-
seizures	epileptic seizures
Epilepsy	Psychogenic seizures
Complex partial seizure	Pseudoepileptic seizures
Partial seizure	Pseudo seizures
Generalized seizure	Functional seizures
Grand-mal	Stress-related seizures
Petit mal	Hysterical seizures
Myoclonicseizure	Somatoform/ somatic seizures
Tonic seizure	Dissociative seizures
Tonic-clonic seizure	Non-organic seizures
Focal seizures	Hysterical seizures
Absence seizures	Psychophysiological seizures
	Non-epileptic attack disorder (NEAD)
	PNES
	Conversion disorder (with seizures)

# Appendix E

Table E.1. Summary of participants with missing data and actions taken

Scale or sub-scale	Max number of missing items allowed	No of participants who viewed the scale who were excluded	No of cases with missing data that were scored	How missing data was treated
Revised Liverpool Impact of epilepsy scale	6	3	2	Item scored 0
Experiences in Close Relationships Anxiety	1	4	1	Replaced with mean of completed items
Experiences in Close Relationships avoidance	1	4	0	
Toronto Alexithymia Scale total score	3	1	4	Replaced with mean of completed items
Toronto Alexithymia Scale difficulty identifying feeling	1	2	2	Replaced with mean of completed items
Toronto Alexithymia Scale difficulty describing feelings	1	1	1	Replaced with mean of completed items
Toronto Alexithymia Scale externally- oriented thinking	1	1	3	Replaced with mean of completed items
Early Trauma Inventory total score	4	1	60	Item scored as 0
Early Trauma Inventory general trauma	1	1	0	
Early Trauma Inventory physical punishment	1	1	0	
Early Trauma Inventory emotional abuse	1	1	0	
Early Trauma Inventory sexual events	1	1	2	Item scored as 0
Early Trauma Inventory dissociation	0	98	0	

#### Appendix F. Details of statistical tests and analyses

# Exploratory data analysis

Group means were compared using ANOVA, Kruskal-Wallis, Welch, and Brown-Forsythe. Levene's test was used to check for homogeneity of variance. Post hoc tests used Games-Howell. EDA established that seizure frequency and trauma subscale scores were not normally distributed.

Frequencies were compared using Pearson chi-square tests. Results associated with expected cell counts less than 5 in more than 20% cells, or less than 1 in any cell were checked with Fisher's Exact tests.

Where the assumption of normality was broken for ANOVA i.e. for childhood trauma and seizure frequency data, Asymptotic K-Sample Fisher-Pitman permutation tests were used via the COIN package in R  $^{91}$ . Post hoc tests used the same test with code adapted from Mangiafico's $^{92}$  to assess each possible comparison.

#### Cluster analysis

Ward's method is sensitive to outliers<sup>93</sup> therefore these were removed by examining the dendrogram produced using nearest neighbour cluster analysis. Ward's method proceeds by combining the two clusters that have the smallest sum of the squares of error within clusters. In order to determine the number of clusters in the solution the agglomeration schedule was examined for sharp increases, which indicated clusters that were quite different being amalgamated. Average linkage within groups uses the smallest average distance between all possible pairs of cases in the resulting combined cluster.

# Comparison of means

For some variables the assumption of equal variances was broken therefore, for ease of reference, robust tests were consulted for all variables. The mean and standard deviation for the epilepsy group were used to calculate effect sizes. Robust tests for comparisons of means were Welch, Brown-Forsythe and Games-Howell. Permutation tests were used as for the EDA.

# Correlation analysis

As some variables were not normally distributed and had small sample sizes, for ease of presentation, Spearman's rho correlations were used for all variables. The correlations were compared across clusters and epilepsy data using permutation tests.

Correlation results were checked following the removal of outliers (case numbers 186, 243, & 113), which did not alter them significantly. Scatter plots were examined and there was no evidence of issues likely to affect the correlation such as non-linearity.

#### Effect sizes

Cohen's d effect sizes were calculated using the standard deviation for the ES group. This statistic is also sometimes called Glass's delta  $\Delta$ . Effect size descriptors for Cohen's d were based on Cohen's rules of thumb: 0.2 small, 0.5 medium, and 0.8 large<sup>94</sup>.

The following effect size descriptors were used for correlations, based on recommendations by Cohen<sup>94</sup>; small, 0.10; medium, 0.30; and large, 0.50.

# Appendix G. Section of the dendrogram for nearest neighbour linkage using squared Euclidean distance based on the childhood trauma and alexithymia total scores




Figure G.1. Section of dendrogram for nearest neighbour cluster analysis

# Appendix H. Results tables for subscales

Table H.1. Subscale descriptive statistics for each seizure type group in the study

	ES only $\bar{x}$ (SD)	NES only $\bar{x}$ (SD)	ES+NES $\bar{x}$ (SD)
Childhood trauma:			
general trauma	2.09(1.80)	2.87 (2.02)	3.74 (2.07)
physical punishment	1.21(1.51)	1.93 (1.69)	2.87 (1.63)
emotional abuse	1.55(1.78)	2.52 (1.91)	2.70 (1.92)
sexual events	0.46 (1.19)	1.70 (2.09)	2.13 (2.51)
Alexithymia:			
difficulty identifying feelings	21.98 (6.73)	23.68 (7.38)	24.59 (7.16)
difficulty describing feelings	14.96 (4.87)	15.41 (5.21)	16.50 (4.84)
externally-oriented thinking	20.37 (4.88)	19.71 (5.10)	20.27 (4.96)

Table H.2. Subscale descriptive statistics for each NES cluster

	Cluster 1 $\overline{x}$ (SD)	Cluster 2 $\overline{x}$ (SD)	Cluster 3 $\overline{x}$ (SD)	
Childhood trauma:				
general trauma	1.98 (1.63)	2.24 (2.12)	4.07 (1.74)	
physical punishment	1.18 (1.33)	0.57 (0.87)	3.23 (1.26)	
emotional abuse	1.53 (1.60)	1.43 (1.78)	3.98 (1.13)	
sexual events	0.41 (0.76)	1.10 (1.81)	3.30 (2.10)	
Alexithymia:				
total score	61.77(9.41)	37.43(5.90)	66.81(10.43)	
difficulty identifying feelings	24.16(5.75)	14.24(4.79)	28.25(4.96)	
difficulty describing feelings	16.51(4.32)	8.62(2.71)	17.75(4.08)	
externally-oriented thinking	21.10(3.66)	14.57(2.54)	20.84(5.77)	






Figure I.1. Chart showing mean scores on childhood trauma subscales by seizure type(s)


# Appendix J. Post hoc tests ES vs. NES vs. ES+NES

Table J.1 Effect sizes, confidence intervals, and significance of post hoc tests

Variable	Compariso	on	Effect size (CI) <sup>a</sup>	p
Age	ES only	NES only	-0.41 (-0.72,-0.11)**	0.004
		ES + NES	-0.52 (-1.12,0.07)	0.09
	NES only	ES + NES	-0.11 (-0.71,0.48)	0.89
Childhood trauma (total score)	ES only	NES only	-0.85(-1.21,-0.49)***	< 0.001
		ES + NES	-1.40(-2.16,-0.64)***	< 0.001
	NES only	ES + NES	-0.55 (-1.32,0.22)	0.06
Adult attachment anxiety	ES only	NES only	0.03 (-0.32,0.38)	0.98
	-	ES + NES	-0.13 (-0.59,0.33)	0.77
	NES only	ES + NES	-0.16 (-0.64,0.32)	0.70
Adult attachment avoidance	ES only	NES only	0.11 (-0.19,0.41)	0.65
		ES + NES	-0.28 (-0.78,0.22)	0.36
	NES only	ES + NES	-0.40 (-0.88,0.09)	0.13
Alexithymia (total score)	ES only	NES only	-0.11 (-0.44,0.22)	0.71
		ES + NES	-0.31 (-0.92,0.30)	0.44
	NES only	ES + NES	-0.20 (-0.81,0.42)	0.71
Seizure frequency	ES only	NES only	-0.33 (066, 0.00)*	0.02
		ES + NES	-0.07 (-0.37, 0.23)	0.72
	NES only	ES + NES	0.26 (0.00, 0.52)	0.20
Impact of seizures	ES only	NES only	0.98(0.67,1.29)***	< 0.001
		ES + NES	0.40 (-0.35,1.16)	0.40
	NES only	ES + NES	-0.57 (-1.33,0.18)	0.16

<sup>&</sup>lt;sup>a</sup>Effect sizes are cohen's d calculated using the epilepsy data standard deviations, \*The mean difference between the groups is significant at the 0.05 level. CI 95% confidence interval

# Appendix K. Agglomeration schedule for cluster analysis using Ward's method



Figures along the bottom indicate the steps in the process

Figure K.1. Illustration of agglomeration schedule

# Appendix L. Illustration of average linkage clustering




Figure L.1 Illustration of clusters formed via average linkage within groups

# Appendix M. Permutation tests for significance of differences between correlations

Each permutation test compares the observed difference between correlations with the differences between correlations for 1000 group permutations. Each permutation has the same group sizes as the original groups. These permutations are drawn from a combined pool of pairs of observations from the two groups being compared. This is based on the null hypothesis that the correlations are the same in both groups.

Table M.1. Comparing cluster 1 and the ES group correlations

Correlation of characteristics	Observed difference between	P-value from permutation test	
	correlations		
Childhood trauma and	0.45	0.006	
attachment anxiety			

Table M.2. Comparing cluster 3 and the ES group correlations

Correlation of characteristics	Observed difference between correlations	P-value from permutation test
Alexithymia and impact of seizures	0.35	0.03
Alexithymia and attachment anxiety	0.33	0.06
Alexithymia and attachment avoidance	0.06	0.80

Table M.3. Comparing cluster 1 and cluster 3 correlations

Correlation of characteristics	Observed difference between correlations	P-value from permutation test
Attachment anxiety and alexithymia	0.46	0.04
Alexithymia and childhood trauma	0.19	0.34
Attachment anxiety and childhood trauma	0.41	0.05

Section Three: C	ritical Appraisal
Mind-body duali	ism: an illusion?
A critical reflect	ion on the impact of dualism on this research
Liz Tallentire	
Doctorate in Clinical	Psychology
Division of Health Re	search, Lancaster University
Word Count:	3,993 excluding tables, figures, references, & appendices
	4,974 in total

In this critical appraisal, I will focus on the theme of mind-body dualism, which has arisen repeatedly in this research. I will first explain the concept of mind-body dualism and my reasons for attending to it, before summarising my results, and critically reflecting on the design, implementation, interpretation, and dissemination of my literature review and empirical research.

My interest in mind-body dualism is in its early stages. Therefore, this will not be a comprehensive review of the literature. It reflects my thoughts regarding my limited, reading and experience to date and its implications for my research.

The concept of mind-body dualism refers to thinking of the mind and body as two separate entities. It dates back to the concept of Cartesian dualism introduced by Descartes in the seventeenth century, who thought of the world as consisting of 'mind' and 'matter'1. He proposed that the mind, thoughts, feelings, etc., is qualitatively different from the physical body and that the physical body is part of matter along with inanimate objects. Dualism has been a topic of much debate among philosophers. The separation of the mind and body may be a natural assumption as we grow to realise that our thoughts, feelings, and dreams, cannot be directly observed by other people, unlike our physical body<sup>2</sup>. It also means beliefs, such as afterlife and reincarnation, can exist, as it allows the mind to exist independently of the body. However, this perception has been questioned for many years; one alternative is the concept of physicalism, which suggests that it is possible to explain all functions of the mind in terms of the physical sciences (if science was advanced enough), which is essentially a positivist view of the mind<sup>3</sup>. Advances in neuropsychology, and functional magnetic imaging (fMRI) may provide support for the physicalist perspective. For example, evidence has been proposed for a semantic control network operating across several brain regions 4. Several researchers have suggested that consciousness could be a by-product of

preconscious brain activity and that control over our own actions could be an illusion<sup>5</sup>. This is a topic of much debate. An alternative concept is that of the 'lived-body' in which the mind and body are part of a system that forms our conscious being; its intention is to self-develop. It does this through a range of strategies, including organic processes and behaviours. Difficulties (diseases) arise through a combination of these processes, not through a process that is either purely physical (matter) or of the mind, as in the Cartesian dualism approach<sup>6</sup>.

In Western medicine, organisation of our services and training into separate physical and mental health departments is consistent with dualism. Mehta<sup>7</sup> proposed that medicine is in crisis, due to its definition of illness through the lens of Cartesian dualism, which has self-defeating consequences. Gold<sup>6</sup> suggested that patients' interactions with doctors in this system encourage them to think of the body as an object, which needs to be 'repaired' by the doctor. In clinical settings, one example where this is evident is in relation to pain. Patients with diagnoses such as chronic pain often go from one physician to another searching for a medical diagnosis that they feel would justify their pain. An explanation related to the mind appears less acceptable than a medical diagnosis; despite fMRI studies indicating that emotional and physical pain activate the same areas in the brain<sup>8, 9</sup>.

This Cartesian dualism in services and training persists, despite evidence suggesting other approaches would be more effective. This evidence includes: the success of cognitive behaviour therapy, wherein the basic model includes thoughts, feelings, behaviours and physical feelings, and therapy involves identifying links and cycles between these elements; the recognition of many conditions, such as, irritable bowel syndrome, shingles, psoriasis, non-epileptic seizures (NESs), and other functional diagnoses, as both physical and psychological; and evidence that conditions that are

thought of as physical, such as cancer, are influenced by people's beliefs. For example, beliefs that cancer is incurable have been found to decrease the likelihood of survival from cancer as they affect behaviours, such as treatment compliance <sup>10</sup>. The current organisation of services and training is even more surprising when you consider that the most frequently quoted definition of health as "a complete state of physical, mental and social well-being, and not merely the absence of disease or infirmity" was defined by the World Health Organisation, in 1948<sup>11</sup>. Issues are also reflected through patient complaints; a study found that 99% of patients were satisfied with an apology and an explanation<sup>12</sup>. They suggested that this indicates the main problem was communication skills, which were lacking due to the disproportionate attention that is given to biomedical and technical skills<sup>12</sup>.

However, not all medicine is arranged according to dualism. Chinese medicine is more holistic in its approach; underpinned by beliefs that imbalance in the body's organs can lead to physical and emotional symptoms<sup>13</sup>. There is also evidence that few people hold entirely dualistic beliefs. For example, in a sample of 180 US residents only 1 was categorised as strongly dualistic, whereas 15 were strongly physicalist and 60 had roughly equal beliefs in physicalism and dualism<sup>14</sup>. Some authors have stated the opinion that dualism should be abandoned as it is not helpful for patients<sup>15</sup>. An experiment designed to test the effects of patients being primed with physicalism or dualism found that those primed with dualism were less likely to engage in healthy behaviours, and more likely to make decisions that could compromise their health<sup>2</sup>. Fotopoulou has argued that dualism in terms of psychogenic and neurogenic explanations for confabulation and delusion has been unhelpful, and that combining these fields of study allows a greater understanding of the relationship between cognition and emotion<sup>16</sup>.

Seizures (both epileptic and non-epileptic) produce symptoms that would be traditionally associated with the mind or the body. For example, associated with the body are convulsions, eye movements, and incontinence; associated with the mind are changes in behaviour, emotions, and perception. This means that seizure research naturally crosses the hypothetical mind- body divide. One study reported that patients see both epileptic and NESs as both physical and psychological<sup>17</sup>. Despite this evidence, neurologists are reported to view NESs as largely psychological and epileptic seizures as largely physical<sup>17</sup>. This view can be problematic for NES patients as they may feel like they are not believed and it is 'all in the mind' i.e. imaginary<sup>18, 19</sup>. The view is also apparent in the treatments and research relating to the two conditions, which have emphasised the physical for epilepsy (medication, surgery) and the psychological for NESs (psychotherapy, education). However, the limited research that has been completed outside of this dichotomy has had some positive results, e.g. psychological therapy that reduced epileptic seizure frequency<sup>20, 21</sup>. Many people who work in the field of functional symptoms (including NESs) view them as being both neurological and psychological. For example, Dr Jon Stone, a consultant neurologist specialising in functional disorders, describes them as 'symptoms that exist at the interface between brain and mind'18. This quote reflects the difficulty we have in conceiving the brain and mind as being part of one system; it is a 'lived-body' explanation that makes use of Cartesian dualism to make the concept understandable. Using models that move away from Cartesian dualism, such as a biopsychosocial model in explaining NESs to patients, has been found to be helpful for most people<sup>22</sup>. The non-epileptic seizure treatment (NEST) group<sup>23</sup> have trialled a communication strategy for sharing the diagnosis of NESs with patients, which emphasises the combination of the reality of physical symptoms associated with psychological stresses. The NEST group reported this

strategy to be successful<sup>23</sup>; Following the consultation, 86% of patients acknowledged that psychological factors were at least a contributing factor in their seizures<sup>23</sup>.

The term 'psychological' is unclear; it originally referred to a study of the mind<sup>24</sup>, and this is likely to be how it is used in lay language. However, the definition has expanded to include behaviour; and its origins in biology and philosophy<sup>24</sup> are evident as it includes the anatomy of the brain amongst other biological topics. This is a particularly important area for neuropsychologists who often consider the impact of brain damage on individual's cognitive and emotional processing. Many neuropsychologists are trained in the interpretation of neuroimaging data<sup>25</sup>. It has been suggested that brain imaging in research attracts greater interest and funding as it conflicts with mind-body dualism<sup>26</sup>. A research study aimed to investigate this possibility, using a population taken from an online database of people who have signed up to do human intelligence tasks, which found that beliefs about dualism did not predict interest in articles using fMRI and suggested this refuted the above hypothesis<sup>14</sup>.

Given the pervasiveness of mind-body dualism, despite evidence that it is not helpful, especially for people with symptoms such as NESs, it is not surprising that the theme arose repeatedly during my research. I therefore decided it was important to reflect on mind-body dualism and chose it as a focus for this critical appraisal. In the next sections, I will summarise my results, and consider the strengths and limitations of this research with regard to mind-body dualism.

# **Summary of results**

The results of my literature review indicated three possible types of subgroups of adults who experience NESs: [1] A subgroup who had trauma experiences, elevated mental health problems and problematic coping strategies, consistent with Bodde et

al.'s integrated model<sup>27</sup>. [2] A subgroup that may be over-controlled in their emotion regulation, which could be linked to psychodynamic theory of emotion repression. [3] A subgroup with intellectual difficulties who are more likely to have environmental triggers for seizures, consistent with a behavioural model.

Through my cluster analysis in the empirical research I identified 3 clusters: [C1] Cluster 1 had a relatively low number of reported childhood trauma categories associated with elevated attachment anxiety and alexithymia. [C2] Cluster 2 was the most distinct from the other clusters and epilepsy data. It had lower mean alexithymia scores than reported in a community sample (n=1933)<sup>28</sup> and lower attachment anxiety and avoidance than the other clusters and the ES group. This cluster is consistent with subgroups in Reuber et al.'s<sup>27</sup> research and similar those in Brown et al.'s<sup>29</sup> results. [C3] Cluster 3 was quite similar to cluster 1 with slightly greater elevation of attachment anxiety and alexithymia and a much higher score on the childhood trauma measure.

The subgroups I suggested in the literature review and the clusters I identified in the empirical paper do not correspond directly. Cluster 3 in the research paper appears to be congruent with the subgroup [1] consistent with Bodde et al.'s model. Cluster 1 may also be congruent with this integrated model, as although childhood trauma was lower in this group than cluster 3, it did seem to play an important role. I suggested that in cluster 1 trauma may be pivotal to development of non-epileptics seizures and therefore correspond to 'level 1 psychogenic causation' in Bodde et al.'s <sup>27</sup> model (Section 1, Figure 1, p1.52). However, in cluster 3 the trauma may be secondary to a disrupted attachment relationship, the relationship being the main psychogenic causation.

Cluster 2 in the empirical paper appears consistent with the 'over-controlled' subgroup [2] from the literature review, as indicated by lower than normal levels of

alexithymia. There was no evidence of a subgroup [3] with characteristics resembling the behavioural model identified in the literature review. This is probably because people with intellectual disabilities may not have been able to understand or access the study and there was no assessment of seizure triggers.

The recommendations made in the literature review regarding the use of cluster analysis based on trauma and alexithymia were demonstrated to be effective in identifying subgroups. The empirical paper was successful in identifying acceptable and effective measures for this purpose.

Both papers provide further evidence for the complexity of NES aetiology, consistent with previous research and specifically the need to consider subgroups in research and clinical settings. This emphasises the need for assessment and formulation of individual differences in order to identify appropriate support. The papers go further by suggesting specific measures that could be used for this purpose and therapeutic interventions appropriate for further research, based on subgroup characteristics.

# The impact of mind body dualism on this research

The subsequent sections evaluate this research's design, implementation, analysis and interpretation, across the literature review and the empirical paper, in relation to the issues of mind-body dualism described above.

# Design

Mind-body dualism had an impact on the design of both my literature review and empirical project. In the literature review I chose to exclude studies that looked at differences based on the physical characteristics of seizures, such as Hill and Gale's<sup>30</sup> study, which considered the neurocognitive functioning of groups based on seizure

semiology. Neurologists more often write articles, such as this considering observable and measurable features, whereas neuropsychologists are less likely to include these features. My concerns about the effect of mind-body dualism were evidenced fairly early in the process of conducting this research, as illustrated by this excerpt from my research journal

Thinking about...articles that are neurology based or psychology based and how different they seem.

Many neurology articles seem to focus on observable differences, although not all. Where

psychological ones [articles] do not seem to consider these [observable differences] at all. It seems silly not to consider both [physical and psychological]

Given the view I am expressing in this article it seems surprising that I went on to exclude observable characteristics from my literature review and largely from my empirical project. One clue to my reason for this perhaps was apparent in the next line of my journal, which stated 'I wonder how this would fit with thesis criteria, of what I bring as a psychologist?' Here I am questioning how including both these aspects would fit with my view of what a psychologist should bring. I go on to state

Perhaps what I bring as a psychologist is an ability to step back and bring a challenge to my own profession, rather than accepting the way things are done. We're not in an ivory tower.

Reflecting on this statement, I think the amount I have achieved in this is limited within the context of the research. However, my decision to write the critical appraisal on this topic reflects a desire and willingness to make this challenge by starting with myself.

Reflecting on the decision to exclude articles based on seizure semiology, and thus most of the articles written by neurologists, I think that there were a number of reasons for this decision. Some of the reasons were pragmatic, e.g. to reduce the number of articles to a manageable level. Other reasons were deeply affected by mind-body dualism. For example, the training route for a neurologist is via medical school before

specialising in neurology, so they have an in depth knowledge of the human body. My training involved undergraduate psychology degree, which included a modest amount of biology, followed by doctoral level training which is largely focussed on psychotherapy. These completely different training routes mean that articles written by neurologists can be very difficult for me, as a trainee clinical psychologist, to understand. However, I do wonder whether I was slightly over concerned about this. From my notes, it seemed an overheard conversation was significant. The conversation related to the dangers of using literature from outside your area of expertise. In fact, I have studied a substantial amount of literature relating to neurology and I took an optional extra course at undergraduate level on 'biology and the brain', I have completed a neuropsychology placement and have participated in teaching on various related topics as part of doctoral training. I did acknowledge in my literature review that it would have been better to do this research collaboratively with a neurologist, a view that is also held by Schwann et al.<sup>31</sup>. However, the very need for collaboration is underpinned by the mind-body dualism that separates our training into, physical and psychological approaches. This is particularly unhelpful when addressing difficulties, such as seizures, which are (arguably) the result of the lived-body system that is both physical and psychological.

The design of my empirical project was perhaps less affected by mind-body dualism; the concepts of alexithymia and attachment both have broad theoretical and evidence bases, which could be considered consistent with a lived-body perspective. For example, neuroimaging studies have found that people with different levels of alexithymia have differing patterns of neural activity in the brain in response to emotional stimuli<sup>32</sup> and attachment theory is linked to evolution<sup>33</sup>. Experiences of trauma could also be thought of as something that affect the lived-body, or to use the

Cartesian terms mind (e.g. feeling afraid) and body (e.g. physical injury). However, one participant made me question the effects of dualism on my design when they emailed saying they were surprised I did not ask more about the characteristics of their seizures (semiology). Reflecting on this I realised that I had few questions relating to this, only seizure frequency, and I wondered about my reasons for this. I think part of my reason was keeping the study design and number of questions as minimal as possible, but I also had an assumption that these factors would not be related to experiences of trauma, alexithymia, and attachment. Inherent in this assumption is the separation of the mind and body. If we view seizures as produced by a lived-body then there is no reason why these factors should not be related, and in fact one study (n=272) found that combining both seizure characteristics (duration and years since first seizure) with the conversion subscale of the personality assessment inventory, resulted in a model that achieved 84% correct classification of seizure type (epileptic or non-epileptic)<sup>34</sup>.

# *Implementation*

I experienced difficulties at various points in the research, it often felt like it was complex, and getting people to help was challenging. At various points, I wondered whether this was connected with the physical/psychological divide, as I had not had this experience when carrying out previous research. I think at some points it was. For example, when I was questioned about why it was relevant to ask people with epilepsy about their emotions. However, I think there were also other reasons for this difficulty. For example, the fact that I was approaching a number of different NHS services in different areas of the country meant that I needed approval from each different research and development (R & D) departments. The practicality of communicating with several different R & D departments at once was quite difficult to manage and I

needed to keep clear records of my progress with each one; see sample in Appendix 1. I noted in my journal on 25<sup>th</sup> Feb 2015 that it would have been 'better to have had more involvement [of R&D departments] from the start'. I did have some of them involved much earlier in the process and the implementation was much less problematic with these organisations. The fact that my study included questions about childhood trauma was also something that understandably made people anxious and perhaps made them hesitant about implementing the project.

# Analysis and interpretation

An area that I think was less affected by mind-body dualism was the data analysis as there are many examples of similar data analysis methods being applied to variables that would be traditionally associated with the body<sup>35</sup> or those that would be traditionally associated with mind<sup>36</sup>, and some that consider both<sup>34</sup>. However, as I mentioned in my literature review it was interesting that there was little qualitative research in this area. Qualitative research is common in other areas of psychological study, and would use very different analysis methods. I wonder whether my choice to use quantitative analysis in this area of research was sub-consciously influenced by a mind-body dualism that saw this as an area closer to medicine (the body) and therefore associated it with quantitative methods.

Another strength of this research was that I was aware of mind-body dualism and reflected on it throughout, which made me alert to how it may be influencing my research. My psychological training, which includes many models that attempt to move away from the dualistic perspective, such as cognitive behavioural therapy and the biopsychosocial model, was also helpful in interpreting the results. It means that whilst I was considering how the findings related to each other and to other literature I was

open minded to relationships between physical and psychological characteristics. Also, that when I think about psychological characteristics, such as attachment and alexithymia, I am not thinking about them as purely related to the mind, rather as features of the lived-body, and being made up of elements that, from a Cartesian perspective, would include both mind and matter.

# Dissemination

One strength of this area of research is that it provides a forum for literature from different disciplines to converge, journals, such as Epilepsia include neurology, psychology, neuropsychology, molecular biology, and neurochemistry. This enables people from different disciplines to consider how their work relates to each other.

### Future research

I believe that it is important that future researchers consider the influence of mind-body dualism on their design, implementation, interpretation, and dissemination. The pervasiveness of dualism makes it difficult, or perhaps impossible, to move away from its influence altogether, but reflecting on this issue and working collaboratively across disciplines is likely to help. This is particularly important in areas of research, such as seizures that fall between the dualistic categories of mind and matter, and this has been recommended by others, such as, Schwan et al.<sup>31</sup>. It could also be useful to include such consideration in other areas of research, as it may lead to advances, as we break down the illusion of mind-body dualism.

An important area of research, I recommended in the research papers, was the assessment of therapeutic interventions appropriate to individual psychological characteristics. I suggested using alexithymia and attachment measures alongside

individual formulations to allocate people to subgroups who receive different treatments. Possible therapies are detailed in the research papers and they included behavioural therapy, mindfulness, emotion regulation training, and psychodynamic approaches. This research could be undertaken through collaboration of a research team involving psychologists, neurologists, psychiatrists, and non-epileptic and epileptic seizure patients. I hope that such collaboration would reduce the influence of mind-body dualism and I would also recommend that specific attention is paid to the influence of dualism from the outset, especially during the design phase. It would be important to consider how the research would interact with other aspects of treatment, such as medication.

# Clinical implications

Increased awareness and a critical approach to mind-body dualism may lead to different ways of practicing clinically perhaps through joined up working or broader training. There is evidence of this already happening. For example some clinics for functional neurological symptoms are starting to provide joint appointments with a neurologist and neuropsychologist present, and many areas of medical training include elements of psychology.

# Conclusion

Mind-body dualism is pervasive in our society and health services, despite much criticism and evidence suggesting that perceiving our mind and body as qualitatively different can be unhelpful in a health context. Seizures, especially NESs are not consistent with dualism. This can lead to difficulties for patients, doctors, and researchers. Based on my limited knowledge at this point, I suggest that the concept of

lived-body provides an alternative, and potentially more helpful, way of thinking about ourselves. This may be particularly helpful for people experiencing functional difficulties, such as NESs. This research has been affected by the pervasive nature of dualism, but also had some strengths in terms of my alertness to the impact of mind-body dualism, and that I have had training in models that are more consistent with a lived-body concept.

# References

- 1. Dualism. The essentials of philosophy and ethics: Routledge; 2006.
- 2. Forstmann M, Burgmer P, Mussweiler T. "The mind is willing, but the flesh is weak":

  The effects of mind-body dualism on health behavior. Psychol Sci 2012;23:12391245.
- 3. Reber AS. The penguin dictionary of psychology [electronic resource]. 4th ed. Reber ES, Allen R, Credo R, editors. London Penguin Books; 2009.
- 4. Jefferies E. The neural basis of semantic cognition: Converging evidence from neuropsychology, neuroimaging and tms. Cortex 2013;49:611-625.
- 5. Navon D. How plausible is it that conscious control is illusory? Am J Psychol 2014;127:147.
- 6. Gold J. Cartesian dualism and the current crisis in medicine--a plea for a philosophical approach: Discussion paper. J R Soc Med 1985;78:663.
- 7. Mehta N. Mind-body dualism: A critique from a health perspective. Mens Sana Monographs 2011;9:202-209.
- 8. Kross E, Berman MG, Mischel W, et al. Reply to iannetti and mouraux: What functional mri responses to physical pain tell us about why social rejection 'hurts'. Proc Natl Acad Sci U S A 2011;108:E344.

9. Kross E, Berman MG, Mischel W, et al. Social rejection shares somatosensory representations with physical pain. Proc Natl Acad Sci U S A 2011;108:6270-6275.

- 10. Soler-Vila H, Kasl S, Jones B. Cancer-specific beliefs and survival: A population-based study of african-american and white breast cancer patients. Cancer Causes Control 2005;16:105-114.
- 11. Awofeso N. Re-defining 'health'. Available at http://www.who.int/bulletin/bulletin\_board/83/ustun11051/en/. Accessed January 3, 2016
- 12. Siyambalapitiya S, Caunt J, Harrison N, et al. A 22 month study of patient complaints at a national health service hospital. Int J Nurs Pract 2007;13:107-110.
- 13. Chinese medicine. Chambers dictionary of the unexplained: Chambers Harrap; 2007.
- 14. Hook CJ, Farah MJ. Look again: Effects of brain images and mind- brain dualism on lay evaluations of research. J Cogn Neurosci 2013;25:1397.
- 15. Wade D. Why physical medicine, physical disability and physical rehabilitation? We should abandon cartesian dualism. Clin Rehabil 2006;20:185-190.
- 16. Fotopoulou A. The affective neuropsychology of confabulation and delusion. Cogn Neuropsychiatry 2010;15:38-63.
- 17. Whitehead K, Kandler R, Reuber M. Patients' and neurologists' perception of epilepsy and psychogenic nonepileptic seizures. Epilepsia 2013;54:708-717.
- 18. Stone J. Functional and dissociative neurological symptoms: A patient's guide in the mind? Available at http://www.neurosymptoms.org/#/in-the-mind/4533053408.
  Accessed May 13, 2015
- 19. Stone J. What should we say to patients with symptoms unexplained by disease%3f the%22 number needed to offend%22. Br Med J 2002;325:1449.

20. Fenwick PB. Behavioural treatment of epilepsy. Int Rev Psychiatry 1989;1:297-306.

- 21. McLaughlin D, McFarland K. A randomized trial of a group based cognitive behavior therapy program for older adults with epilepsy: The impact on seizure frequency, depression and psychosocial well-being. J Behav Med 2011;34:201-207.
- 22. Karterud HN, Risør MB, Haavet OR. The impact of conveying the diagnosis when using a biopsychosocial approach: A qualitative study among adolescents and young adults with nes (non-epileptic seizures). Seizure-Eur J Epilep 2015;24:107-113.
- 23. Hall-patch L, Brown R, House A, et al. Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic nonepileptic seizures. Epilepsia 2010;51:70-78.
- 24. A dictionary of psychology [electronic resource]. 3rd ed. Oxford: Oxford University Press; 2009. Psychology.
- 25. Benitez A, Hassenstab J, Bangen KJ. Neuroimaging training among neuropsychologists: A survey of the state of current training and recommendations for trainees. Clin Neuropsychol 2014;28:600-613.
- 26. Bloom P. Seduced by the flickering lights of the brain. Seed Magasine 2006.
- 27. Bodde NM, Brooks JL, Baker GA, et al. Psychogenic non-epileptic seizures—
  definition, etiology, treatment and prognostic issues: A critical review. Seizure
  2009;18:543-553.
- 28. Parker JDA, Taylor GJ, Bagby RM. The 20-item toronto alexithymia scale: Iii.

  Reliability and factorial validity in a community population. J Psychosom Res
  2003;55:269-275.
- 29. Brown RJ, Bouska JF, Frow A, et al. Emotional dysregulation, alexithymia, and attachment in psychogenic nonepileptic seizures. Epilepsy Behav 2013;29:178-183.

30. Hill SW, Gale SD. Neuropsychological characteristics of nonepileptic seizure semiological subgroups. Epilepsy Behav 2011;22:255-260.

- 31. Schwan R, Hingray C, Laprevote V, et al. How can we identify psychiatric morbidity in patients with psychogenic nonepileptic seizures? Epilepsy Behav 2012;23:507-507.
- 32. Moriguchi Y, Komaki G. Neuroimaging studies of alexithymia: Physical, affective, and social perspectives. Biopsychosoc Med 2013;7:8.
- 33. Kraemer G. A psychobiological theory of attachment. Behav Brain Sci 1992;15:493-511.
- 34. Hill SW, Gale SD. Predicting psychogenic nonepileptic seizures with the personality assessment inventory and seizure variables. Epilepsy Behav 2011;22:505-510.
- 35. Rodriguez AJ, Buechler RD, Lahr BD, et al. Temporal lobe seizure semiology during wakefulness and sleep. Epilepsy Res 2007;74:211-214.
- 36. Ramirez MJ, Schefft BK, Howe SR, et al. The effects of perceived emotional distress on language performance in intractable epilepsy. Epilepsy Behav 2010;18:64-73.

Contact Organisation <sup>a</sup>			Notes re numbers				
*******Partnership NHS Foundation Trust	NHS	20/1/15 agreed to support, send sponsorship, final R&D form and REC approval when available. 26/1/15 only REC approval outstanding. 28/1/15 all docs now sent. R&D approval received	Initial contact email sent	17/1/15 follow up email sent	20/1/15 emailed R&D with main docs. 26/1/15 All rec submission docs, final R&D form and sponsorship sent. 28/1/15 rec approval sent	11/2/15 emailed R&D asking if any updates 24/2/15 further prompt sent	2 people asked, 1 pack given out
********** NHS Foundation Trust	NHS	2/2/15 await go ahead to contact R&D	Initial contact email sent, interested, requested details of measures	17/1/15 email sent to ask if decision made about supporting project	28/1/15 email sent with REC approval and asking re support 11/2/15 prompt sent		
********* NHS Foundation Trust	NHS	4/2/15 waiting to hear back from R&D 11/2/15 awaiting response from R&D 12/2/15 awaiting response from R&D 17/2/15 R&D approval received	Initial contact email sent, requested details of measures	17/1/15 follow up email sent to confirm if able to support	28/1/15 email sent with REC approval and asking re support 4/2/15 email received to say they will chase R&D	9/2/15 queries from R&D re PIC/research site responded to 12/2/15 feedback that issue re R&D form resolved, CV sent as requested	7 packs given out

<sup>&</sup>lt;sup>a</sup> Names have been removed

Section four: <sup>1</sup> Ethics	
Liz Tallentire	
Doctorate in Clinical Psycho Division of Health Research,	
Word Count:	2353 excluding form text & appendices 8,244 in total excluding form text

 $<sup>^{\</sup>rm 1}$  The participant information sheet and measures were also including in the ethics application, please see these documents in Section 2, appendices B and D

# Health Research Authority National Research Ethics Service

# **NRES Committee North West - Liverpool Central**

3rd Floor Barlow House 4 Minshull Street Manchester M1 3DZ

Telephone: 0161 625 7818 Fax:0161 625 7299

27 January 2015

Ms Liz M. Tallentire
Trainee Clinical Psychologist
Lancashire NHS Trust
Doctorate in Clinical Psychology
Department of Health Research
Lancaster University
LA1 4YG

Dear Ms Tallentire

Study title: Relationships between early life events, individual

differences, and seizures

REC reference: 15/NW/0110 IRAS project ID: 166247

The Proportionate Review Sub-committee of the NRES Committee North West - Liverpool Central reviewed the above application on 27 January 2015.

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this favourable opinion letter. The expectation is that this information will be published for all studies that receive an ethical opinion but should you wish to provide a substitute contact point, wish to make a request to defer, or require further information, please contact the REC Manager Mrs Carol Ebenezer, nrescommittee.northwest-liverpoolcentral@nhs.net. Under very limited circumstances (e.g. for student research which has received an unfavourable opinion), it may be possible to grant an exemption to the publication of the study.

### **Ethical opinion**

On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

# Conditions of the favourable opinion

The favourable opinion is subject to the following conditions being met prior to the start of the study.

Management permission or approval must be obtained from each host organisation prior to the start of the study at the site concerned.

Management permission ("R&D approval") should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements.

Guidance on applying for NHS permission for research is available in the Integrated Research Application System or at http://www.rdforum.nhs.uk.

Where a NHS organisation's role in the study is limited to identifying and referring potential participants to research sites ("participant identification centre"), guidance should be sought from the R&D office on the information it requires to give permission for this activity.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of approvals from host organisations.

# Registration of Clinical Trials

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database. This should be before the first participant is recruited but no later than 6 weeks after recruitment of the first participant.

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to request a deferral for study registration within the required timeframe, they should contact <a href="https://doi.org/10.21/10.1016/j.net">https://doi.org/10.21/10.1016/j.net</a>. The expectation is that all clinical trials will be registered, however, in exceptional circumstances non registration may be permissible with prior agreement from NRES. Guidance on where to register is provided on the HRA website.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

# Ethical review of research sites

The favourable opinion applies to all NHS sites taking part in the study, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion").

The members had no ethical issues with this application.

# **Approved documents**

The documents reviewed and approved were:

Document	Version	Date
Copies of advertisement materials for research participants [Poster Advert]	1	22 December 2014
Copies of advertisement materials for research participants [Card with Link]	1	22 December 2014
Copies of advertisement materials for research participants [Online Forum Advert]	1	25 November 2014
Covering letter on headed paper [Covering Letter]	1	14 January 2015
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Employers Liability]	1	01 August 2014

Letter from sponsor [Sponsorship Letter]	1	21 January 2015
Other [Gant Chart]	1	14 October 2015
Other [Review Process Evidence]	1	26 June 2014
Other [Online Survey Format Illustration]	1	25 November 2014
Other [Professional Indemnity Insurance]	1	04 August 2014
Other [Public Liability Insurance]	1	04 August 2014
Participant information sheet (PIS) [PIS Online Version ]	1	22 December 2014
Participant information sheet (PIS) [PIS Paper Version]	1	22 December 2014
Participant information sheet (PIS) [Thank you and Support Information]	1	25 November 2014
REC Application Form [REC_Form_22012015]		22 January 2015
Research protocol or project proposal [Protocol]	1	22 December 2014
Summary CV for Chief Investigator (CI) [CV Liz Tallentire]	1	14 January 2015
Summary CV for supervisor (student research) [CV lan Fletcher]	1	16 August 2014
Validated questionnaire [Questionnaires Pack]	1	25 November 2014

# **Membership of the Proportionate Review Sub-Committee**

The members of the Sub-Committee who took part in the review are listed on the attached sheet.

# Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

# After ethical review

# Reporting requirements

The attached document "After ethical review – guidance for researchers" gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.

# **User Feedback**

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: <a href="http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/">http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/</a>

# **HRA Training**

We are pleased to welcome researchers and R&D staff at our training days – see details at <a href="http://www.hra.nhs.uk/hra-training/">http://www.hra.nhs.uk/hra-training/</a>

With the Committee's best wishes for the success of this project.

# 15/NW/0110

# Please quote this number on all correspondence

Yours sincerely

Mrs Julie Brake

Chair

Email: nrescommittee.northwest-liverpoolcentral@nhs.net

Enclosures: List of names and professions of members who took part in the review

"After ethical review – guidance for researchers"

Copy to: Ms Debbie Knight

Dave Watling, The NHS Foundation Trust

# **NRES Committee North West - Liverpool Central**

# Attendance at PRS Sub-Committee of the REC meeting on 27 January 2015

# **Committee Members:**

Name	Profession	Present	Notes
Mrs Julie Brake	Specialist Diabetes Nurse / Chair	Yes	
Mrs Hannah Chambers	Lay Member	Yes	
Mr Fotios Polydoros	Statistician	Yes	

# Also in attendance:

Name	Position (or reason for attending)
Mrs Carol Ebenezer	REC Manager

**Welcome to the Integrated Research Application System** 

Scotland
Wales

Northern Ireland

3a. In which country of the UK will the lead NHS R&D office be located:

# **IRAS Project Filter** The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications. Please enter a short title for this project (maximum 70 characters) Early life events, individual differences, and seizures V1 1. Is your project research? Yes \( \cap \) No 2. Select one category from the list below: Clinical trial of an investigational medicinal product Clinical investigation or other study of a medical device Combined trial of an investigational medicinal product and an investigational medical device Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice Basic science study involving procedures with human participants Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative methodology Study involving qualitative methods only Study limited to working with human tissue samples (or other human biological samples) and data (specific project Study limited to working with data (specific project only) Research tissue bank Research database If your work does not fit any of these categories, select the option below: Other study 2a. Please answer the following question(s): a) Does the study involve the use of any ionising radiation? O Yes No O Yes No b) Will you be taking new human tissue samples (or other human biological samples)? c) Will you be using existing human tissue samples (or other human biological samples)? O Yes No 3. In which countries of the UK will the research sites be located? (Tick all that apply) ✓ England

10/11/10
England
Scotland
○ Wales
O Northern Ireland
This study does not involve the NHS
4. Which review bodies are you applying to?
NHS/HSC Research and Development offices
Social Care Research Ethics Committee
Research Ethics Committee
<ul><li>■ National Information Governance Board for Health and Social Care (NIGB)</li><li>■ National Offender Management Service (NOMS) (Prisons &amp; Probation)</li></ul>
Trational Chemical Management Corvice (ITCMO) (Friction & Friction)
For NHS/HSC R&D offices, the CI must create Site-Specific Information Forms for each site, in addition to the study-wide forms, and transfer them to the PIs or local collaborators.
5. Will any research sites in this study be NHS organisations?
5a. Are all the research costs and infrastructure costs for this study provided by an NIHR Biomedical Research Centre, NIHR Biomedical Research Unit, NIHR Collaboration for Leadership in Health Research and Care (CLAHRC) or NIHR Research Centre for Patient Safety & Service Quality in all study sites?  Yes No
If yes, NHS permission for your study will be processed through the NIHR Coordinated System for gaining NHS Permission (NIHR CSP).
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN) support and inclusion in the NIHR Clinical Research Network (CRN) Portfolio? Please see information button for further details.
○ Yes ● No
If yes, NHS permission for your study will be processed through the NIHR Coordinated System for gaining NHS Permission (NIHR CSP) and you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form immediately after completing this project filter and before completing and submitting other applications.
6. Do you plan to include any participants who are children?
◯ Yes ● No
7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent for themselves?
○ Yes   No
Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the NIGB Ethics and Confidentiality Committee to set aside the common law duty of confidentiality in England and Wales. Please consult the

8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or who are offenders supervised by the probation service in England or Wales?

guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.

Date: 22/01/2015 2 166247/726475/1/74

○ Yes • No
9. Is the study or any part of it being undertaken as an educational project?
Please describe briefly the involvement of the student(s):
Chief investigator is a doctoral student on the Clinical Psychology Doctorate at Lancaster University
9a. Is the project being undertaken in part fulfilment of a PhD or other doctorate?
out to the project soming undertaken in part running or a rins of other deciclate.
● Yes ○ No
10. Will this research be financially supported by the United States Department of Health and Human Services or any of its divisions, agencies or programs?
◯ Yes    No
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project (including identification of potential participants)?
○ Yes ● No

**Integrated Research Application System** 

Application Form for Research administering questionnaires/interviews for quantitative analysis or mixed methodology study



# **Application to NHS/HSC Research Ethics Committee**

The Chief Investigator should complete this form. Guidance on the questions is available wherever you see this symbol displayed. We recommend reading the guidance first. The complete guidance and a glossary are available by selecting <u>Help</u>.

Please define any terms or acronyms that might not be familiar to lay reviewers of the application.

**Short title and version number:** (maximum 70 characters - this will be inserted as header on all forms) Early life events, individual differences, and seizures V1

Please complete these details after you have booked the REC application for review.

REC Name:

NRES Committee North West - Liverpool Central

REC Reference Number: Submission date: 15/NW/0110 22/01/2015

# **PART A: Core study information**

# 1. ADMINISTRATIVE DETAILS

# A1. Full title of the research:

Relationships between early life events, individual differences, and seizures

# A2-1. Educational projects

Name and contact details of student(s):

# Student 1

Title Forename/Initials Surname
Ms Liz M. Tallentire

Address Doctorate in Clinical Psychology, Furness Building

Divison of Health Research

Lancaster University

Post Code LA1 4YG

E-mail I.tallentire@lancaster.ac.uk

Telephone

Fax

Give details of the educational course of degree for which this research is being undertaken:
Name and level of course/ degree:
Doctorate in Clinical Psychology
Name of educational establishment: Lancaster University

Name and contact details of academic supervisor(s):

### Academic supervisor 1

Title Forename/Initials Surname
Dr Ian Fletcher

Address Clinical Psychology

Division of Health Research

Lancaster University

Post Code LA1 4YG

E-mail i.j.fletcher@lancaster.ac.uk

Telephone 01524 593301

Fax

Please state which academic supervisor(s) has responsibility for which student(s):

Please click "Save now" before completing this table. This will ensure that all of the student and academic supervisor details are shown correctly.

Student(s) Academic supervisor(s)

Student 1 Ms Liz M. Tallentire

To lan Fletcher

A copy of a <u>current CV</u> for the student and the academic supervisor (maximum 2 pages of A4) must be submitted with the application.

# A2-2. Who will act as Chief Investigator for this study? Student Academic supervisor Other

# A3-1. Chief Investigator:

Title Forename/Initials Surname Ms Liz M. Tallentire

Post Trainee Clinical Psychologist

Qualifications BSc Psychology, MA Leadership and Management

Employer Lancashire NHS Trust

Work Address Doctorate in Clinical Psychology

Department of Health Research

Lancaster University

Post Code LA1 4YG

Work E-mail I.tallentire@lancaster.ac.uk

NHS REC Form Reference: IRAS Version 3.5 15/NW/0110 4.12

\* Personal E-mail I.tallentire@lancaster.ac.uk

Work Telephone

\* Personal Telephone/Mobile 07539294316

Fax

\* This information is optional. It will not be placed in the public domain or disclosed to any other third party without prior

A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the application.

**A4.** Who is the contact on behalf of the sponsor for all correspondence relating to applications for this project? This contact will receive copies of all correspondence from REC and R&D reviewers that is sent to the CI.

Title Forename/Initials Surname

Ms Debbie Knight

Address Research Support Office,

B58 Bowland Main, Lancaster University,

Post Code LA1 4YT

E-mail ethics@lancaster.ac.uk

Telephone 01524 592605

Fax

A5-1. Re	search reference numbers. Flease give any relevant references for your study.
Applica availabl	nt's/organisation's own reference number, e.g. R & D (if e):

Sponsor's/protocol number:

Protocol Version: 1

Protocol Date:

Funder's reference number:

Project website:

# Additional reference number(s):

Ref.Number Description Reference Number

AF 4 December of commence in the base of the control of the contro

Registration of research studies is encouraged wherever possible. You may be able to register your study through your NHS organisation or a register run by a medical research charity, or publish your protocol through an open access publisher. If you have registered your study please give details in the "Additional reference number(s)" section.

# A5-2. Is this application linked to a previous study or another current application?

O Yes 

No

Please give brief details and reference numbers.

# 2. OVERVIEW OF THE RESEARCH

To provide all the information required by review bodies and research information systems, we ask a number of specific questions. This section invites you to give an overview using language comprehensible to lay reviewers and members of the public. Please read the guidance notes for advice on this section.

**A6-1. Summary of the study.** Please provide a brief summary of the research (maximum 300 words) using language easily understood by lay reviewers and members of the public. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, this summary will be published on the website of the National Research Ethics Service following the ethical review.

This research will investigate the link between early experiences, individual differences, and seizures. It will consider whether a person having particular early experiences, such as, being emotionally neglected or physically abused is associated with specific individual differences and seizures. The individual differences the research will consider are processing of emotions and the way people relate to others. Processing of emotions includes a person being able to recognise their own emotions and describe them. The way people relate to others is how much a person avoids or is anxious about close relationships with others. In relation to seizures, the research will include, type of seizure, how often they happen, and how much impact the person reports seizures have on their daily life. Seizure type in this research is epileptic (due to unusual electrical activity in the brain) or non-epileptic (not due to unusual electrical activity in the brain).

Participants will anonymously complete questionnaires about each of the factors described above. They will fill in questionnaires online and send them electronically; or on paper and send them in the post. The researchers will then work out scores based on the questionnaires. These scores will be analysed using statistical tests, in order to look for relationships between them, which represent relationships between the above factors.

**A6-2.** Summary of main issues. Please summarise the main ethical, legal, or management issues arising from your study and say how you have addressed them.

Not all studies raise significant issues. Some studies may have straightforward ethical or other issues that can be identified and managed routinely. Others may present significant issues requiring further consideration by a REC, R&D office or other review body (as appropriate to the issue). Studies that present a minimal risk to participants may raise complex organisational or legal issues. You should try to consider all the types of issues that the different reviewers may need to consider.

Potential participants may be distressed due to experiencing seizures. One of the questionnaires may highlight possible childhood issues. The consent form will provide information about the topics the questions will cover so that people have opportunity to make an informed decision about whether they would like to participate or not. Participants will not receive individual feedback on their answers, and sign-posting to appropriate services will be provided.

<b>A6-3. Proportionate review of REC application</b> The initial project filter has identified that your study <u>may</u> be suitable for
proportionate review by a REC sub-committee. Please consult the current guidance notes from NRES and indicate whether
you wish to apply through the proportionate review service or, taking into account your answer to A6-2, you consider there
are ethical issues that require consideration at a full REC meeting.

Yes - proportionate review \( \circ\) No - review by full REC meeting

Further comments (optional):

The researchers are applying for proportionate review as in accordance with point four of 'is my study suitable for Proportionate Review' on the HRA guidance (link below), the sensitive questionnaires have been validated and widely used with the proposed population or very similar populations (see protocol measures section for details). In addition, all sensitive information will be anonymous.

http://www.hra.nhs.uk/documents/2014/05/pr\_website\_v\_ 5\_15\_05\_2014.pdf

Note: This question only applies to the REC application.

# 3. PURPOSE AND DESIGN OF THE RESEARCH

A7. Select the appropriate methodology description for this research. Please tick all that apply:
Case series/ case note review
Case control
Cohort observation
Controlled trial without randomisation
✓ Cross-sectional study
☐ Database analysis

NHS REC Form	Reference:	IRAS Version 3.5
	15/NW/0110	4.14

Epidemiology	
Feasibility/ pilot study	
Laboratory study	
Metanalysis	
Qualitative research	
✓ Questionnaire, interview or observation study	
Randomised controlled trial	
Other (please specify)	

A10. What is the principal research question/objective? Please put this in language comprehensible to a lay person.

The principle objective of the research is to identify how early experiences, individual differences and seizures are related to each other.

**A11. What are the secondary research questions/objectives if applicable?** Please put this in language comprehensible to a lay person.

N/A

A12. What is the scientific justification for the research? Please put this in language comprehensible to a lay person.

Previous research has found that certain childhood experiences, particularly traumatic ones, are associated with experiencing particular types of seizure in later life. Research also indicates that people, who experience trauma in childhood, are more likely to have difficulty processing emotions and to be more anxious and/or avoidant of close relationships. Other studies have found that difficulty processing emotions is associated with certain types of seizures and how often they occur. Therefore, it makes sense to consider these factors in one study, in order to investigate how they relate to each other for people who experience seizures.

Understanding more about how these factors relate to each other for people who have different types of seizure may help to identify people who are more likely to experience particular seizure types. Understanding the relationships between factors will also help to identify appropriate treatments. This is important, to be able to reduce the distress caused by seizures, as well as the potential harm to patients and cost to health services of inappropriate treatments.

A13. Please summarise your design and methodology. It should be clear exactly what will happen to the research participant, how many times and in what order. Please complete this section in language comprehensible to the lay person. Do not simply reproduce or refer to the protocol. Further guidance is available in the guidance notes.

The project will be advertised to potential research participants using a variety of methods, which will include: Adverts on online support forums for relevant groups;

Contacting support groups in person or via email to ask them to advertise the project to members; Asking health clinic staff to inform potential participants about the research and provide them with packs if requested. The packs will contain the participant information sheet, questionnaires and support information; and Displaying posters in relevant health clinics.

The advertisement will explain the options for participation, which are via online survey, or paper forms in the post.

For online participation a link will be included in adverts to direct the person to an online survey site. This site will provide full details of what the study involves and a consent form, to enable the person to make an informed decision about whether they would like to participate or not.

The paper packs and online site will include the same information with slight adaptions (as shown on the attached documents).

For all methods of participation the same information will be collected, including gender, age, seizure frequency, country of residence, and responses to the questionnaires (see attached documents). No identifying information will be collected as part of the survey. A page will be included thanking participants for taking part and providing contact details of support organisations. Participants will have the option to give their email or postal address if they would like

to receive a summary of the overall finding of the research. The email/postal address will be kept separate from the questionnaire data and will not be linked with it. In the paper version participants will be requested to post back their email/ postal address, if provided, separately from their completed questionnaires.

Participants will be asked to share information about the study with anyone else they think may be interested and eligible to participate.

Data from the electronic survey system will be imported directly to statistical analysis software. Data from paper versions will be entered onto the electronic statistical software by the researchers or their administrative support. Statistical tests will then be carried out on the anonymous data by the researchers.

A14-1. In which aspects of the research process have you actively involved, or will you involve, patients, service users, and/or their carers, or members of the public?
✓ Design of the research
Management of the research
Undertaking the research
Analysis of results
Dissemination of findings
None of the above
Give details of involvement, or if none please justify the absence of involvement.  Members of the 'P.N.E.S awareness' support group for people who experience non-epileptic seizures have been
consulted in relation to the design of the study, by asking five volunteers to feedback on the participant information
sheet and adverts. The feedback received was positive; an additional link was added to the support information based on a suggestion from one of these reviewers.
based on a suggestion from one or these reviewers.

# 4. RISKS AND ETHICAL ISSUES

# RESEARCH PARTICIPANTS

### A17-1. Please list the principal inclusion criteria (list the most important, max 5000 characters).

Adults over the age of 18 years

Who experience epileptic and/or non-epileptic seizures

# A17-2. Please list the principal exclusion criteria (list the most important, max 5000 characters).

Unable to understand the level of English language required to complete the measures

# RESEARCH PROCEDURES, RISKS AND BENEFITS

A18. Give details of all non-clinical intervention(s) or procedure(s) that will be received by participants as part of the research protocol. These include seeking consent, interviews, non-clinical observations and use of questionnaires.

Please complete the columns for each intervention/procedure as follows:

- 1. Total number of interventions/procedures to be received by each participant as part of the research protocol.
- 2. If this intervention/procedure would be routinely given to participants as part of their care outside the research, how many of the total would be routine?
- 3. Average time taken per intervention/procedure (minutes, hours or days)
- 4. Details of who will conduct the intervention/procedure, and where it will take place.

Intervention or procedure	1 2 3	4
Reading the participant information sheet and	1 0 3	Potential participant via the online survey site or

NHS REC Form Reference: IRAS Version 3.5 15/NW/0110 4.16

consent information minutes in the paper pack

Completing demographic questions 1 0 1 Participant via online survey site or paper form.

minutes

Completing measures 1 0 10 mins Participant via online survey site or paper form.

(Details of measures are given in the protocol)

Thank you and support information 1 0 1 minute Participant via online survey site or paper form.

# A21. How long do you expect each participant to be in the study in total?

15 - 20 minutes

### A22. What are the potential risks and burdens for research participants and how will you minimise them?

For all studies, describe any potential adverse effects, pain, discomfort, distress, intrusion, inconvenience or changes to lifestyle. Only describe risks or burdens that could occur as a result of participation in the research. Say what steps would be taken to minimise risks and burdens as far as possible.

Risk of becoming distressed due to answering questions about childhood experiences. Minimised by: making it clear participants should stop answering questions if they become distressed, including support information, and

providing a link to exit the survey and access support information on every page of the online version.

A23. Will interviews/ questionnaires or group discussions include topics that might be sensitive, embarrassing or upsetting, or is it possible that criminal or other disclosures requiring action could occur during the study?

Yes \( \cap \) No

If Yes, please give details of procedures in place to deal with these issues:

The survey does not include open questions therefore it is unlikely that disclosures will occur. Some questionnaires include sensitive topics, however the survey will be anonymous, which reduces issues relating to this.

# A24. What is the potential for benefit to research participants?

There will be no direct benefit.

### A26. What are the potential risks for the researchers themselves? (if any)

None

# RECRUITMENT AND INFORMED CONSENT

In this section we ask you to describe the recruitment procedures for the study. Please give separate details for different study groups where appropriate.

**A27-1.** How will potential participants, records or samples be identified? Who will carry this out and what resources will be used? For example, identification may involve a disease register, computerised search of GP records, or review of medical records. Indicate whether this will be done by the direct healthcare team or by researchers acting under arrangements with the responsible care organisation(s).

Potential participants may be identified in several ways:

self-identification following viewing an advertisement,

identification by a member of their healthcare team who makes them aware of the study,

identification by their membership of a relevant forum or support group through which they receive study advertising, or

being forwarded the information by another participant.

A27-2. Will the identification of potential participants involve reviewing or screening the identifiable personal information of patients, service users or any other person?		
○ Yes   No		
Please give details below:		
A28. Will any participants be recruited by publicity through posters, leaflets, adverts or websites?		

Yes No

If Yes, please give details of how and where publicity will be conducted, and enclose copy of all advertising material (with version numbers and dates).

Publicity will be conducted via online forums, support groups, and at relevant health clinics.

#### A29. How and by whom will potential participants first be approached?

This will include:

by a professional who works with the person face to face, or over the phone,

by viewing a poster/ advert in a clinic or other location, or online,

by another participant who forwards them information about the study.

#### A30-1. Will you obtain informed consent from or on behalf of research participants?

Yes \( \cap \) No

If you will be obtaining consent from adult participants, please give details of who will take consent and how it will be done, with details of any steps to provide information (a written information sheet, videos, or interactive material). Arrangements for adults unable to consent for themselves should be described separately in Part B Section 6, and for children in Part B Section 7.

If you plan to seek informed consent from vulnerable groups, say how you will ensure that consent is voluntary and fully informed.

For the paper version consent will be inferred from the fact that they have posted the survey forms back to the researcher. Guidance from the British Psychological Society suggests that participants may be less likely to read participant information for online surveys. Therefore, for those participating electronically, a page will include tick boxes to draw attention to key study information and a button to click to indicate consent. No identifying details will be collected during the consent procedures.

If you are not obtaining consent, please explain why not.

N/a

Please enclose a copy of the information sheet(s) and consent form(s).

#### A30-2. Will you record informed consent (or advice from consultees) in writing?

O Yes 

No

If No, how will it be recorded?

It will be recorded electronically by the online survey system, in the case of paper forms it will be inferred from the act of posting the forms to the researcher.

#### A31. How long will you allow potential participants to decide whether or not to take part?

They will have the option to think about the participant information sheet and come back to it at any time whilst the study is still open for data collection. The participant information sheet will include a planned close date and the option to print information.

#### A33-1. What arrangements have been made for persons who might not adequately understand verbal explanations or

Date: 22/01/2015 11 166247/726475/1/74

written information given in English, or who have special communication needs?(e.g. translation, use of interpreters)

As not all measures have been tested in languages other than English, translation is not available as this would compromise the validity and reliability of the data.

A35. What steps would you take if a participant, who has given informed consent, loses capacity to consent during the study? Tick one option only.
The participant and all identifiable data or tissue collected would be withdrawn from the study. Data or tissue which is not identifiable to the research team may be retained.
The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would be retained and used in the study. No further data or tissue would be collected or any other research procedures carried out on or in relation to the participant.
The participant would continue to be included in the study.
Not applicable – informed consent will not be sought from any participants in this research.
Not applicable – it is not practicable for the research team to monitor capacity and continued capacity will be assumed.
Further details:
As the research team will not be in direct contact with the participants during data collection they will be unable to monitor capacity. However, it seems unlikely that capacity will change in the time that it takes to complete the surveys.

#### CONFIDENTIALITY

In this section, personal data means any data relating to a participant who could potentially be identified. It includes pseudonymised data capable of being linked to a participant through a unique code number.

Storage and use of personal data during the study
A36. Will you be undertaking any of the following activities at any stage (including in the identification of potential participants)?( <i>Tick as appropriate</i> )
Access to medical records by those outside the direct healthcare team
☑ Electronic transfer by magnetic or optical media, email or computer networks
Sharing of personal data with other organisations
Export of personal data outside the EEA
✓ Use of personal addresses, postcodes, faxes, emails or telephone numbers
Publication of direct quotations from respondents
Publication of data that might allow identification of individuals
Use of audio/visual recording devices
✓ Storage of personal data on any of the following:
Manual files including X-rays
NHS computers
Home or other personal computers
✓ University computers
Private company computers
Laptop computers
Fronth and date the
Further details:  The only personal data that will be collected is a list of email/postal addresses, if participants wish to give them, so that

the researchers can send them a copy of the overall results.

In the case of postal participation, participants will be asked to send their email/postal address in a separate envelope to the survey data. Online this information will be collected with a separate survey so that it is not linked to the questionnaire data.

Where I have ticked 'University computers' above this refers to the university secure server and not individual computers.

**A38. How will you ensure the confidentiality of personal data?** Please provide a general statement of the policy and procedures for ensuring confidentiality, e.g. anonymisation or pseudonymisation of data.

The researchers will not link the email/postal addresses and the rest of the survey data. Also see A37 above.

**A40. Who will have access to participants' personal data during the study?** Where access is by individuals outside the direct care team, please justify and say whether consent will be sought.

The non-identifiable personal information i.e. demographics and responses to measures will be accessible to the research team and any person standing in for or replacing a member of the research team.

The list of email/postal addresses to send out a summary of the study will be available to the research team but will not be linked to any other study data.

#### Storage and use of data after the end of the study

A43. How long will personal data be stored or accessed after the study has ended?
O Less than 3 months
<ul><li>● 3 – 6 months</li></ul>
○ 6 – 12 months
O 12 months – 3 years
Over 3 years
INCENTIVES AND PAYMENTS
A46. Will research participants receive any payments, reimbursement of expenses or any other benefits or incentives for taking part in this research?
◯ Yes
A47. Will individual researchers receive any personal payment over and above normal salary, or any other benefits or incentives, for taking part in this research?
○ Yes   No
A48. Does the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g. financial, share holding, personal relationship etc.) in the organisations sponsoring or funding the research that may give rise to a possible conflict of interest?
◯ Yes ● No

#### NOTIFICATION OF OTHER PROFESSIONALS

A49-1. Will you inform the participants' General Practitioners (and/or any other health or care professional responsible for their care) that they are taking part in the study?			
◯ Yes ● No			
If Yes, please enclose a copy of the information sheet/letter for the GP/health professional with a version number and date.			
PUBLICATION AND DISSEMINATION			
A50. Will the research be registered on a public database?			
◯ Yes ● No			
Please give details, or justify if not registering the research.			
Registration of research studies is encouraged wherever possible. You may be able to register your study through your NHS organisation or a register run by a medical research charity, or publish your protocol through an open access publisher. If you are aware of a suitable register or other method of publication, please give details. If not, you may indicate that no suitable register exists. Please ensure that you have entered registry reference number(s) in question A5-1.			
A51. How do you intend to report and disseminate the results of the study? Tick as appropriate:			
<ul> <li>✓ Peer reviewed scientific journals         <ul> <li>Internal report</li> <li>✓ Conference presentation</li> <li>Publication on website</li> <li>Other publication</li> <li>Submission to regulatory authorities</li> <li>Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee on behalf of all investigators</li> <li>No plans to report or disseminate the results</li> <li>✓ Other (please specify)</li> </ul> </li> <li>As part of a doctoral thesis</li> </ul> A53. Will you inform participants of the results? <ul> <li>✓ Yes</li> <li>No</li> </ul> <li>Please give details of how you will inform participants or justify if not doing so.</li> <li>Participants will have the option of providing an email/postal address so that the research team can send them a summary of the results.</li>			
5. Scientific and Statistical Review			
A54. How has the scientific quality of the research been assessed? Tick as appropriate:			
Independent external review			
Review within a company			
Review within a multi-centre research group			
☑ Review within the Chief Investigator's institution or host organisation			
Review within the research team			

Date: 22/01/2015 14 166247/726475/1/74

		15/1000/0110	4.21
Review by edu	icational supervisor		
Justify and describe the review process and outcome. If the review has been undertaken but not seen by the researcher, give details of the body which has undertaken the review:  Review took place in initial stages with members of the research team (see attached form). The academic supervisor and research officer for Lancaster University have checked this application and all supporting documents.			
	pt non-doctoral student related correspondence.	esearch, please enclose a copy of any availab	ole scientific critique reports,
For non-doctoral st	udent research, please e	nclose a copy of the assessment from your ed	lucational supervisor/ institution.
A56. How have the	statistical aspects of th	ne research been reviewed?Tick as appropria	 ate:
Review by ind	enendent statistician cor	nmissioned by funder or sponsor	
	y independent statisticia		
	npany statistician	·	
	•	f Investigator's institution	
		arch team or multi-centre group	
	icational supervisor	3 · · ·	
_	-	statistical expertise	
<ul> <li>Other review by individual with relevant statistical expertise</li> <li>No review necessary as only frequencies and associations will be assessed – details of statistical input not required</li> </ul>			
		individual responsible for reviewing the statist fthe department and institution concerned.	tical aspects. If advice has
	Title Forename/Initials	Surname	
	Dr lan	Fletcher	
Department	Division of Health Rese	earch	
Institution Work Address	Lancaster University Clinical Psychology		
Work Address	Division of health resea	arch	
	Lancaster University	ai Gii	
Post Code	LA1 4YG		
Telephone	01524 593301		
Fax			
Mobile			
E-mail	i.j.fletcher@lancaster.a	c.uk	
Please enclose a c	opy of any available com	ments or reports from a statistician.	
A57. What is the pr	imary outcome measure	e for the study?	
Impact of seizures			
4=0.147			
A58. What are the	secondary outcome me	asures? (if any)	

**A59. What is the sample size for the research?** How many participants/samples/data records do you plan to study in total? If there is more than one group, please give further details below.

Seizure frequency and type (epileptic or non-epileptic)

Total UK sample size:

Total international sample size (including UK): 98

Total in European Economic Area:

Further details:

**A60.** How was the sample size decided upon? If a formal sample size calculation was used, indicate how this was done, giving sufficient information to justify and reproduce the calculation.

The sample size above is the minimum recommended to achieve an appropriate level of power (0.8) in the statistical calculations (regression analysis). This is based on the expectation that the effect sizes (impact) of the mediators will be medium, as this has been indicated in other research. It also takes into account the fact that there will be six variables, including the demographic questions. The figure is obtained from the graphs given on page 314 of Field's (2013) book, 'discovering statistics using IBM SPSS statistics', see protocol for full reference.

#### A61. Will participants be allocated to groups at random?

Yes

No

A62. Please describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) by which the data will be evaluated to meet the study objectives.

Data will be analysed using statistical analysis software such as IBM SPSS. The main analysis is planned to be regression analysis, if appropriate it may also include analysis of mediators and moderators. Tests will be carried out to assess appropriateness of regression analysis. Should regression analysis be inappropriate due to insufficient number of participants, or other issues, alternate appropriate tests will be carried out, such as, tests for correlation between measures, and tests for significance of differences between means for different groups.

#### 6. MANAGEMENT OF THE RESEARCH

**A63. Other key investigators/collaborators.** Please include all grant co-applicants, protocol co-authors and other key members of the Chief Investigator's team, including non-doctoral student researchers.

Title Forename/Initials Surname

Dr Jayne Martlew

Post Consultant Clinical Neuropsychologist

Qualifications BSc, MPhil, Doctorate in Clinical Psychology

Employer The NHS Foundation Trust

Work Address Lower Lane

Fazakerley

Liverpool

Post Code L9 7LJ

Telephone 0151 529 5693

Fax

Mobile

Work Email Jayne.Martlew@thewaltoncentre.nhs.uk

#### A64. Details of research sponsor(s)

#### A64-1. Sponsor

Lead Sponsor			
Status: ONHS o	or HSC care organisation	Commercial status:	
Acade	emic		
O Pharm	naceutical industry		
O Medica	al device industry		
O Local /	Authority		
Other	social care provider (including voluntary sector or priva	ate organisation)	
Other			
If Other, pl	ease specify:		
Contact person			
Name of organisa	tion Lancaster University		
Given name	Debbie		
Family name	Knight		
Address	Research Support Office,		
Town/city	B58 Bowland Main,		
Post code	LA1 4YT		
Country	UNITED KINGDOM		
Telephone	01524 592605		
Fax			
E-mail	ethics@lancaster.ac.uk		
Is the sponsor bas	sed outside the UK?		
	th Governance Framework for Health and Social Care, e established in the UK. Please consult the guidance i		
65. Has external fu	inding for the research been secured?		
Funding secure	d from one or more funders		

A65. Has external funding for the research been secured?				
Funding secured from one or more funders				
External funding application to one or more funders in progress				
✓ No application for external funding will be made				
What type of research project is this?				
Standalone project				
OProject that is part of a programme grant				
OProject that is part of a Centre grant				
Project that is part of a fellowship/ personal award/ research training award				
Other				
Other – please state:				

A67. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK or another country?

O Yes 

No

Please provide a copy of the unfavourable opinion letter(s). You should explain in your answer to question A6-2 how the reasons for the unfavourable opinion have been addressed in this application.

#### A68-1. Give details of the lead NHS R&D contact for this research:

Title Forename/Initials Surname
Dave Watling

Organisation The NHS Foundation Trust

Address Lower Lane

Fazakerley Liverpool

Post Code L9 7LJ

Work Email dave.watling@thewaltoncentre.nhs.uk

Telephone 01515295667

Fax Mobile

Details can be obtained from the NHS R&D Forum website: http://www.rdforum.nhs.uk

#### A69-1. How long do you expect the study to last in the UK?

Planned start date: 01/01/2015 Planned end date: 30/05/2015

Total duration:

Years: 0 Months: 4 Days: 30

#### A71-2. Where will the research take place? (Tick as appropriate)

✓ England

Scotland

Wales

✓ Northern Ireland

✓ Other countries in European Economic Area

Total UK sites in study

Number of sites anticipated in the Community

Does this trial involve countries outside the EU?

Yes No

**USA** 

✓ Other international (please specify)

Anyone with internet access may choose to complete the online measures

**A72. What host organisations (NHS or other) in the UK will be responsible for the research sites?** Please indicate the type of organisation by ticking the box and give approximate numbers of planned research sites:

 NHS REC Form
 Reference:
 IRAS Version 3.5

 15/NW/0110
 4.25

NHS organisations in England     1
□ NHS organisations in Wales
☐ NHS organisations in Scotland
☐ HSC organisations in Northern Ireland
GP practices in England
GP practices in Wales
GP practices in Scotland
GP practices in Northern Ireland
Social care organisations
☐ Phase 1 trial units
☐ Prison establishments
☐ Probation areas
☐ Independent hospitals
☐ Educational establishments
☐ Independent research units
Other (give details)
One site is lead for R& D, other sites will be participant identification centres.
Total UK sites in study: 1
A76. Insurance/ indemnity to meet potential legal liabilities
71 Of moderation in definitely to mode peromial regain indumined
Note: in this question to NHS indemnity schemes include equivalent schemes provided by Health and Social Care
(HSC) in Northern Ireland
(HSC) in Northern Ireland
(HSC) in Northern Ireland  A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)  Other insurance or indemnity arrangements will apply (give details below)
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)  Other insurance or indemnity arrangements will apply (give details below)  Lancaster University legal liability cover will apply.
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)  Other insurance or indemnity arrangements will apply (give details below)  Lancaster University legal liability cover will apply.
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)  Other insurance or indemnity arrangements will apply (give details below)  Lancaster University legal liability cover will apply.  Please enclose a copy of relevant documents.  A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the sponsor(s) or employer(s) for harm to participants arising from the design of the research? Please tick box(es) as
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)  Other insurance or indemnity arrangements will apply (give details below)  Lancaster University legal liability cover will apply.  Please enclose a copy of relevant documents.  A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the sponsor(s) or employer(s) for harm to participants arising from the design of the research? Please tick box(es) as applicable.  Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol authors (e.g. company employees, university members), please describe the arrangements and provide evidence.
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)  Other insurance or indemnity arrangements will apply (give details below)  Lancaster University legal liability cover will apply.  Please enclose a copy of relevant documents.  A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the sponsor(s) or employer(s) for harm to participants arising from the design of the research? Please tick box(es) as applicable.  Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol authors (e.g. company employees, university members), please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (protocol authors with NHS contracts only)
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)  Other insurance or indemnity arrangements will apply (give details below)  Lancaster University legal liability cover will apply.  Please enclose a copy of relevant documents.  A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the sponsor(s) or employer(s) for harm to participants arising from the design of the research? Please tick box(es) as applicable.  Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol authors (e.g. company employees, university members), please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (protocol authors with NHS contracts only)  Other insurance or indemnity arrangements will apply (give details below)
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the sponsor(s) for harm to participants arising from the management of the research? Please tick box(es) as applicable.  Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all other sponsors, please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (NHS sponsors only)  Other insurance or indemnity arrangements will apply (give details below)  Lancaster University legal liability cover will apply.  Please enclose a copy of relevant documents.  A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the sponsor(s) or employer(s) for harm to participants arising from the design of the research? Please tick box(es) as applicable.  Note: Where researchers with substantive NHS employment contracts have designed the research, indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For other protocol authors (e.g. company employees, university members), please describe the arrangements and provide evidence.  NHS indemnity scheme will apply (protocol authors with NHS contracts only)

A76-3. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of investigators/collaborators arising from harm to participants in the <u>conduct</u> of the research?
<u>Note:</u> Where the participants are NHS patients, indemnity is provided through the NHS schemes or through professional indemnity. Indicate if this applies to the whole study (there is no need to provide documentary evidence). Where non-NHS sites are to be included in the research, including private practices, please describe the arrangements which will be made at these sites and provide evidence.
NHS indemnity scheme or professional indemnity will apply (participants recruited at NHS sites only)
Research includes non-NHS sites (give details of insurance/ indemnity arrangements for these sites below)
Lancaster University legal liability cover will apply.
Please enclose a copy of relevant documents.

#### PART C: Overview of research sites

Please enter details of the host organisations (Local Authority, NHS or other) in the UK that will be responsible for the research sites. For NHS sites, the host organisation is the Trust or Health Board. Where the research site is a primary care site, e.g. GP practice, please insert the host organisation (PCT or Health Board) in the Institution row and insert the research site (e.g. GP practice) in the Department row.

Research site Investigator/ Collaborator/ Contact

Institution name THE NHS FOUNDATION TRUST Title

Department name First name/
Street address | LOWER LANE | Initials

Street address LOWER LANE Initials

Town/city Surname Tallentire

Town/city Surname Fallentire

Post Code L9 7LJ

Participant Identification Centre(PIC)-Collaborator/ Contact

#### **PART D: Declarations**

#### D1. Declaration by Chief Investigator

- 1. The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it.
- 2. I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice guidelines on the proper conduct of research.
- 3. If the research is approved I undertake to adhere to the study protocol, the terms of the full application as approved and any conditions set out by review bodies in giving approval.
- 4. I undertake to notify review bodies of substantial amendments to the protocol or the terms of the approved application, and to seek a favourable opinion from the main REC before implementing the amendment.
- 5. I undertake to submit annual progress reports setting out the progress of the research, as required by review bodies.
- 6. I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines relating to security and confidentiality of patient or other personal data, including the need to register when necessary with the appropriate Data Protection Officer. I understand that I am not permitted to disclose identifiable data to third parties unless the disclosure has the consent of the data subject or, in the case of patient data in England and Wales, the disclosure is covered by the terms of an approval under Section 251 of the NHS Act 2006.
- 7. I understand that research records/data may be subject to inspection by review bodies for audit purposes if required.
- 8. I understand that any personal data in this application will be held by review bodies and their operational managers and that this will be managed according to the principles established in the Data Protection Act 1998
- 9. I understand that the information contained in this application, any supporting documentation and all correspondence with review bodies or their operational managers relating to the application:
  - Will be held by the REC (where applicable) until at least 3 years after the end of the study; and by NHS R&D offices (where the research requires NHS management permission) in accordance with the NHS Code of Practice on Records Management.
  - May be disclosed to the operational managers of review bodies, or the appointing authority for the REC (where applicable), in order to check that the application has been processed correctly or to investigate any complaint.
  - May be seen by auditors appointed to undertake accreditation of RECs (where applicable).
  - Will be subject to the provisions of the Freedom of Information Acts and may be disclosed in response
    to requests made under the Acts except where statutory exemptions apply.
  - May be sent by email to REC members.
- I understand that information relating to this research, including the contact details on this application, may be held on national research information systems, and that this will be managed according to the principles established in the Data Protection Act 1998.
- 11. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I understand that the summary of this study will be published on the website of the National Research Ethics Service (NRES), together with the contact point for enquiries named below. Publication will take place no earlier than 3 months after issue of the ethics committee's final opinion or the withdrawal of the application.

#### Contact point for publication(Not applicable for R&D Forms)

NRES would like to include a contact point with the published summary of the study for those wishing to seek further information. We would be grateful if you would indicate one of the contact points below.

Chief Investigator

Sponsor

<ul> <li>Study co-ordinator</li> </ul>				
Student				
Other – please giv	e details			
None				
Access to application	for training purposes (Not applicable for R&D Forms)			
Optional – please tick as appropriate:				
■ I would be content for members of other RECs to have access to the information in the application in confidence				
removed.	All personal identifiers and references to sponsors, funders and research units would be			
This section was signed electronically by Ms Elizabeth TALLENTIRE on 16/01/2015 11:51.				
Job Title/Post:	Trainee Clinical Psychology			
Organisation:	Lancaster University			
Email:	I.tallentire@lancaster.ac.uk			

#### D2. Declaration by the sponsor's representative

If there is more than one sponsor, this declaration should be signed on behalf of the co-sponsors by a representative of the lead sponsor named at A64-1.

#### I confirm that:

- This research proposal has been discussed with the Chief Investigator and agreement in principle to sponsor the research is in place.
- An appropriate process of scientific critique has demonstrated that this research proposal is worthwhile and of high scientific quality.
- Any necessary indemnity or insurance arrangements, as described in question A76, will be in place before
  this research starts. Insurance or indemnity policies will be renewed for the duration of the study where
  necessary.
- 4. Arrangements will be in place before the study starts for the research team to access resources and support to deliver the research as proposed.
- Arrangements to allocate responsibilities for the management, monitoring and reporting of the research will be in place before the research starts.
- 6. The duties of sponsors set out in the Research Governance Framework for Health and Social Care will be undertaken in relation to this research.
- 7. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I understand that the summary of this study will be published on the website of the National Research Ethics Service (NRES), together with the contact point for enquiries named in this application. Publication will take place no earlier than 3 months after issue of the ethics committee's final opinion or the withdrawal of the application.
- 8. Specifically, for submissions to the Research Ethics Committees (RECs) I declare that any and all clinical trials approved by the HRA since 30th September 2013 (as defined on IRAS categories as clinical trials of medicines, devices, combination of medicines and devices or other clinical trials) have been registered on a publically accessible register in compliance with the HRA registration requirements for the UK, or that any deferral granted by the HRA still applies.

This section was signed electronically by An authorised approver at ethics@lancaster.ac.uk on 21/01/2015 17:34.

Job Title/Post: Research Support Officer

Organisation: Lancaster University

Email: s.c.taylor@lancaster.ac.uk

#### D3. Declaration for student projects by academic supervisor(s)

- 1. I have read and approved both the research proposal and this application. I am satisfied that the scientific content of the research is satisfactory for an educational qualification at this level.
- 2. I undertake to fulfil the responsibilities of the supervisor for this study as set out in the Research Governance Framework for Health and Social Care.
- 3. I take responsibility for ensuring that this study is conducted in accordance with the ethical principles underlying the Declaration of Helsinki and good practice guidelines on the proper conduct of research, in conjunction with clinical supervisors as appropriate.
- 4. I take responsibility for ensuring that the applicant is up to date and complies with the requirements of the law and relevant guidelines relating to security and confidentiality of patient and other personal data, in conjunction with clinical supervisors as appropriate.

#### Academic supervisor 1

This section was signed electronically by Dr Ian Fletcher on 16/01/2015 13:09.

Job Title/Post: Senior Lecturer

Organisation: Lancaster University

Email: i.j.fletcher@lancs.ac.uk

Protocol 4.33

#### Relationships between early life events, individual differences, and seizures

Epileptic seizures are associated with atypical electrical activity in the brain, seen during electroencephalography (EEG). Non-epileptic seizures appear similar when observed, but the changes in electrical activity are not seen on the EEG (Hubsch, Baumann, & Maillard, 2010). Differentiating between these types of seizures can be difficult, but it is important, in order to help people to access appropriate treatment; the most reliable way to differentiate has been found to be video-electroencephalography (Cragar, Berry, Fakhoury, Cibula, & Schmitt, 2002). The task of differentiating is made difficult by high levels of comorbidity of epileptic and non-epileptic seizures. For example Hoepner et al. (2014) reported that 36% of their sample of 114 people who experienced non-epileptic seizures also had epileptic seizures. This causes complications for the use of EEG for differential diagnosis, as people may receive a diagnosis of epileptic or non-epileptic seizures when in fact they experience both. Therefore, understanding how early life events and individual differences interact in relation to seizure type is important to be able to increase understanding of the aetiologies of different seizure types, to improve recognition of individual differences that may be contributing to seizure experiences, and to indicate specific psychological therapies that can target these individual differences.

Research has established a link between childhood traumatic experiences and seizure type; high rates of traumatic experiences, particularly childhood trauma and abuse, are associated with non-epileptic seizures (Bodde et al., 2009; Cragar et al., 2002; Fiszman, Alves-Leon, Nunes, D'Andrea, & Figueira, 2004). Trauma history has also been associated with seizure frequency for people who have non-epileptic seizures but not for people who have epileptic seizures (Lally, Spence, McCusker, Craig, & Morrow, 2010). It is also important to consider the impact seizures have in a person's life, which Corallo et al. (2013) said gives a clearer indication of the health of a patient. Therefore, this research will consider

the seizure outcomes of seizure type, seizure frequency, and impact of seizures on a person's life. This research will examine the relationship between these seizure outcome measures and childhood trauma. This research will also consider how individual differences in adult attachment styles, and emotion processing (alexithymia), influence the relationship between childhood trauma and seizure outcomes.

Bowlby (1988) proposed that the type of attachment relationship a child has with their main caregiver shapes the way that person relates to others throughout life (their attachment style). Bowlby suggested that the child forms an internal working model based on repeated experiences of the way the caregiver responds to the child's communication of their internal state or emotion, e.g. crying. Brennan, Clark, and Shaver (1998, cited in Wei, Russell, Mallinckrodt, & Zakalik, 2004) developed a two-dimensional model of adult attachment style, consisting of attachment anxiety and attachment avoidance. In their model, high levels of attachment anxiety represent an excessive need for approval, and fear of rejection from others; high levels of attachment avoidance indicate excessive self-reliance and fear of being close to others in relationships. They suggest that people with low levels of attachment anxiety and avoidance are able to form secure attachments in their adult relationships.

Research indicates that adult attachment style mediates the relationship between trauma and various psychological difficulties. For example, a study found that adult attachment was a mediator between childhood abuse (especially psychological) and current symptomology including trauma related symptoms (Muller, Thornback, & Bedi, 2012). Another study found that attachment anxiety partially mediated the relationship between experiences of violence in relationships or sexual victimisation and posttraumatic symptoms (Sandberg, Suess, & Heaton, 2010); and Dimitrova et al. (2010) found that attachment mediated the relationship between experiences of child and adolescent sexual abuse and psychopathology.

Understanding the relationship of attachment to distress is important because adult attachment style has been recognised to impact on therapy outcomes and it has been suggested that therapy should be adapted to consider different styles (Jellema, 2000).

Theoretically, Quinn, Schofield and Middleton (2008) propose that trauma, in the presence of non-validating attachment experiences, is one pathway which leads to the development of non-epileptic seizures. Attachment has not been widely studied in relation to non-epileptic seizures. Brown et al. (2013) did consider it, and did not find a significant difference in attachment style between two subgroups of people experiencing non-epileptic seizures and a group who experience epileptic seizures. However, they had difficulties with the sub-scale reliability of their attachment measure (Brown et al., 2013). A different measure will be used in this study, which has a strong theoretical basis and extensive reliability and validity data (Brenning, Van Petegem, Vanhalst, & Soenens, 2014; Picardi, Martinotti, Paci, Simi, & Caroppo, 2011; Wei, Russell, Mallinckrodt, & Vogel, 2007).

The concept of Alexithymia refers to a difficulty with the ability to recognise and describe feelings and external orientation of behaviour (R. Michael Bagby, Parker, & Taylor, 1994). Alexithymia has been identified as a mediator between trauma related predictors and various indicators of distress including: between trauma and diagnosis of personality disorder (Gaher, Hofman, Simons, & Hunsaker, 2013); between childhood emotional maltreatment and somatic complaints in young adults (Smith & Flannery-Schroeder, 2013); between childhood maltreatment and self-injurious behaviours (Paivio & McCulloch, 2004)

People who experience non-epileptic seizures have been found to have higher levels of alexithymia than those who experience epileptic seizures (Kaplan et al., 2013). A relationship between trauma symptoms and alexithymia has also been suggested for people who experience non-epileptic seizures (Myers, Matzner, Lancman, Perrine, & Lancman, 2013).

The concepts of alexithymia and emotion regulation are closely related (Gratz & Roemer, 2004). Cassidy (1994) proposes that the child develops their style of emotion regulation as an adaptive response to the way their caregiver interacts with them, and that the style of emotion regulation serves the function of maintaining the relationship with their caregiver. They also suggest that a child, who has experienced repeated rejection from their caregiver, and therefore, has an avoidant attachment style, minimises their emotions in order to avoid further rejection. However, a child whose caregiver has been unavailable or inconsistently available, and has developed an ambivalent or anxious attachment style, maximises their feelings, in order to increase the likelihood of getting a response from the caregiver.

Given this proposed link between childhood attachment style and emotional regulation, it is not surprising that research has found a relationship between adult attachment style and alexithymia. For example, low levels of alexithymia have been associated with a secure adult attachment style (Hexel, 2003). High levels of alexithymia have been associated with a fearful or anxious style of attachment (Troisi, Argenio, Peracchio, & Petti, 2001). Emotional competence, including alexithymia, has been indicated as a mediator or link between childhood psychological maltreatment and adult attachment style (Kapeleris & Paivio, 2011). Kapeleris and Paivio (2011) suggested that the reason for this link is that psychological abuse or neglect in childhood means that the child does not develop the skills to understand and manage their emotions, which makes it more difficult for them to relate to others in adulthood.

This research will investigate the relationships between the predictors: childhood trauma, alexithymia and adult attachment style, and the outcomes: seizure type, frequency and impact of seizures. Initially this will involve regression analyses to investigate the relationships between variables. If viable, this research may go on to investigate complex

models of the relationship between childhood trauma and seizure outcomes, such as, alexithymia and/or adult attachment style acting as mediators.

#### Hypothesis

The research hypothesis is that higher levels of childhood trauma will be associated with higher levels of alexithymia, adult attachment anxiety, and avoidance; seizure type of non-epileptic; increased seizure frequency; and greater impact of seizures.

#### Method

This research will use self-report questionnaires, a method which other researchers in the area have used. For example, Kaplan et al. (2013) used self-report questionnaires to ask people with epileptic or non-epileptic seizures about childhood trauma, alexithymia, and psychological defence strategies. Van Merode et al. (2004) used self-report measures of symptoms, childhood trauma, dissociative experiences, anxiety and coping. Lehavot and Simpson (2014) used a self-report online survey to ask female war veterans, a group who like those with non-epileptic seizures have elevated levels of depression, PTSD and trauma, about childhood trauma, assault, PTSD and depression symptoms. These researchers have not reported any ethical issues arising from the use of self-report measures.

Chase, Beatty and Ondersma (2011) found that reporting of childhood trauma is increased when participants are able to be completely anonymous. Therefore, no identifiers will be collected.

#### **Participants**

Researchers will recruit participants via advertising on online forums such as the PNES awareness discussion forum ("P.N.E.S. Awareness Discussion Forum," 2014), contacting support groups, such as Epilepsy Action (Epilepsy Action, 2014), advertising in

4.38

relevant clinics, such as NHS epilepsy clinics, and other appropriate locations. Other people,

such as NHS staff, promoting the research on behalf of the researchers may also recruit

participants indirectly. Inclusion criteria are:

• adults over the age of 18,

• who identify themselves as experiencing epileptic and/or non-epileptic seizures.

**Exclusion Criteria** 

• level of English insufficient to understand the instructions and measures

It is not possible to offer translation as not all measures are available in other

languages and translation would be likely to impact on reliability and validity of

measures.

Design

The study will use a quantitative cross sectional survey design. It will use

convenience and snowball sampling.

**Materials** 

This research will use the Qualtrics online survey platform and/or printed copies of

the same materials to provide information, obtain consent and collect data. The study will

use SPSS (or similar software) to the analyse data.

Measures

Demographic Questions

Participants will be asked their age, gender, and county of residence.

Childhood Trauma

The Early Trauma Inventory Self Report- Short Form (ETISR-SF), is available free

(D. Bremner, 2004, 2009). It has 29 items, on a trial; the ETISR-SF took 3 minutes to complete. It consists of four domains, which are physical, emotional, sexual abuse, and general trauma. It has been tested for validity using a large sample of 288 people, which included healthy controls (28%) and people with a variety of psychiatric disorders including PTSD, depression and borderline personality disorder, 11% of the sample had a psychiatric disorder with a history of abuse (J. D. Bremner, Bolus, & Mayer, 2007).

#### Attachment

The experience in close relationships (ECR) short form has 12 items, and it assesses attachment anxiety and attachment related avoidance. Its factor structure, reliability and validity has been assessed (Wei et al., 2007). Its validity has been tested using clinical and non-clinical populations, including patients with drug-resistant epilepsy (Alessandri et al., 2014; Wongpakaran & Wongpakaran, 2012)

#### Alexithymia

The Toronto Alexithymia scale (TAS-20) has 20 items, and costs £35 (Taylor, 2014). Its factor structure, reliability and validity has been assessed (Wei et al., 2007). It has been validated for use in a wide variety of clinical and non-clinical populations including somatoform disorders (which are related to non-epileptic seizures) and psychiatric inpatients, as well as using internet administration (Bach & Bach, 1996; R. M. Bagby, Ayearst, Morariu, Watters, & Taylor, 2014; Caretti et al., 2011)

#### Seizure Frequency and type

The seizure type part of the outcome will be identified by participants' self-reports of experiencing epileptic, and/or non-epileptic seizures. For the seizure frequency part of the outcome participants will be asked to report the number of seizures they experience in a

month.

#### Impact of seizures

The revised Liverpool impact of epilepsy scale is a measure of the impact of seizures on daily life. It has 12 items and the researcher estimates it to take 2-3 minutes to complete. The scale has been found to have good reliability and acceptable validity (Crossley, Jacoby, & Baker, 2012).

#### Expected completion time of measures

Table 1, below summarises the measures and expected completion times

Measure	Items	Expected completion time
ECR-short form	12	3 minutes, based on test completion by researcher
TAS-20	20	4 minutes, estimate by researcher
ETISR-SF	29	3 minutes, based on test completion by researcher
Revised Liverpool impact of epilepsy scale	12	3 minutes estimate by researcher
Demographic questions, seizure type & frequency	8	2 minutes, estimate by researcher
Total	81	15 minutes

#### **Procedure**

The researchers will contact NHS and private clinics, support groups, and online forums that people who experience epileptic and/or non-epileptic seizures are likely to be in contact with, and ask if they are willing to support with the recruitment of participants.

Following gaining any necessary ethical and R&D approval for each setting, the researcher will provide them with materials in order to promote the study. This will include posters,

electronic adverts, participant information sheets, and printed study packs. The way the clinic, forum or support group supports recruitment will be at their discretion. This may range from allowing the researcher to display posters or electronic adverts, to giving out or posting packs to potential participants. This would not involve the researchers having access to any personal information or records related to potential participants.

The adverts and posters will explain the options available to participants if they wish to take part. The options will be to complete the survey online, or on paper.

Potential participants wishing to access the survey online will access the Qualtrics site via a link, which will give details of the research on a participant information page, enabling them to give informed consent if they wish to participate. The Qualtrics survey site will guide them through several pages including basic demographics and questions about their seizures. People who answer these questions in a way that indicates it is not appropriate for them to participate will be given explanation of this and then transferred directly to the support information, end of study page. This will happen if a person indicates they do not understand the participant information, they are under 18 or do not experience seizures. Those who are not redirected will then progress onto completing the measures. The support information, end of study page will include the contact details of relevant support groups and other sources of assistance, should the participant become distressed. There will also be a link to exit directly to this page from every page of the study. The host survey site will collect data anonymously, and store it electronically and securely.

Participants wishing to take part using paper forms will access a printed pack including the same information as on the survey site. The researcher will provide relevant contacts with copies of the printed pack to pass on to potential participants, packs will be left alongside posters, and potential participants will have the option to print out their own pack from the survey site. The information in the postal pack will be adapted to explain that

posting the forms to the researchers will indicate consent, thus negating the need to collect any identifiers on consent forms. The pack will include a freepost address in order for participants to return their questionnaires to the researcher.

Participants will be asked to pass on information about the research to others who may be interested.

#### Proposed analysis

The researchers will complete regression analyses on the data. The researcher may use other types of statistical analyses on the anonymous data instead of, or in addition to the regression analysis depending on data obtained and number of participants. Following the regression analyses the researchers will consider using the data to test more complex models, for example, mediation models, using structural equation modelling.

#### Power calculation

This research expects to find medium effect sizes (0.39) as studies considering childhood trauma, alexithymia and attachment have found medium to large effect sizes (Carpenter & Chung, 2011; Paivio & McCulloch, 2004). Including the demographic variables there are six predictors. Therefore, based on tables provided by Field (2013, p. 314) the minimum sample size to achieve a power of 0.8 (80% chance of rejecting the null hypothesis if it is false), and a medium effect size is 98.

#### Practical issues (e.g., costs/logistics)

The sponsor, who will also cover costs related to printing of research materials by the researchers, and freepost return address, will meet the cost of £35 for the use of measures.

#### Ethical concerns

Some of the people this study aims to recruit are likely to be people who experience high levels of distress in their lives. It is possible that completing measures related to their life experiences and emotions may remind people of their distress. In order to address this issue, prior to starting the measures, potential participants will be given an explanation of the types of questions they will be asked so they can make an informed decision about whether they would like to participate or not. In addition, the researchers will not give any individual feedback on responses. Participants will be made aware they can stop completing the measures or miss out questions at any point. A debriefing screen or sheet highlighting relevant support organisations e.g. Samaritans will be provided.

#### **Timescale**

See attached Gant Chart for timescales.

- Alessandri, G., Fagnani, C., Di Gennaro, G., Meldolesi, G. N., Pasquini, P., Caroppo, E., . . . Picardi, A. (2014). Measurement Invariance of the Experiences in Close Relationships Questionnaire across Different Populations. *Spanish Journal Of Psychology, 17*. doi: 10.1017/sjp.2014.19
- Bach, M., & Bach, D. (1996). Alexithymia in Somatoform Disorder and Somatic Disease: A Comparative Study. *Psychother. Psychosom.*, 65(3), 150-152.
- Bagby, R. M., Ayearst, L. E., Morariu, R. A., Watters, C., & Taylor, G. J. (2014). The Internet Administration Version of the 20- Item Toronto Alexithymia Scale. *Psychol. Assess., 26*(1), 16-22. doi: 10.1037/a0034316
- Bagby, R. M., Parker, J. D. A., & Taylor, G. J. (1994). The Twenty- Item Toronto Alexithymia Scale— I. Item Selection and Cross- Validation of the Factor Structure. *Journal of Psychosomatic Research*, *38*(1), 23-32. doi: 10.1016/0022-3999(94)90005-1
- Bodde, N. M. G., Brooks, J. L., Baker, G. A., Boon, P. A. J. M., Hendriksen, J. G. M., Mulder, O. G., & Aldenkamp, A. P. (2009). Psychogenic Non-Epileptic Seizures—Definition, Etiology, Treatment and Prognostic Issues: A Critical Review. *Seizure*, *18*(8), 543-553. doi: 10.1016/j.seizure.2009.06.006
- Bowlby, J. (1988). A Secure Base: Clinical Implications of Attachment Theory. London: Routledge.
- Bremner, D. (2004). Early Trauma Inventory Self Report-Short Form (Etisr-Sf), from <a href="http://www.psychiatry.emory.edu/documents/research/ETISR-SF%20Adult%20traumas.pdf">http://www.psychiatry.emory.edu/documents/research/ETISR-SF%20Adult%20traumas.pdf</a>
- Bremner, D. (2009). Early Trauma Inventory Self Report-Short Form (Etisr-Sf), from http://www.psychiatry.emory.edu/documents/research/ETISR-SF.pdf

- Bremner, J. D., Bolus, R., & Mayer, E. A. (2007). Psychometric Properties of the Early Trauma Inventory- Self Report. *The Journal of nervous and mental disease, 195*(3), 211.
- Brenning, K., Van Petegem, S., Vanhalst, J., & Soenens, B. (2014). The Psychometric Qualities of a Short Version of the Experiences in Close Relationships Scale Revised Child Version. Personality and Individual Differences, 68, 118-123. doi: 10.1016/j.paid.2014.04.005
- Brown, R. J., Bouska, J. F., Frow, A., Kirkby, A., Baker, G. A., Kemp, S., . . . Reuber, M. (2013). Emotional Dysregulation, Alexithymia, and Attachment in Psychogenic Nonepileptic Seizures. *Epilepsy Behav., 29*(1), 178-183. doi: 10.1016/j.yebeh.2013.07.019
- Caretti, V., Porcelli, P., Solano, L., Schimmenti, A., Bagby, R. M., & Taylor, G. J. (2011). Reliability and Validity of the Toronto Structured Interview for Alexithymia in a Mixed Clinical and Nonclinical Sample from Italy. *Psychiatry Research*, *187*(3), 432-436. doi: 10.1016/j.psychres.2011.02.015
- Carpenter, L., & Chung, M. C. (2011). Childhood Trauma in Obsessive Compulsive Disorder: The Roles of Alexithymia and Attachment. *Psychology and Psychotherapy: Theory, Research and Practice*, *84*(4), 367-388. doi: 10.1111/j.2044-8341.2010.02003.x
- Cassidy, J. (1994). Emotion Regulation: Influences of Attachment Relationships. *Monographs of the Society for Research in Child Development, 59*(2-3), 228-249. doi: 10.1111/j.1540-5834.1994.tb01287.x
- Chase, S., Beatty, Jr., & Ondersma, S. J. (2011). A Randomized Trial of the Effects of Anonymity and Quasi Anonymity on Disclosure of Child Maltreatment- Related Outcomes among Postpartum Women. *Child Maltreatment*, *16*(1), 33-40. doi: 10.1177/1077559510387659
- Corallo, F., De Luca, R., Leonardi, R., De Salvo, S., Bramanti, P., & Marino, S. (2013). The Clinical Use of Quality-of-Life Scales in Neurological Disorders. *Acta Neuropsychiatrica*, *25*(4), 193-205.
- Cragar, D., Berry, D., Fakhoury, T., Cibula, J., & Schmitt, F. (2002). A Review of Diagnostic Techniques in the Differential Diagnosis of Epileptic and Nonepileptic Seizures. *Neuropsychol Rev, 12*(1), 31-64. doi: 10.1023/A:1015491123070
- Crossley, J., Jacoby, A., & Baker, G. A. (2012). The Reliability and Validity of the Revised Liverpool Impact of Epilepsy Scale for Use in People with New-Onset Epilepsy. *Epilepsy & amp; Behavior*, 26(2), 175-181. doi: 10.1016/j.yebeh.2012.11.046
- Dimitrova, N., Pierrehumbert, B., Glatz, N., Torrisi, R., Heinrichs, M., Halfon, O., & Chouchena, O. (2010). Closeness in Relationships as a Mediator between Sexual Abuse in Childhood or Adolescence and Psychopathological Outcome in Adulthood. *Clin. Psychol. Psychother.*, 17(3), 183-195. doi: 10.1002/cpp.650
- Epilepsy Action. (2014). Epilepsy Action, from https://www.epilepsy.org.uk/
- Field, A. P. (2013). Discovering Statistics Using Ibm Spss Statistics: And Sex and Drugs and Rock 'N' Roll (4th ed. ed.): London: SAGE.
- Fiszman, A., Alves-Leon, S. V., Nunes, R. G., D'Andrea, I., & Figueira, I. (2004). Traumatic Events and Posttraumatic Stress Disorder in Patients with Psychogenic Nonepileptic Seizures: A Critical Review. *Epilepsy & Behavior*, *5*(6), 818-825.
- Gaher, R., Hofman, N., Simons, J., & Hunsaker, R. (2013). Emotion Regulation Deficits as Mediators between Trauma Exposure and Borderline Symptoms. [Article]. *Cognitive Therapy & Research*, *37*(3), 466-475. doi: 10.1007/s10608-012-9515-y
- Gratz, K. L., & Roemer, L. (2004). Multidimensional Assessment of Emotion Regulation and Dysregulation: Development, Factor Structure, and Initial Validation of the Difficulties in Emotion Regulation Scale. *Journal of Psychopathology and Behavioral Assessment, 26*(1), 41-54.
- Hexel, M. (2003). Alexithymia and Attachment Style in Relation to Locus of Control. *Personality and Individual Differences*, 35(6), 1261-1270. doi: 10.1016/S0191-8869(02)00333-1
- Hoepner, R., Labudda, K., May, T. W., Schöndienst, M., Bien, C. G., & Brandt, C. (2014). Distinguishing between Patients with Pure Psychogenic Nonepileptic Seizures and Those with Comorbid

- Epilepsy by Means of Clinical Data. [Article]. *Epilepsy & Behavior, 35*, 54-58. doi: 10.1016/j.yebeh.2014.04.002
- Hubsch, C., Baumann, C., & Maillard, L. (2010). P01-389 Psychogenic Non-Epileptic Seizures: Clinical Classification Based on the Video-Eeg Analysis of 145 Seizures. [Abstract]. *European Psychiatry*, 25, 602-602. doi: 10.1016/S0924-9338(10)70597-6
- Jellema, A. (2000). Insecure Attachment States: Their Relationship to Borderline and Narcissistic Personality Disorders and Treatment Process in Cognitive Analytic Therapy. [Article]. *Clinical Psychology & Psychotherapy, 7*(2), 138-154.
- Kapeleris, A. R., & Paivio, S. C. (2011). Identity and Emotional Competence as Mediators of the Relation between Childhood Psychological Maltreatment and Adult Love Relationships. *Journal of Aggression, Maltreatment & Dournamy, Trauma, 20*(6), 617-635. doi: 10.1080/10926771.2011.595764
- Kaplan, M. J., Dwivedi, A. K., Privitera, M. D., Isaacs, K., Hughes, C., & Bowman, M. (2013). Comparisons of Childhood Trauma, Alexithymia, and Defensive Styles in Patients with Psychogenic Non-Epileptic Seizures Vs. Epilepsy: Implications for the Etiology of Conversion Disorder. *Journal of Psychosomatic Research*, 75(2), 142-146.
- Lally, N., Spence, W., McCusker, C., Craig, J., & Morrow, J. (2010). Psychological Processes and Histories Associated with Nonepileptic Versus Epileptic Seizure Presentations. [Article]. *Epilepsy & Behavior*, *17*(3), 360-365. doi: 10.1016/j.yebeh.2009.12.001
- Lehavot, K., & Simpson, T. L. (2014). Trauma, Posttraumatic Stress Disorder, and Depression among Sexual Minority and Heterosexual Women Veterans. *Journal of Counseling Psychology, 61*(3), 392-403. doi: 10.1037/cou0000019
- Muller, R., Thornback, K., & Bedi, R. (2012). Attachment as a Mediator between Childhood Maltreatment and Adult Symptomatology. *J Fam Viol, 27*(3), 243-255. doi: 10.1007/s10896-012-9417-5
- Myers, L., Matzner, B., Lancman, M., Perrine, K., & Lancman, M. (2013). Prevalence of Alexithymia in Patients with Psychogenic Non-Epileptic Seizures and Epileptic Seizures and Predictors in Psychogenic Non-Epileptic Seizures. [Article]. *Epilepsy & Behavior*, 26(2), 153-157. doi: 10.1016/j.yebeh.2012.11.054
- . P.N.E.S. Awareness Discussion Forum. (2014), from https://www.facebook.com/groups/153086878071352/?pnref=story
- Paivio, S. C., & McCulloch, C. R. (2004). Alexithymia as a Mediator between Childhood Trauma and Self- Injurious Behaviors. *Child Abuse & Description of the Computation of the Computa*
- Picardi, A., Martinotti, G., Paci, M., Simi, C., & Caroppo, E. (2011). Reliability of Self-Reported Attachment Style in Patients with Severe Psychopathology. *Journal of Personality Assessment*, *93*(5), 491-499. doi: 10.1080/00223891.2011.594128
- Quinn, M., Schofield, M., & Middleton, W. (2008). Conceptualization and Treatment of Psychogenic Non-Epileptic Seizures. [Article]. *Journal of Trauma & Dissociation*, *9*(1), 63-84. doi: 10.1080/15299730802073676
- Sandberg, D. A., Suess, E. A., & Heaton, J. L. (2010). Attachment Anxiety as a Mediator of the Relationship between Interpersonal Trauma and Posttraumatic Symptomatology among College Women. *Journal of Interpersonal Violence*, 25(1), 33-49. doi: 10.1177/0886260508329126
- Smith, A. M., & Flannery-Schroeder, E. C. (2013). Childhood Emotional Maltreatment and Somatic Complaints: The Mediating Role of Alexithymia. [Article]. *Journal of Child & Adolescent Trauma*, 6(3), 157-172. doi: 10.1080/19361521.2013.811456
- Taylor, G. J. (2014). Twenty-Item Toronto Alexithymia Scale (Tas-20), from http://www.gtaylorpsychiatry.org/tas.htm
- Troisi, A., Argenio, A., Peracchio, F., & Petti, P. (2001). Insecure Attachment and Alexithymia in Young Men with Mood Symptoms. *The Journal of nervous and mental disease, 189*(5), 311.

- van Merode, T., Twellaar, M., Kotsopoulos, I. A. W., Kessels, A. G. H., Merckelbach, H., de Krom, M. C. T. F. M., & Knottnerus, J. A. (2004). Psychological Characteristics of Patients with Newly Developed Psychogenic Seizures. *Journal of Neurology, Neurosurgery & Company of The Seizures*, 75(8), 1175. doi: 10.1136/jnnp.2003.016923
- Wei, M., Russell, D., Mallinckrodt, B., & Vogel, D. (2007). The Experiences in Close Relationship Scale (Ecr)-Short Form: Reliability, Validity, and Factor Structure. *Journal of Personality Assessment*, 88(2), 187-204. doi: 10.1080/00223890701268041
- Wei, M., Russell, D. W., Mallinckrodt, B., & Zakalik, R. A. (2004). Cultural Equivalence of Adult Attachment across Four Ethnic Groups: Factor Structure, Structured Means, and Associations with Negative Mood. *Journal of Counseling Psychology*, *51*(4), 408-417. doi: 10.1037/0022-0167.51.4.408
- Wongpakaran, T., & Wongpakaran, N. (2012). A Short Version of the Revised 'Experience of Close Relationships Questionnaire': Investigating Non-Clinical and Clinical Samples. *Clinical Practice And Epidemiology In Mental Health: CP & EMH, 8,* 36-42. doi: 10.2174/1745017901208010036

#### Thank you, results, forwarding, and support information

### Thank You!

Thank you for completing the survey, the time you have spent is appreciated. The researchers hope it will lead to improvements for people who experience epileptic and non-epileptic seizures.

#### Results

If you would like the researchers to send you a copy of the overall results of the study, please fill in the tear off slip, and send it **in a separate envelope to your questionnaires.** 

#### Forwarding the study

If you know anyone else who experiences epileptic and/or non-epileptic seizures and may want to participate, the researchers would appreciate it, if you pass on details about the survey.

A poster is included in the pack for you to pass on as you wish

#### **Support Information**

You may find the following support sources helpful:

- Talking to someone you know and trust
- Contacting the NHS on 111 (UK)
- Speaking to your doctor or other health professionals
- Calling the Samaritans (UK and ROI)
  - o http://www.samaritans.org
  - o 08457 90 90 90 \* (UK)

- o 116 123(ROI)
- Calling the Epilepsy Society Helpline 01494 601 400 (UK)

For further information and support related to epileptic and non-epileptic seizures, the

following websites may be helpful:

Epileptic seizures:

NHS Choices: <a href="http://www.nhs.uk/conditions/Epilepsy">http://www.nhs.uk/conditions/Epilepsy</a>

Epilepsy Society <a href="http://www.epilepsysociety.org.uk">http://www.epilepsysociety.org.uk</a>

Epilepsy Action <a href="https://www.epilepsy.org.uk/">https://www.epilepsy.org.uk/</a>

Non-epileptic seizures:

Information about non-epileptic seizures <a href="http://www.nonepilepticattacks.info">http://www.nonepilepticattacks.info</a>

Information about functional symptoms including seizures (click on blackouts /

attacks) <a href="http://www.neurosymptoms.org">http://www.neurosymptoms.org</a>

Information on the epilepsy society website


http://www.epilepsysociety.org.uk/non-epileptic-seizures

NEAD Trust Facebook page

https://www.facebook.com/pages/NEAD-Trust/101554536567742

PNES awareness facebook discussion forum

https://www.facebook.com/groups/153086878071352/



I would like to be sent a copy of the results of the study.

Please send it to (name and email or postal address):

\_\_\_\_\_

\_\_\_\_\_

Please return this form, in a separate envelope to your questionnaires, to:

Liz Tallentire, FREEPOST: RTAU-SYXU-YCZZ, Clinical Psychology,

Furness College, Bailrigg, LANCASTER, LA1 4YG



# Do you experience seizures?

Would you like to help increase understanding about seizures and their impact on people's lives?

Then you may want to take part in my research

Hello, my name is Liz Tallentire and I'm in my final year of training as a clinical psychologist

My research involves completing a short anonymous survey. If you are interested in participating and would like to know more take a card below with the link, pick up a pack from ...(insert detail) or go to www......(insert link)

For more information about my seizure research go to www.....(insert link)

or scan this code with your mobile

Thank you Liz Tallentire **Trainee Clinical Psychologist** 22/12/14 V1







For more information about my seizure research go to www.....(insert link)

or scan this code with your mobile

Thank you Liz Tallentire Trainee Clinical Psychologist 22/12/14 V1







For more information about my seizure research go to www.....(insert link)

or scan this code with your mobile

Thank you Liz Tallentire **Trainee Clinical Psychologist** 22/12/14 V1







For more information about my seizure research go to www.....(insert link)


or scan this code with your mobile

Thank you Liz Tallentire **Trainee Clinical Psychologist** 22/12/14 V1









or scan this code with your mobile

Thank you Liz Tallentire Trainee Clinical Psychologist 22/12/14 V1



For more information about my seizure research go to www.....(insert link)

or scan this code with your mobile

Thank you Liz Tallentire Trainee Clinical Psychologist 22/12/14 V1







For more information about my seizure research go to www.....(insert link)

or scan this code with your mobile

Thank you Liz Tallentire Trainee Clinical Psychologist 22/12/14 V1







For more information about my seizure research go to www.....(insert link)

or scan this code with your mobile

Thank you Liz Tallentire Trainee Clinical Psychologist







For more information about my seizure research go to www.....(insert link)

or scan this code with your mobile

Thank you Liz Tallentire Trainee Clinical Psychologist 22/12/14 V1







For more information about my seizure research go to www.....(insert link)

or scan this code with your mobile

Thank you Liz Tallentire Trainee Clinical Psychologist 22/12/14 V1




#### Online Forum advert

Hello, my name is Liz Tallentire and I'm in my final year of training as a clinical psychologist at Lancaster University, UK. I'm looking for people who have experienced seizures to take part in my research. I'm aiming to increase understanding about seizures and their impact on people's lives. The research involves completing a short anonymous survey. Please click here if you are interested in participating and would like to know more. (link to online survey site to be included)

Online survey 4.52

Below are some screen shots illustrating what the survey will look like online. The separate file 'Online Survey Questions' illustrates the text for each question, but not the formatting. Not all questions will be displayed to all potential participants. Survey logic and flow will be used to divert people whose answers indicate they should not take part and to hide irrelevant questions and information. There may be some minor adjustments to the online survey, for example, the order of questions on the Experiences in Close Relationships questionnaire will be altered to match the printed version.



Area of work/ deadline	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Apr-15	May-15	Jun-15	Jul-15	Aug-15	
Literature review section:			<b>†</b> `	- 0,												
Reviewing Literature for critical review	m	m	m	h							Key:					
Write up literature review section				m	h	h	h									
1st draft deadline						14th					Dema	nds on	time			
2nd draft deadline							19th									
Research paper section:											L = lov	V				
Reviewing literature for introduction/protocol				m							M = m	edium				
Prepare ethics application, protocol and other documents				h	h						H = Hi	gh				
Submit to university to check and then NHS ethics					31st								e of de	adline	or even	it
Set up online survey system					h	h										
Promote project to support groups, nhs and other services							*	h	h							
Data collection							*	m	m							
Analyse data									h	h						
Write up research paper introduction and methods						m										
1st draft deadline for intro and methods							5th									
Write up research paper results and discussion										h	h					
1st draft deadline for results and discussion											10th					
2nd draft deadling for whole empirical paper												1st				
Critical appraisal:																
Write critical appraisal										h	h	m				
1st draft deadline											24th					
Submit papers for publication														m	m	
* start as soon as ethical approval received																

Version 1 14 Oct 2014

#### **CURRICULUM VITAE**

Name:					
Liz Tallentire					
Present appointment:					
Trainee Clinical Psychologist					
Address:					
26 Bainbridge Road, Sedbergh, Cumbria, LA10 5AU					
Telephone number:	Email address:				
07539 294316	I.tallentire@lancaster.ac.uk				

#### **Qualifications:**

MA Leadership and Management in Integrated Children's Services (2011)

BSc (Hon) Psychology (2005)

Diploma Life Sciences (2005)

Level 5 Certificate Supervision Skills (2010)

NVQ Level 3 Promoting Independence (2003)

CACHE Level 3 Diploma Support Work in Schools (Pilot)(Parent Support) (2008)

Level 4 module Preparing to Teach in the Life-long Learning Sector (2010)

'A' Levels: Mathematics, Further Mathematics, Biology, Chemistry, General Studies

#### **Professional registration:**

#### **Previous and other appointments:**

Volunteer Psychology Assistant
Principal Family Worker
Supported Lodgings Provider
Parent Support Adviser Coordinator
Parent Support Adviser
Day Service Worker Level 2 Qualified
Home Care Assistant

2010 - 2012
2011 - 2012
2009 - 2012
2007 - 2008
2001 - 2007
1999 - 2000

#### Research experience:

I successfully completed a study as part of my current course, which involved working with, and interviewing people who live in a secure service for people with learning disabilities. Because of this study, I have spoken at several conferences including the International Conference on the Care and Treatment of Offenders with an Intellectual or Developmental Disability.

I completed mixed methods service evaluation research as part of my post as Parent Support Adviser Coordinator.

I have carried out research as part of my undergraduate and masters qualifications.

#### Research training:

I am in the final year of my doctorate in clinical psychology; this course has included teaching on research skills.

My Masters Qualification included taught modules on research philosophy and methodology as well as completion of research for the dissertation.

My undergraduate degree also involved practical and taught research elements.

#### Relevant publications:

In my role as Parent Support Adviser Coordinator I have completed the following reports which have been disseminated:

Parent Support Adviser Coordinator Evaluation (2010)

PSA Coordinators Locality Report Durham Dales (2009)

Parent Support Adviser Coordinator Supervision Evaluation (2009)

Signature:	Date:
Liz Tallentire	14/01/15

#### Dr Ian Fletcher CV

#### Current post - Senior Lecturer in Clinical Psychology, Lancaster University

Doctorate in Clinical Psychology, Division of Health Research Furness College, Lancaster University LA1 4YG

#### Research Interests

Health provider-patient communication, cancer, migration and health, attachment, emotional intelligence.

#### **Oualifications**

PhD. University of Manchester, 2006

MSc. Applied Psychology, University of Manchester, 2001

BSc (Hons) Psychology, University of Central Lancashire, 1995

#### External examiner

Staffordshire & Keele University, Doctorate in Clinical Psychology

#### Reviewer

National Institute for Health Research (NIHR) - applications

Patient Education and Counseling - journal

BMC Medical Education - journal

Clinical Ethics – journal

Personality & Individual Differences - journal

#### Research Grants

2007 €7000 'An eye for quality – the patient as a research partner'

International study (Belgium, Italy, Netherlands, and UK)

Funder: Netherlands 'Patient Oriented Research' charity

2010 £95000 'Can high-quality evidence-based information about emotional reactions to cancer empower patients to manage their emotional problems more effectively? A pilot study.' Funder: Liverpool PCT

2011 £5000 'Cultural health beliefs of the Chinese community in Merseyside'

Funder: Knowledge Exchange, University of Liverpool

2012 £20000 'Pathways to health among Chinese populations in Liverpool and

Manchester'

Funder: Liverpool PCT

#### **Publications**

Cherry MG, Fletcher I, O'Sullivan (2013) The influence of medical students' and doctors' attachment style and emotional intelligence on their patient–provider communication. *Patient Education and Counseling*; doi.org/10.1016/j.pec.2013.05.010

Cherry G, Fletcher I, O'Sullivan H (2013) Exploring the relationships between attachment, emotional intelligence & communication. *Medical Education*; 47: 317-325

Baker P, Beesley H, Dinwoodie R, Fletcher I, Ablett, J, Holcombe, C, Salmon, P (2013) 'You're putting thoughts into my head': a qualitative study of the readiness of patients with breast, lung or prostate cancer to address emotional needs through the first 18 months after diagnosis. *Psycho-Oncology*; 22: 1402-1410 2

Mazzi M, Bensing J, Rimondini M, Fletcher I, van Vliet L, Zimmermann C, Deveugele M (2013) How do lay people assess the quality of physicians' communicative responses to patients' emotional cues and concerns? An international multicentre study based on videotaped medical consultations. *Patient Education and Counseling*; 90: 347-353

Mazzi M, Rimondini M, Deveugele M, Zimmermann C, Moretti F, van Vliet L, Deledda G, Fletcher I, Bensing J (2013) What do people appreciate in physicians' communication? An international study with focus groups using videotaped medical consultations. Health Expectations; doi: 10.1111/hex.12097

Huntley CD, Salmon P, Fisher PL, Fletcher I, Young, B (2012) LUCAS: A theoretically informed instrument to assess clinical communication in objective structured clinical examinations. *Medical Education*; 46: 267-276

Cherry G, Fletcher I, Shaw N, O'Sullivan H, Shaw N (2012) What impact do structured educational sessions to increase emotional intelligence have on medical students? BEME Guide No.17. *Medical Teacher*: 34: 11-19

Moretti F, Fletcher I, Mazzi M, DeVeugele M, Rimondini M, Geurts C, Zimmermann C, Bensing J (2011) GULiVER—travelling into the heart of good doctor—patient communication from a patient perspective: study protocol of an international multicentre study. *European Journal of Public Health*; doi:10.1093/eurpub/ckr071

Bensing J, Deveugele M, Moretti F, Fletcher I, Zimmermann C, van Vliet E, Van Bogaert M, Rimondini M (2011) How to make the medical consultation more successful from a patient's perspective? Tips for doctors and patients from lay people in the United Kingdom, Italy, Belgium and the Netherlands. *Patient Education and Counseling*; 84:287-293

Moretti F, van Vliet L, Bensing J, Deledda G, Mazzi M, Rimondini M, Zimmermann C, Fletcher I (2011) A standardized approach to qualitative content analysis of focus group discussions from different countries. *Patient Education & Counseling*; 82:420-428

Fletcher I, Mazzi M, Nuebling M (2011) When coders are reliable: the application of three measures to assess inter-rater reliability/agreement with doctor-patient communication data coded with the VR-CoDES. *Patient Education & Counseling*; 82:341-345

Fletcher I, Leadbetter P, Curran A, O'Sullivan H (2009) A pilot study assessing emotional intelligence training and communication skills with 3rd year medical students. *Patient Education & Counseling*; 76:376–9

Pitceathly C, Maguire P, Fletcher I, Parle M, Tomenson B, Creed F (2009) Can a brief psychological intervention prevent anxiety or depressive disorders in cancer patients? A randomised controlled trial; *Annals of Oncology*, 20:928–34

Connor M, Fletcher I, Salmon P (2009) The analysis of verbal interaction sequences in dyadic clinical communication: A review of methods. *Patient Education & Counseling*; 75(2):169-177

Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P (2008) The psychosocial impact of human papillomavirus testing in primary cervical screening—a study within a randomized trial. *International Journal of Gynecological Cancer*; 18:743-8

#### Lancaster Doctorate in Clinical Psychology

#### Thesis feedback form



The purpose of this form is to record feedback on the discussions from the thesis presentation day. Please complete the details for the form as soon as possible after your presentation and email it to a member of the presentation panel for approval. The staff member will then forward it to the research coordinator.

You are then encouraged to share this with your field supervisor (if appropriate) and your research support person in order to develop your proposal. Please remember that it is not the role of the presentation panel to 'approve' or otherwise your proposal. The aim of the presentation panel is to provide feedback on the proposal and discuss practical and ethical issues. You will need to consider how to respond to these points when discussing your proposal further with your supervisors.

Trainee name Liz Tallentire

/Date of presentation 26/3/14

Research team members present

Ian Fletcher, Craig Murray

Title of proposed thesis:

Predictors relevant to seizure experience

Field supervisor's name and contact details (if appropriate)

**Necessary changes/actions:** These suggestions must be taken forward in order for the project to be viable.

Further discussions: These recommendations are optional and should be discussed with your academic supervisor.

#### Comments on Thesis content area

There was a discussion around whether the literature review Liz wishes to complete in order to inform a model she can then test using multiple regression analysis could be used as the literature review for the thesis.

lan F thought this would be OK as it would be publishable in its own right and would be to be quite broad and include Medically Unexplained Symptoms more generally due to lack of literature.

There was discussion of the clinical relevance of the study; Liz hopes this will contribute to identifying appropriate psychological support for people affected by these experiences. It may also contribute to understanding of non-epileptic seizures and their identification being more accurate and/or cost effective.

being mere accurate and, or cost effective.						
Necessary changes/action:	Further considerations:					
I will need to come up with a question for						
my literature review, which will be						
separate from the research question for the						
empirical part.						
I was thinking of:						
What are our understandings and evidence						
about how non-epileptic seizures develop						
and are maintained? This would be a mixed						
methods literature review ( action not						
discussed in review session)						
Comments on Thesis methodology						
Liz asked for advice on her plans to complete	literature review in order to develop a					
model as no suitable one seems to be available						
lan F explained. Two options available a) mo	del (theory) driven b) exploratory. Also					
possible to try a) first and then do b) if this does not work						
lan suggests literature review could be completed alongside empirical part, predictors can						
be identified beforehand, and then the literate						
to interact.	, and the second					
Necessary changes/action:	Further considerations:					
, ,						
Comments on analysis						
none						
Necessary changes/action:	Further considerations:					
Comments on practical and ethical issues						
lan prefers Liz to have an external field sup	ervisor					
Necessary changes/action:	Further considerations:					
Liz to discuss possibility with the people						
she has identified. Ideally field supervisor						
to be someone working in NHS who has						
contact with people who experience						
seizures.						
Please put a tick in this box if it is dec	ided that the project must be brought					
back to another peer review	•					



#### To Whom it may Concern

Your reference

Our reference MH

Date 04/08/2014

Professional Indemnity Insurance To whom it may concern

Zurich Municipal 1 East Parade Leeds

LS1 2BQ Phone 0113 242 7742 Mobile 07730 735 395

http://www.zurich.com

**Dear Sirs** 

This is to confirm that the Lancaster University have Professional Indemnity cover in place with ourselves with effect from the 1<sup>st</sup> of August 2014, the policy is renewable on the 31<sup>st</sup> of July, 2015. Cover will be in place until at least 31<sup>st</sup> July 2017.

The Policy Number is NHE07CA04-0013. Cover is in place with a limit of Indemnity of at least £1m.

Please do not hesitate to contact me should you require any additional information.

Yours Sincerely

M I Horsfield

Assistant Sales Manager Education.

Zurich Municipal is a trading name of Zurich Insurance Company a limited company incorporated in Switzerland

Registered in the canton of Zurich No 3.749.620.01 UK branch registered in England No BR105

Registered Office Zurich House, Stanhope Road Portsmouth, Hampshire PO1 1DU

A member of the Association of British Insurers and the Insurance Ombudsman Bureau



#### Certificate of Employers' Liability Insurance(a)

(Where required by regulation 5 of the Employers' Liability (Compulsory Insurance) Regulations 2008 (the Regulations), a copy of this certificate must be displayed at all places where you employ persons covered by the policy or an electronic copy of the certificate must be retained and be reasonably accessible to each employee to whom it relates).

Policy No.

NHE-07CA04-0013

1. Name of policy holder

Lancaster University

2. Date of commencement of insurance policy

1st August 2014

3. Date of expiry of insurance policy

31" July 2015

We hereby certify that subject to paragraph 2:

- The policy to which this certificate relates satisfies the requirements of the relevant law
  applicable in Great Britain, Northern Ireland, the Isle of Man, the Island of Jersey, the
  Island of Guernsey and the Island of Alderney (b)
- 2. (a) the minimum amount of cover provided by this policy is no less than £5 million (c)

Signed on behalf of Zurich Insurance plc (Authorised Insurer).

Signature

S.Len

Stephen Lewis

Chief Executive Officer Zurich Insurance plc, UK Branch.

#### Notes

- (a) Where the employer is a company to which regulation 3(2) of the Regulations applies, the certificate shall state in a prominent place, either that the policy covers the holding company and all its subsidiaries, or that the policy covers the holding company and all its subsidiaries except any specifically excluded by name, or that the policy covers the holding company and only the named subsidiaries.
- (b) Specify applicable law as provided for in regulation 4(6) of the Regulations.
  - (c) See regulation 3(1) of the Regulations and delete whichever of paragraphs 2(a) or 2(b) does not apply. Where 2(b) is applicable, specify the amount of cover provided by the relevant policy.

Zurich Insurance plc
A public limited company
incorporated in Ireland
Registration No.13460 Registered
Office Zurich House, Ballsbridge
Park , Dublin 4 Ireland.
UK branch registered in England
and Wales Registration No.
. BR 7985
UK Branch Head Office
The Zurich Centre, 3000 Parkway,
Whiteley, Fareham, Hampshire
PO15 7/Z

Authorised by the Irish Financial
Regulator and subject to limited
regulation by the Financial Conduct
Authority. Details about the extent
of our regulation by the Financial
Conduct Authority are available
from us on request



#### To Whom it may Concern

Your reference

Our reference MH

Date 04/08/2014

Public Liability Insurance To whom it may concern

Zurich Municipal 1 East Parade

Leeds LS1 2BQ

Phone 0113 242 7742 Mobile 07730 735 395

Dear Sirs

This is to confirm that the Lancaster University have Public Liability cover in place with ourselves with effect from the 1<sup>st</sup> of August 2014, the policy is renewable on the 31<sup>st</sup> of July, 2015. Cover will be in place until at least 31<sup>st</sup> July 2017.

The Policy Number is NHE07CA04-0013. Cover is in place with an indemnity Limit of at least £15m

http://www.zurich.com least £15r

Please do not hesitate to contact me should you require any additional information.

Yours Sincerely

M I Horsfield

Assistant Sales Manager Education.

Zurich Municipal is a trading name of Zurich Insurance Company a limited company incorporated in Switzerland

Registered in the canton of Zurich No 3.749.620.01 UK branch registered in England No BR105

Registered Office Zurich House, Stanhope Road Portsmouth, Hampshire PO1 1DU

A member of the Association of British Insurers and the Insurance Ombudsman Bureau

## Research and Enterprise Lancaster University



Applicant name: Liz Tallentire Supervisor: Dr Ian Fletcher

Department: DHR

16 January 2015

Dear Liz and Ian,

#### Re: Relationships between early life events, individual differences, and seizures

The University of Lancaster undertakes to perform the role of sponsor in the matter of the work described in the accompanying grant application. The sponsor as we understand it assumes responsibility for monitoring and enforcement of research governance. As principal investigator you will confirm that the institution's obligations are met by ensuring that, before the research commences and during the full term of the grant, all the necessary legal and regulatory requirements in order to conduct the research are met, and all the necessary licenses and approvals have been obtained. The Institution has in place formal procedures for managing the process for obtaining any necessary or appropriate ethical approval for this grant. Full ethical approval must be in place before the research commences and should be reviewed at all relevant times during the grant.

Yours sincerely,

Fiona Aiken,

University Secretary,

Chair, University Research Ethics Committee.

Cc Sarah Taylor, Secretary, UREC.

Lancaster University Research and Enterprise Services Division

Lancaster University Bowland Main Lancaster, LA1 4YT, UK T: +44 (0)1524 592 002 F: +44 (0)1524 593 229 www.lancaster.ac.uk